Bloomage Biotechnology Corporation Limited
O?ce Address: 33/F, Building D, Bloomage International Center, No.A6 Jianguomenwai Street, Beijing, China.Email: esg@bloomagebiotech.comWebsite: https://www.bloomagebiotech.com/
Stock code688363.SH
Sustainability Report
2024
Bloomage Biotechnology Corporation Limited
About This ReportReport IntroductionThis report is the second Sustainability Report (hereinafter referred to as "this Report") released by Bloomage Biotech-nology Corporation Limited (hereinafter referred to as "Bloomage Biotech","the Group","the Company" or "We"), follow-ing four consecutive annual Corporate Social Responsibility (CSR) reports since the Company's listing in 2019. Thisreport discloses information pertinent to the Company's sustainable development and ful?lment of social responsibili-ties.Report ScopeThis Report covers Bloomage Biotechnology Corporation Limited together with its subsidiaries, in line with the report-ing period covered in Bloomage Biotech's Annual Report, unless speci?cally stated otherwise. The reporting period ofthis Report spans from 1 January 2024 to 31 December 2024. To ensure continuity, integrity and comparability, certaincontent extends beyond the scope mentioned above, with detailed explanations provided within the report.Basis of CompilationSelf-Regulatory Guidelines for Listed Companies of the Shanghai Stock Exchange No. 14 - Sustainability Reporting (forTrial Implementation)’, with reference to the standards of the GRI Sustainability Reporting Standards (hereinafter referredto as the “GRI Standards”) issued by the Global Commission, International Financial Reporting Standard on SustainabilityDisclosure 1 - General Requirements for Disclosure of Sustainability-Related Financial Information (“IFRS S1”), the FrameworkRecommendations of International Financial Reporting Standard on Sustainability Disclosure 2 - Climate-Related Disclosure("IFRS S2"), the United Nations Sustainable Development Goals (SDGs), the Ten Principles of the United Nations GlobalCompact (UNGC) ("the Ten Principles of the UNGC"), issues monitored by Morgan Stanley Capital International ESGRatings (MSCI), and issues monitored by EcoVadis Ratings. For readers' convenience, a comprehensive index is providedin the appendix for easy reference.Data SourcesAll information presented in this report originates from internal o?cial documents, statistical reports, third-partyquestionaries and surveys, and relevant public sources within Bloomage Biotech. Financial data is meticulously sourcedfrom the Company's annual reports, with all monetary amounts denoted in Chinese Renminbi (RMB) unless explicitlystated otherwise.Board StatementThis report has been deliberated and approved by the Board of Directors of Bloomage Biotech. The Board of Directorssolemnly assures that there are no falsi?cations or misleading statements within this report, and assumes full account-ability for the truthfulness, accuracy and completeness of its content.
Report ReleaseBoth a Simpli?ed Chinese and English version of this report will be o?cially published. In case of any ambiguity, theSimpli?ed Chinese version shall take precedence.Electronic copies of this report in both Chinese and English are readily accessible through the Company's o?cialwebsite and the Shanghai Stock Exchange's website:
https://www.bloomagebiotech.com/http://www.sse.com.cn/
FeedbackFor inquiries or feedback regarding this report and its contents, you are welcome to reach out through the followingcontacts:
O?ce Address: 33/F, Building D, Bloomage International Center, No. A6 Jianguomenwai Street, Beijing, China.Email: esg@bloomagebiotech.com
CONTENTS
About This ReportChairwoman and CEO's Message
Appendices
Index of IndicatorsGHG Veri?cation StatementESG Key Performance Tables
Social Welfare andCommunity Relations
Fair and Standardized EmploymentTalent DevelopmentSafety and HealthEmployee Rights and Bene?ts
Company OverviewMajor Honors of the Year
About Bloomage Biotech
2024 Sustainability ReportCONTENTSChairwoman and
CEO's Message
About UsSafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
| 03 | 07 |
SustainableDevelopmentManagement
Sustainable DevelopmentManagement SystemSustainability StrategyStakeholders EngagementDouble Materiality AssessmentMajor Honors in Sustainability
Board of DirectorsCompliance ManagementInternal Control and RiskManagementBusiness EthicsCybersecurity and PrivacyInvestor Rights Protection
R&D InnovationQuality ManagementProduct Accessibility andA?ordabilityCustomer Services and RightsProtection
Ensuring Supply Chain SecuritySupply Chain Quality ManagementSupply Chain ESG Management
| 01 | 05 |
Symbiosis:
Green, Low-Carbon,and Resilience
Growth:
Talent EmploymentandDevelopment
Addressing Climate ChangeEnvironmental ComplianceManagementPollutant Emissions and WasteManagementResource Utilization andCircular Economy
Safeguard:
Compliance Governanceand Risk Control
Driving Forces:
R&D Innovation andQuality Management
| 02 | 06 |
Achievements:
A Sustainable ValueChain
Responsibility:
Community Care andContributions
0201
At Bloomage Biotech, we remain committed tocreating a win-win situation for all stakeholders. Westrictly adhere to compliant operations, upholdhigh-standard business ethics, safeguardemployees’ rights and interests, ful?ll our socialresponsibilities, address stakeholders’ concerns,and protect the interests of all parties. In the pastyear, Bloomage Biotech o?cially joined the UnitedNations Global Compact (UNGC), promoting thesustainable development of both our company andthe entire industry. We strengthened our compli-ance, risk management, and audit monitoringsystems, obtaining ISO 37301 and ISO 37001management system certi?cations. We adhere to apeople-centered approach and have become asignatory to the United Nations Women's Empower-ment Principles (WEPs). By optimizing our humanresources system, we have created a fair, safe, andhealthy working environment that supports employ-ees’ growth and development. In addition, we haveestablished a supplier ESG management mecha-nism. This mechanism strengthens cooperationwith suppliers in areas such as business ethics,environmental protection, and labor rights, promot-ing high-quality development. Furthermore, for the14th consecutive year, we have carried out the “InCloud” Public Welfare campaign, contributing to theinheritance of national culture, rural development,and the improvement of more people's lives.
We ?rmly believe that in future development,enterprises must place greater emphasis onintegrating economic, environmental, and socialvalues, aligning pro?t-seeking with righteousness.Looking ahead, Bloomage Biotech will continue touphold the concept of sustainable development,further enhance our ESG management capabilities,and resolutely advance our sustainable develop-ment strategy. We are committed to creatinggreater value and contributing to the developmentof society at large.
Chairwoman and CEO
of Bloomage Biotech
Zhao Yan
Sustainable development has become a globalconsensus, and ESG serves as a crucial language forChinese enterprises to communicate with the globalmarket. As a globally in?uential biotechnologycompany, Bloomage Biotech, driven by a strongsense of social responsibility, has integrated sustain-able development into its corporate strategy. Wehave carefully implemented it across all aspects ofour operations, ensuring the Company's healthy,long-term growth while contributing to the future ofour planet and the sustainable development ofhuman society.In 2024, the global landscape was marked by volatili-ty, with domestic and international economiesfacing formidable challenges and consumerdemand remaining subdued. These numerousuncertainties posed substantial obstacles tobusiness development. However, challenges andopportunities coexist, and change is the onlyconstant. Confronting dynamic challenges, Bloom-age Biotech spearheaded sustainable innovationand resilient adaptation. We made every e?ort topromote and implement various managementtransformation initiatives, including the establish-ment of an ESG management system. This hasenhanced our operational resilience and e?ciency,fostering a healthier organization and enabling thegrowth and development of our talent.Science and technology form the cornerstone ofBloomage Biotech's development. Starting withfrontier research in basic biology, particularly inglycobiology and cell biology, we harness thepower of synthetic biology to drive industrialtransformation. We have established anend-to-end value chain for biomaterials, cover-
Low-carbon and green development is the inevitablepath for Bloomage Biotech. We base our e?orts onthe entire product lifecycle, covering R&D,procurement, production, and sales. We arecommitted to promoting the green and low-car-bon transition. In the past year, we successfullyinitiated greenhouse gas Scope 3 accounting andproduct lifecycle assessment (LCA) for the ?rst time,establishing a robust data foundation for emissionreduction. We continued to optimize our productionprocesses, consistently reducing energy and
Chairwoman and CEO's Message
To Our Esteemed Stakeholders,In 2024, Bloomage Biotech was deeply committed to sustainable development. We made remarkableprogress in ESG management and entered a new stage of development. To comprehensively showcaseour management philosophy, guiding principles, strategic vision, and dedication to social responsibility,we're proud to present our second annual Sustainability Report. We sincerely invite you to read thisreport. On behalf of Bloomage Biotech, I express our deepest gratitude for your attention and support.
ing upstream R&D, industrial solutions, andbrand building. Leveraging our strengths in R&Dinnovation, result transformation, and marketexpansion, we are advancing the developmentof the biotechnology and broader health indus-tries. We provide high-quality, e?cientlife-health products and services globally,delivering health, well-being, and opportunitiesto more people. In the past year, Bloomage Biotechhas reached several signi?cant milestones. Weo?cially opened the world's ?rst Bio-Manufacturing
5.0 Science and Technology Museum in Tianjin; we
established our health food headquarters inHangzhou, expanding our in?uence in thelarge-scale health sector. The commissioning of ourpharmaceutical-grade pilot-scale results transfor-mation workshop has established the world'slargest platform for this purpose. Our Xiangtanproduction base has o?cially begun operations,marking a new phase in the development of ourmedical terminal business. By integrating cross-dis-ciplinary technologies like AI and micro?uidics, wehave developed personalized production equip-ment and introduced customized skincare services.These innovations provide consumers with precisesolutions for skin health.
resource consumption. We actively participated ingreen power market-based trading, introducedbiomass heat energy, and e?ectively decreased ourreliance on fossil fuels. We continuously improvedour product packaging designs to facilitate multipleuses and recycling. Furthermore, we enhanced ourdigital energy management platform and environ-mental data management platform, signi?cantlyimproving our low-carbon and green data manage-ment capabilities. In line with our strategic vision,we have established clear pathways and targets forcarbon emission reduction by 2030, fully integratingthese goals into our performance managementsystem to ensure the comprehensive implementa-tion of our low-carbon transformation.
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement2024 Sustainability ReportAbout Us
Established in 2000 and publicly listed on the A-share Science and Technology Innovation Board (Stock Code: 688363. SH) inNovember 2019, Bloomage Biotech is a biotechnology company propelled by innovation in synthetic biology and a platformcompany for the whole industrial chain of biological materials, dedicated to improving people's quality of life by creating healthierexperiences with a mission of “Let every life be alive”.The R&D and business layout of Bloomage Biotech is based on the understanding of aging, and the essence of all aging is cellularaging, so the Company starts from the basic research of biology, focuses on two basic disciplines of glycobiology and cell biology,and relies on the advantages of industrial transformation in the ?eld of synthetic biology, to provide scienti?c solutions for life andhealth, including cellular regulation-grade raw materials, medical end-products, translational dermatology innovation productsand nutritional science innovation translation business, through biotechnology to achieve anti-aging intervention and regenerationto extend the healthy life, leading the new era of cellular anti-aging, and truly achieving “let every life be alive”.Embracing the development logic of “science to technology, to product, to branding", Scienti?c and technological innovation formsthe foundational bedrock of Huaxi Bio’s enterprise development, anchored in fundamental and applied research. The company'sbusiness model comes from its three core capabilities, the ?rst most core and bottom support is the R&D innovation capability; thesecond is the results conversion capability; the third is the market conversion capability. We have built a biomaterials all-chainconversion path, which opens up the whole process from material discovery, to product conversion and product development, andthus we are able to take the business of B-B, B-B-C and B-C to serve companies and consumers around the world.In the future, Bloomage Biotech will always adhere to the long-termism, holding an open and embracing attitude to create more‘healthy, beautiful and happy’ life experiences with all industry chain partners, and promote the development of the global lifescience and technology industry.
Honours received by Bloomage Biotech in 2024 (partial)
Included in the All-China Federation ofIndustry and Commerce's list of 500 privateenterprises with invention patents in 2024All-China Federation of Industry
and CommerceNational March 8Red Flag CollectiveAll-China Women's Federation(PRC, established 1949)Demonstration project on innovation andapplication of new materials in Shandong Province(innovation platform demonstration project)
Department of Industry and InformationTechnology of Shandong Province2024 Water ConservationIncentive Second Prize of Jinan CityJinan Urban and Rural Water Bureau
The 26th ‘Golden Trust and
Disclosure Award’ for Listed Companies
China Securities Journal
Listed Company Board Best Practice Cases2024, Sustainability Best Practice Cases 2024China Listed Companies AssociationSelected for the ‘China GoodTechnology’ Project Pool
China Association ofProductivity Promotion Centre
China's 500 Most Valuable Brands 2024
World Brand Lab
Top 10 Innovative Biotech Companies of 2024
China Times
Major Honors of the Year
In recent years, Bloomage Biotech has won the second prize of National Science and Technology Progress Award, NationalEnterprise Technology Centre, National Manufacturing Individual Champion Demonstration Enterprise, National Green Factory,China Patent Gold Medal, First Prize of Shandong Province Science and Technology Progress Award, Shandong Province Governor'sQuality Prize, and other national and provincial honours, as well as several national association honours such as Science andTechnology Prize of China Association for the Food Industry, China Association of Technology Markets' Golden Bridge Prize, andChina Good Technology (China Productivity Promotion Centre) and many other national association honours.In 2024, Bloomage Biotech continues to communicate with the government, industry associations, research institutions, media andother related parties to maintain a good relationship, and jointly promotes the industry and even the society to the good develop-ment of the Company harvested a number of honours and awards, some of the honours are as follows:
About Bloomage BiotechCompany Overview
0403
Received “A” in the rating of companieslisted on the Science and Technology Board
(2023-2024)Shanghai Stock Exchange
CONTENTSSafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagementChairwoman andCEO's Message2024 Sustainability ReportAbout Us
2024 Sustainability ReportCONTENTSChairwoman and
CEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendices
SustainableDevelopmentManagement
Bloomage Biotech has joined the United Nations Global Compact (UNGC)and become a global signatory to the United Nations Women's Empower-ment Principles (WEPs). We are accelerating the integration of sustainabledevelopment principles into our business operations and systematicallyadvancing our ESG management initiatives. By optimizing our ESG manage-ment system, formulating comprehensive ESG strategic plans, fosteringcommunication and collaboration among stakeholders, and enhancing ourfocus on material issues, we are steadily elevating the quality of our ESGmanagement.
Sustainable DevelopmentManagement
About Us
2024 Sustainability ReportCONTENTSChairwoman and
CEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendices
SustainableDevelopmentManagement
Management
0807
Bloomage Biotech has established a top-down ESG governance structure and an e?ective ESG management mechanism. Thisenables the Company to synergistically promote ESG management practices in a multi-faceted manner and among multipledepartments.
Sustainable Development Management Framework
Bloomage Biotech places signi?cant emphasis on fostering employees' awareness of sustainable development and enhancing theircapabilities in this area. In 2024, the Company organized 32 specialized sharing sessions that covered ESG concepts, policies, indus-try trends, and professional skills. These sessions reached out to 21 departments and involved nearly 400 employees. Moreover,the Company has been actively promoting initiatives focused on green o?ce practices and low-carbon living. Employees areencouraged to take personal responsibility by practicing sustainable development in their daily lives. For example, the Companyorganized awareness-raising campaigns during key observances including the International Day for Biological Diversity and WorldEnvironment Day. Furthermore, an ESG literacy initiative was launched enterprise-wide. Interactive quizzes were used to deepenemployees' understanding of sustainability principles and practices.
Building a Sustainability Culture
In 2024, Bloomage Biotech integrated ESG performance requirements into the performance evaluations of relevant senior execu-tives and departments to ensure the e?ective implementation of our sustainable development initiatives. The Company assigneda speci?c weight to ESG performance within the annual Personal Business Commitment for senior executives, department heads,and relevant personnel. Evaluations were conducted based on two key aspects: the e?ectiveness of management improvementsand the completion status of key projects. The assessment results directly in?uence the performance ratings of these individuals,which subsequently a?ect their salary and bonus determinations.
Sustainability Performance Management
Bloomage Biotech's ESG Management and Governance Structure
Board of Directors
ESG CommitteeESG Management Center
Composed of various business lines,production bases, and functional departments
ESG Working Groups
Governance
Execution
In 2024, both the Company's Board of Directors and the ESG Committee conducted one review of ESG initiatives each, while theChairwoman and CEO reviewed these initiatives three times. The review encompassed signi?cant areas such as ESG managementsystem, sustainable development strategy, low-carbon transformation plan, supplier ESG management system, digital ESGmanagement, sustainable corporate culture development, and information disclosure practices. Furthermore, the Company'smanagement has approved a key plan for its 2025 ESG projects. This comprehensive plan includes various aspects such as supplierengagement in terms of their own sustainability practices, environmental impact assessment throughout product life cycles,development of organizational capabilities for sustainable growth, optimization of our overall ESG management system.
The Board of Directors is responsible for overseeing and coordinating all ESG-related matters. It reviews and approvesrelevant recommendations from the ESG Committee, ensuring that the Company implements sustainable develop-ment principles from top to bottom while integrating ESG management into business decision-making processes
Board of Directors
Additionally, dedicated ESG working groups have been established within each business line, production base, andfunctional department. These teams, consisting of ?xed personnel, are responsible for managing and executing allESG-related tasksESG Working Groups
The ESG Committee, supervised by the Board of Directors and chaired by independent director Cao Fuguo, overseesESG-related a?airs. Established and supervised under the Board of Directors, the ESG Committee reports to theBoard of Directors and aims to achieve high-quality sustainable development for the Company, which also deliberateson ESG-related matters and provides regular reports to the BoardESG Committee
Tasked with overseeing the Company's ESG management, including establishing the ESG management system,assessing ESG risks, formulating ESG strategic plans, facilitating the implementation of key ESG initiatives, evaluatingand optimizing key ESG indicators, and managing ESG communication and disclosure. The center reports annually tothe ESG Committee on its achievements of the year and future plans, receiving guidance and supervision from theCommitteeESG Management
Center
Organized
specialized sharing sessions
Involved nearly
employeesReached out to
departments
Sustainable DevelopmentManagement System
About Us
Sustainability StrategyGuided by our strategic vision, Bloomage Biotech implements a high-quality development model that considers the interests ofmultiple stakeholders, integrates green concepts, and enhances social welfare. We focus on three core pillars: sustainable opera-tions, sustainable society, and sustainable products. By centering our e?orts around six key areas—corporate governance, ESG riskmanagement, sustainable innovation, environmental impact management, protection of employees' rights and interests, andsocial empowerment through philanthropy—we establish a series of management indicators and objectives. Conducting ouroperations in a systematic, scienti?c, and rational manner strengthens our operational resilience and enhances our ability to adaptto future developments.
Stakeholders EngagementBloomage Biotech earnestly listens to the ESG concerns of various stakeholders, including regulatory authorities, shareholders,employees, customers, partners, and local communities. The Company fosters mutual understanding and recognition betweeninternal and external entities, integrates the expectations of all parties into its operational and decision-making processes, andpromptly discloses relevant information through annual reports and other channels. This approach is designed to continuouslyenhance stakeholders' trust and con?dence in the Company.The Company has established a sophisticated ESG audit preparation framework for its production bases. In 2024, we engaged aninternationally renowned auditing ?rm to conduct SMETA (Sedex Members Ethical Trade Audit) on its production bases in Jinan,Dongying, and Tianjin. The Company successfully completed issue recti?cation and closure, meeting the ESG management require-ments of customers and other relevant stakeholders.
We are committed to continuous-ly optimizing our corporategovernance structures and ESGrisk management practices. Thisinvolves identifying, assessing,and managing key risks whileestablishing a healthy,transparent, and equitablecorporate governance mecha-nism that supports the long-termstability of the Company.
Sustainable Operations
ESG riskmanagement
Promoting sustain-
able innovation
Managing environ-
mental impacts
Protecting employ-
ees’ rights
Empowering societyand advancing socialimpact initiatives
We concentrate on innovation todevelop more e?cient andenvironmentally friendlytechnologies and products.Through the optimization ofprocurement, production, andother processes, we reduceemissions, energy consumption,and resource consumption toachieve a sustainable productlifecycle.
Sustainable products
StakeholderExpectations and DemandsEngagement and Response
Compliant operationsTax complianceEconomic developmentAnti-corruptionProduct responsibility
Supervision and inspectionDaily managementMeetings and exchangesPublic consultationGovernment andRegulatory Agencies
Corporate governanceRisk managementShareholder rightsESG performanceBusiness ethicsInformation transparency
Shareholders' meetingsInvestor exchange meetingInformation disclosureField investigationsTeleconferencingEmail and online engagement platformsShareholdersand Investors
Employee rights protectionEmployee compensation and bene?tsEmployee training and developmentEmployees safety and health
Employee roundtablesEmployee trainingEmployee satisfaction surveysPerformance evaluationsEmployees
Support charity and welfareEnvironmental protectionRural revitalizationCommunity development
Public welfare activitiesCommunity eventsMedia communicationPublic consultationCommunity
Scienti?c and technological innovationIndustry developmentProduct responsibility
Industry exchangesFormulation of industry standardsField visitIndustry Associations andChambers of Commerce
Product responsibilityESG performanceResponse to climate changeBusiness performance
Press conferencesSocial media platformsPublic opinion monitoringField interviewsMedia
Scienti?c research innovationTalent development
Education assistanceAcademic researchTechnology cooperationUniversities andResearch Institutes
Product responsibilityProvide excellent servicesProduct accessibilityProduct a?ordabilityClient privacy protection
Client satisfaction surveysCustomer service hotlinesSocial media platformsClient follow-upClients and Consumers
Honorable ful?llment of contractsSustainable purchasingGreen productProduct responsibilityIntellectual property protection
Supplier assessmentsSupplier trainingSupplier meetings and exchangesStrategic cooperationSuppliers and Partners
Bloomage Biotech’s Strategic Framework for Sustainable Development
Bloomage Biotech Stakeholder Engagement Mechanism
We pay close attention toemployees' rights and interestsand strive to create a diverse,inclusive, and fair workingenvironment.We also engage in socialempowerment initiatives andpublic welfare activities,leveraging the Company'stechnology and resources tocreate greater value for society.
Sustainable society
Sustainabilitystrategy
Corporategovernance
Strengthening the board of directors'participation in ESG initiativesImplementing high-standard compliance
management and business ethics
Identifying and managing the
Company's ESG risksIntensifying supply chain ESG
management
Continuously investing in sustainableproduct and technology research and
developmentFostering a culture of sustainableinnovation and stakeholder collaboration
Optimizing energy andresource use in productionOptimizing packaging and waste
management practices
Fostering a safe, diverse, equal, and
inclusive workplace environmentProviding a wide range of employeebene?ts and development opportunities
Carry out public welfare activities to
support community development
Enhancing internal and external
communication and knowledgedissemination
CONTENTSChairwoman and
CEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendices
SustainableDevelopmentManagement2024 Sustainability ReportAbout Us
1211
Double Materiality Assessment
In 2024, Bloomage Biotech conducted a materiality assessment in accordance with relevant regulatory requirements andmainstream information disclosure standards. Building on previous assessments, this evaluation incorporated a ?nancial perspec-tive for the ?rst time. The speci?c steps of the assessment process are outlined below:
Material Issue Assessment
Taking into account international standards and disclosure frameworks, capital marketrating indicators, peer performance, national policies, and Bloomage Biotech's businessdevelopment, 25 sustainable development issues were identi?ed, which formed arepository for material issuesIdenti?cationof MaterialTopics
Impact Materiality:Internal and external stakeholders were invited to assess the
materiality through online questionnaires. The questionnaire survey covered 10 catego-ries of stakeholders, including company management, employees, government orregulatory agencies, shareholders or investors, clients or consumers, suppliers orpartners, universities or research institutions, industry associations or chambers ofcommerce, the public, and sustainable development industry expertsFinancial Materiality: Interviews were conducted with the Company's managementteam to evaluate each issue's ?nancial materiality from various dimensions, includingimpact on costs and revenues, industry context, business model characteristics, opera-tional features, and key concerns of investors
Research of
Material
Topics
Ranking Material Issues: Survey data and interview results were analyzed to perform a
comprehensive quantitative assessment. Issues were ranked based on two dimensions:
“materiality to the Company's ?nancial performance” and “materiality to economic,social, and environmental impacts”Review of Material Issues: External experts provided feedback on the identi?ed materi-
al issues and their rankings. Subsequently, the management team reviewed these?ndings
Analysis of
Material
Topics
Based on the principles of “Double Materiality”, Bloomage Biotech assessed 25 ESG issues, identifying 18 high-impact material issues and 5 ?nanciallymaterial issues, thereby determining key content for this report.
Product EnvironmentalImpactEnvironmental Permitsand Certi?cationsCircular EconomyBiodiversity
Corporate GovernanceCompliance and RiskManagementBusiness EthicsIntellectual PropertyProtectionInformation Security
Employee RightsEmployee DevelopmentOccupational Health andSafetyResponsible MarketingClient ServiceIndustrial Cooperationand Development
Pollutant and Waste ManagementResponse to Climate Change and Energy ManagementSupplier ManagementProduct QualityR&D Innovation
UnimportantImportant
FinancialMateriality
EnvironmentSocialGovernance
Assessment Process of Double Materiality Issues of Bloomage Biotech
Bloomage Biotech’s Double Materiality Matrix
Healthcare AvailabilityResearch EthicsSocial Welfare and CommunityRelations
Environmental ComplianceManagementWater Management
ImpactMateriality
High
Aver-age
CONTENTSChairwoman and
CEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
2024 Sustainability ReportAbout Us
1413
Impact AreasCompany operations
Pollutant and Waste Management
Impact AreasUpstream value chain; company operations; downstream value chain
Potential Financial Impacts
Risks: Asset impairment losses and increased employee and property insuranceexpensesOpportunities: Reduced operational and management costs; increased operatingrevenueFor more management content
Please refer to the “Green, Low-Carbon and Resilience” section and the ESG KeyPerformance Tables
Response to Climate Change and Energy Management
Potential Risks
Physical risks arising from climate change, such as extreme precipitation and heat,pose threats like production disruptions and equipment damage, which canundermine the stability of our production and operational processesTransitional risks related to climate change, including evolving policies, regulations,and market trends, may lead to stricter compliance requirements or increased rawmaterial costs. These factors heighten compliance pressures on the Company whileraising operational expenses
Potential Opportunities
There is an increasing customer demand for green products, enhancing our productcompetitivenessThe ongoing development of energy-e?cient technologies and low-carbon equipmentpresents favorable conditions for cost reduction and e?ciency improvements withinour operationsBy decreasing reliance on fossil fuels, we can mitigate risks associated with energysupply instability
Impact AreasCompany operations; downstream value chain
Potential Risks
If the Company fails to provide higher-quality products, it may lead to customer attrition risksImplementing more comprehensive product testing will incur additional investments and costsPotential Opportunities
Superior quality products will further improve customer satisfaction, thereby consolidating andexpanding the customer baseHigher-quality products contribute to elevating the Company's reputation and image, strengthen-ing market competitiveness, and help explore potential marketsPotential Financial Impacts
Risks: Increased operational and management costsOpportunities: Increased operating revenue
For more management content
Please refer to the “R&D Innovation and Quality Management” section and the ESG KeyPerformance Tables
Product Quality
Impact AreasUpstream value chain; company operations; downstream value chain
R&D Innovation
Impact AreasUpstream value chain; company operations
Supplier Management
For those ?nancial material issues identi?ed, we have summarized their impact areas along with associated potential risks andopportunities, as well as their potential ?nancial impacts. In accordance with the guidance from the Shanghai Stock Exchange'sSustainability Report Guidance Framework, we emphasize relevant management strategies and actions within this report.Financial Material Issues
Potential RisksPotential OpportunitiesPotential Financial ImpactsFor more management content
Improper management of pollutants and waste may cause environmental contami-nation, which may trigger compliance risks resulting in ?nancial penalties or lossesand damage to corporate reputationEnhancing pollutants and waste management can improve our environmentalstewardship while ensuring compliance with regulatory requirements. This proactiveapproach not only bolsters corporate reputation but also strengthens marketcompetitivenessRisks: Increased operational and management costsOpportunities: Increased operating revenuePlease refer to the “Green, Low-Carbon and Resilience” section and the ESG KeyPerformance Tables
Delays in developing green product technologies may hinder compliance with increasinglystringent environmental requirements. Furthermore, if product innovations do not accuratelyalign with consumer demands, this could weaken market competitivenessInsu?cient protection of intellectual property rights may lead to disputes that negatively impactthe application and promotion of the Company's innovative achievementsPotential Risks
Adopting a customer-needs-oriented approach in R&D innovation will enable the Company toadapt e?ectively to market trends while enhancing its competitivenessOngoing e?orts in low-carbon product design aimed at improving energy e?ciency can potential-ly create green business opportunitiesPotential Opportunities
Risks: Increased operational and management costsOpportunities: Increased operating revenue
Potential Financial Impacts
Please refer to the “R&D Innovation and Quality Management” section and the ESG KeyPerformance TablesFor more management content
Factors such as climate change, raw material inventory levels, and turnover rates can a?ect supplychain stability. This instability may pose potential negative impacts on production operationsInadequate supplier auditing, certi?cation processes, or performance management can reducesupply chain transparency. ESG risks, including labor and environmental management issues, mayadversely impact production operations and corporate reputationPotential Risks
Establishing a sustainable supply chain enhances stability in product service delivery while ensuringcontinuity within company operationsDeveloping long-term partnerships with suppliers is crucial for improving product quality, innova-tion capabilities, and market competitivenessEncouraging suppliers to enhance their ESG management practices contributes positively to ourbrand image and reputation within both local markets and the global platformPotential Opportunities
Risks: Increased operating and administrative costsOpportunities: Increased operating revenuePotential Financial Impacts
Please refer to the “A Sustainable Value Chain” section and the ESG Key Performance TablesFor more management content
CONTENTSChairwoman and
CEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendices
SustainableDevelopmentManagement2024 Sustainability ReportAbout Us
1615
Major Honors in SustainabilityBloomage Biotech places signi?cant emphasis on communication with regulatory authorities, capital markets, customers, leadingdomestic and international ESG rating agencies, industry associations, and the media. Through these concerted e?orts, theCompany has signi?cantly enhanced its ESG rating performance and garnered numerous honors.
Bloomage Biotech's Awards and Honors in Sustainability (Selected)
2024 Best Practice Case of SustainableDevelopment for Listed CompaniesChina Association for Public Companies
2024 ESG Best Practices in theFragrance & Cosmetics IndustryChina Association of Fragrance Flavour
and Cosmetic Industries2024 CSR Excellence Cases by CNR
(China National Radio)CNR News
2nd Guoxin Cup ESG Golden Bull Award
China Securities Journal
ESG Zhiyuan Award: Eco-FriendlyEnterprise PioneerCailian Press
2024 ESG Model Enterprise &
Innovation AwardGuancha.cn
Annual ESG Outstanding Practice Award
Hexun.com
2024 Green Development Excellence Case by the
Beijing News Zero Carbon Research Institute
The Beijing News
Bloomage Biotech’s ESG Rating Performance (Selected)
EcoVadis Global Supply Chain
Sustainability Rating
Bronze Medal
CDP Global Environmental Disclosure
Climate Change: BWater Security: A-
MSCI ESG RatingBB
CSI ESG Rating
AA
SynTao Green Finance ESG Rating
A
Wind ESG Rating
A
In 2024, Bloomage Biotech Featured in 2024 Report on Green Transformation Practices of Chinese Enterprises and showcased at COP29
CONTENTSChairwoman and
CEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
2024 Sustainability ReportAbout Us
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
SDGs Addressed in this Chapter
Major Material Topics of Sustainability Covered in this Chapter
· Corporate Governance· Compliance and Risk Management· Business Ethics· Information Security
Safeguard：ComplianceGovernance and Risk ControlRobust and compliant corporate governance is the cornerstone of achievingbusiness growth and long-term sustainability. Bloomage Biotech continu-ously re?nes its corporate governance structure, places signi?cant emphasison risk management and compliance, upholds high standards of businessethics, and establishes a comprehensive information security managementsystem. These e?orts enhance transparency in information disclosure andaim to create more sustainable business value for all stakeholders.
2024 Sustainability ReportAbout Us
2019
Bloomage Biotech strictly adheres to relevant corporate governance laws, regulations, and stock exchange requirements. TheCompany continually strengthens its board of directors and associated committees. In 2024, the Company established the RiskManagement Committee to enhance the board’s capabilities in managing compliance, business ethics, and risk.
In 2024, the Company undertook a comprehensive revision of its board management system. This includes 18 managementregulations and working procedures, such as the Articles of Association, Rules for Board Meetings and Decision-Making Procedures forRelated Party Transactions. New regulations were also introduced, including the System for Selecting Accounting Firms and Rules forConducting Risk Management Committee Meetings, forming a more scienti?cally sound institutional framework.
In 2024, the Company continued to provide training to all board members covering areas such as internal control management,regulatory compliance, standard operational procedures, and information disclosure, thereby enhancing their governance capabil-ities.
The Company values diversity among its board members by considering multiple factors such as gender, age, cultural background,educational quali?cations, professional experience, skills, and knowledge when selecting candidates. Additionally, in accordancewith laws and regulatory requirements, Bloomage Biotech appoints independent directors; revisions to the System for IndependentDirectors were made in 2024. The directors possess diverse backgrounds in biomedicine, skincare products, risk management,?nancial accounting, law, and sustainability, which facilitates informed decision-making in a complex market environment.
Convened
2 meetings
Board Structure at Bloomage Biotech
Bloomage Biotech Compliance Management Structure
Convened
5 meetings
Convened
3meetings
Board of Directors
Bloomage Biotech is committed to continuously enhancing its legal compliance capacity to avoid any regulatory penalties. TheCompany has established an institutionalized, standardized, and regulated compliance management system that instills the princi-ples of “law-abiding compliance and integrity” among all employees and conducts promotional activities related to complianceinitiatives. Furthermore, we adhere strictly to rigorous tax-management principles, ensuring timely and lawful tax contributionsnecessary for stable operations.
Compliance Management
NominationCommittee
Audit Committee
Remunerationand AssessmentCommittee
StrategyCommittee
RiskManagement
Committee
ESG Committee
Board of Directors
Shareholders' Meetings
Leadership BodyBoard of Directors
Primary Responsible Person in
Compliance ManagementTop Managers
Compliance ManagerChief Compliance O?cer
Second Line of Defense inCompliance Management
Legal Center and RiskManagement Center
All Employees
First Line of Defense inCompliance Management
Departments andBusiness Lines
Third Line of Defense inCompliance Management
Audit and Inspection Center
Board of Supervisors
Bloomage Biotech adheres to relevant laws and regulations, as well as the ISO 37301 standards, to establish a robust compliancemanagement framework. The Company has developed internal policies, including the Compliance (Anti-Bribery) ManagementRegulations and the Employee Compliance and Anti-Bribery Handbook. These policies are applicable to all employees and are designedto e?ectively manage external partnerships.The compliance management structure is coordinated by the Legal Center, which is responsible for overseeing and planning allcompliance-related activities. A Chief Compliance O?cer has been appointed to this role, ensuring that there are no con?icts ofinterest in key operational areas such as market development, operations, and procurement. In addition, we have included theCompany's compliance system and major compliance risk prevention and control within the scope of audit supervision.
To enhance its compliance management capabilities further, Bloomage Biotech has implemented systematic and process-orientedmethodologies that provide clear rules and guidelines for compliance throughout all operational phases. The Company hassuccessfully achieved ISO 37301 certi?cation for its compliance management system and undergoes annual surveillance audits tocon?rm the ongoing e?ectiveness of this certi?cation.
Compliance Management System
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement2024 Sustainability ReportAbout Us
2221
Identifying strategic compliancepriorities aligned with corporatedevelopment frameworksResponsible for formulating andoptimizing corporate compliancemanagement systems andprocesses, developing corporatecompliance management tools,promoting complianceknowledge sharing plans, andsubmitting annual compliancemanagement strategies
Launching complianceinitiatives, implementingcompliance inspections, andproviding relevant improve-ment suggestions based onthe inspection results toensure the compliance ofbusiness activities
Compliance Obligations andRisk Management
Daily Compliance Management and
Compliance Culture DevelopmentEstablishment of Compliance
Framework and PoliciesCompliance Management System of Bloomage Biotech
Bloomage Biotech's Tax Management Measures
Bloomage Biotech's Compliance Training Plan
Bloomage Biotech has developed a comprehensive compliance training plan, categorized into three programs: general compliance,key personnel training, and critical regulations training. This plan is designed to encompass all employees while providing special-ized compliance training for key departments and critical positions. Personnel in key positions, including senior management,purchasing managers, and ?nance and sales personnel, are required to complete the training on the Employee ComplianceHandbook within 30 days of joining the Company. The Company delivers compliance training programs through diversi?edchannels, including live webinars, on-site workshops, and a dedicated e-learning platform, with assessments including exams,questionnaires, and attendance checks. This multi-dimensional approach enables the organization to objectively measure employ-ees' comprehension of compliance requirements and their ability to apply knowledge in practical scenarios.
In 2024, Bloomage Biotech implemented multi-faceted compliance training programs covering various specialized topics inalignment with business operations and systemic requirements. These encompassed Compliance Management System Develop-ment, Bribery Risk Mitigation, Criminal Compliance, and Interpretation of the Revised Company Law. Notably, we engaged externallegal experts specializing in commercial law and anti-corruption to deliver lectures on the Revised Company Law and criminalcompliance frameworks.Furthermore, the Company formulated the Compliance Performance Data Collection Management Procedures and Compliance Assess-ment & Evaluation Management Procedures, establishing a comprehensive performance measurement mechanism. Evaluationoutcomes are systematically linked to business units, individual employees, and third-party partners, with correspondingincentives or disciplinary actions implemented to cultivate a robust compliance culture within the organization.
In addition to formal training programs, Bloomage Biotech cultivates a compliance-oriented culture through regular awarenesscampaigns, including compliance-themed poster promotions and compliance knowledge competitions. All employees are requiredto sign a Compliance Commitment Letter to rea?rm their adherence to the Company's ethical standards. Furthermore, theCompany conducts targeted training sessions for third parties (e.g., suppliers) when necessary, ensuring broader dissemination ofits compliance principles and policies.
Compliance Culture Development
Bloomage Biotech strictly complies with tax laws and regulations, and has established and regularly updates tax managementsystems such as the Tax Internal Control Manual. The Company ensures continuous oversight of tax policy implementation throughmeasures including a tax risk monitoring mechanism, tax emergency management protocols, and regular communication with taxauthorities. This systematic approach underscores its proactive ful?llment of tax obligations.
For further insights into the Company's tax management practices, please refer to the Bloomage Biotech 2024 Annual Report.
Tax Compliance Management
Each business department is responsible forthe collection of compliance obligations withinits operational areas to create a comprehensivecompliance obligation and risk list
Responsible for collaboratingwith various departments todevelop compliance workplans that include corporatecompliance inspectionprocesses as well as traininginitiatives
Establish a real-time monitoring and alert system utilizing digital platforms to oversee all tax-relat-ed operations, including ?lings and compliance activitiesMaintain a risk-tracking register to document and follow up on all tax alert noti?cations
Develop tiered contingency plans and communication strategies according to incident severity levelsConstitute a crisis management team composed of C-suite executives, tax directors, ?nancemanagers, and legal counsel to handle urgent tax contingencies
Designate Tax Liaison O?cers (TLOs) undergoing mandatory training programs for end-to-endcoordination with tax authoritiesEstablish a regular communication mechanism with the competent tax authorities, includingstructured face-to-face dialogues and feedback loops
Aggregating departmental information toidentify enterprise-level compliance risks, withrelevant departments to assess risk levels, andformulating response plansConducting regular monitoring of compliancerisk indicators along with early-warning signalsand providing ongoing reports regardingcompliance risk management to the manage-ment, the Risk Management Committee, andthe Board of Directors
2024
The signing rate ofCompliance Commitment Letter
100%
Conducted
3 compliance
training sessions
Coverage forkey personnel
100%
Key Performance
Tax Risk Prevention
Tax EmergencyManagement
Tax ComplianceCoordination
Compliance GeneralKnowledge Training Sessions
For all employeesCovering foundational topicssuch as the employeecompliance handbook, basicknowledge of compliancemanagement, compliancewarning and education, non- compliance cases, andreporting channels
Targeted Trainingfor Key PersonnelFor employees inpharmaceutical, rawmaterialother businessesCarrying out trainingon high-risk compli-ance topics in line withactual business needs
Key Systems Training
Compliance Culture
Development
Supplier Compliance
Training ProgramsFor all employeesConducting compliance(anti-bribery) manage-ment system training,third-party (businesspartner) risk manage-ment training, etc.
For all employeesCovering diverseonline and o?ineengagementinitiatives such aseducational postercampaigns, quizzes,and festive activities
For suppliersIntroducing theCompany's compli-ance philosophy aswell as governanceprinciples applicableto business partners
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement2024 Sustainability ReportAbout Us
2423
In 2024, Bloomage Biotech comprehensivelyupdated its Risk Management Regulations andformulated three critical processes, includingthe Enterprise Risk Framework and the PolicyDevelopment Guidelines. These initiatives aim toinstitutionalize a science-driven and systematicrisk governance mechanism, ensuring thee?ectiveness of the overall risk managementprocess.To cultivate an enterprise-wide risk manage-ment culture, Bloomage Biotech has imple-mented a multi-tiered risk management trainingprogram across all organizational levels. Thisinitiative encompasses customized courses andproject-based learning initiatives designed forboard directors, supervisory committeemembers, C-suite executives, mid-level manag-ers, and frontline operators, with the objectiveof enhancing the skills, capabilities, and exper-tise of risk management personnel.
Internal Control andRisk Management
Bloomage Biotech is committed to continuously re?ning its risk management framework and internal control systems. The Compa-ny conducts regular internal audits and inspections to evaluate the e?ectiveness of these systems in managing compliance risks.By strengthening its risk-emergency management capabilities, the Company proactively identi?es potential risks while establishingcontrols necessary for promoting sustainable growth and stability in its operations.Risk ManagementIn 2024, to further advance the implementation of risk management practices, Bloomage Biotech formulated and publiclydisclosed the Rules of Procedure for the Risk Management Committee, establishing a top-down governance framework. Under thisstructure, the Board of Directors, as the supreme decision-making authority, holds ultimate accountability for the e?cacy of riskmanagement.
Risk Management System
In alignment with its business management and operational practices, Bloomage Biotech categorizes risks into ?ve primary types:
strategic risks, ?nancial risks, market risks, operational risks, and legal-compliance risks. This categorization forms a comprehen-sive risk classi?cation framework that underpins the Company's risk management strategy. In 2024, the Company further re?nedits risk mapping framework and established a robust risk reporting mechanism. As a result, the Company produced essentialinternal documents, including the Quarterly Risk Monitoring Report, Annual Risk Management Report, and Risk Management Matrix.Bloomage Biotech maintains a dynamic risk identi?cation process that systematically evaluates and ranks risks using quantitativeseverity matrices. This enables the prioritization of material risks requiring immediate mitigation. Cross-functional teams aremobilized to develop risk mitigation action plans and re?ne strategies for managing critical risks.In 2024, the Company implemented risk management initiatives across all business units, with a dedicated focus on work safety,product quality, and procurement management. This strategic alignment embeds risk-conscious decision-making into corebusiness processes, supported by systematic risk pro?ling, analytical evaluation frameworks, and continuous management optimi-zation cycles. Additionally, the Company seamlessly incorporated ESG considerations into its daily risk management practices. Inthis regard, 13 ESG-related risks were identi?ed, encompassing key issues such as climate change response; pollutant and wastemanagement; employee rights; product quality; and supplier oversight.
Risk Identi?cation and Response
Bloomage Biotech places strong emphasis on the standardized management of emergency incidents to ensure the sustainabledevelopment of the Company and maintain its corporate image. In 2024, the Company formulated and issued the EmergencyManagement Measures. These measures clearly de?ne the scope, classi?cation criteria, and management procedures for variousemergency incidents across multiple business domains, including brand-related public opinion management, product qualityassurance, pharmacovigilance, safety and environmental compliance, and information security. Each relevant business unit isrequired to develop speci?c emergency response plans in accordance with their respective operational requirements.Additionally, Bloomage Biotech established a company-wide Emergency Response Leadership Team led by the CEO. This team istasked with actively addressing unexpected events in accordance with the Emergency Management Measures. The team is responsi-ble for promptly implementing appropriate reward and punishment mechanisms while e?ectively preventing and managingemergency incidents.
Risk and Emergency Management
Executive Management
Risk Management CenterAudit and Inspection Center
Risk Responsibility Departments
BloomageBiotech’s threelines of Defense inRisk Management
Board of DirectorsAudit CommitteeRisk Management Committee
Bloomage Biotech Risk Management Structure and Supervision Mechanisms
The Company has implemented the Three Lines of Defense (3 LoD) model. Each line ful?lls its designated responsibilities whilesynergizing to form a multi-tiered, cohesive, and mutually constrained operational mechanism. This integrated approach ensurescontinuous monitoring and systematic management of diverse risks across the organization.
Serving as the second line ofdefence, this center coordinatesgroup-wide risk governancethrough formulating institution-al frameworks for risk manage-ment, developing risk ratingcriteria, driving digital transfor-mation of risk managementsystems, and implementingdaily monitoring and correctiveaction tracking
As the third line of defence in thismodel, under the supervision ofthe Board’s Audit Committee,this center independentlyconducts audits and assessmentson the e?ectiveness of theGroup’s risk managementframework. The audit results,identi?ed issues, and improve-ment recommendations areperiodically reported to the AuditCommittee
Risk ResponsibilityDepartments
Risk Management Center
Audit and InspectionCenter
In 2024
Conducted
risk managementtraining sessions
Reaching over
2,000employees
Key Performance
Bloomage Biotech continuously assesses and enhances its internal control system to ensure its robustness and e?ectiveness. In2024, the Company formulated the Economic Responsibility Audit Management Regulations and revised the Internal Audit ManagementSystem. This marked a signi?cant step in re?ning its internal audit framework and enhancing audit e?ciency and quality. In 2024,phased internal special audits were conducted across core management areas, including procurement, production, sales, R&D,investment, performance evaluation, and EHS. These audits aimed to identify any potential de?ciencies that could impact theCompany's operational development. Fortunately, no signi?cant de?ciencies were uncovered.
Internal ControlAs the ?rst line of defence,these departments are respon-sible for risk prevention andcontrol within their operationalscope. Key duties includeconducting risk informationcollection and identi?cation, andmaintaining updates to the riskmanagement matrix
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
All business departments, including
branches and subsidiaries
2024 Sustainability ReportAbout Us
2625
Bloomage Biotech remains steadfast in its commitment to upholding high standards of business ethics. The Company prioritizesthe prevention of corruption, bribery, unfair competition, con?icts of interest, and other fraudulent activities. To this end, Bloom-age Biotech continuously strengthens its business ethics system, enhances its complaint and reporting mechanism, and rigorouslyoversees matters related to business ethics, such as integrity in operations, anti-corruption initiatives, and complaint handling. Thiscomprehensive approach ensures that any form of corruption and unfair competition is avoided.
Business Ethics
Bloomage Biotech is committed to strict compliance with applicable laws and regulations, including the Anti-Monopoly Law of thePeople's Republic of China and the Anti-Unfair Competition Law of the People's Republic of China. The Company has established clearbehavioral principles and standards concerning anti-bribery, anti-fraud, con?ict of interest, anti-unfair competition, responsiblemarketing, and commercial con?dentiality. This governance framework requires all employees to adhere to these standards as abinding obligation. Bloomage Biotech requires all employees to sign a con?rmation form for the Professional Ethics and ConductGuidelines. Any behaviour that violates relevant professional ethics regulations, once discovered by the Company, will be subject toverbal warnings, written warnings, contract termination, or other corresponding penalties.
The Employee Compliance and Anti-Bribery Handbook clearly outlines compliance norms for individual employees, sales operations,and customer interactions. This handbook includes professional ethics that all employees are required to adhere to upon joiningthe Company and throughout their employment. Additionally, it speci?es ethical business conduct expectations for employees incritical roles such as sales and procurement when engaging with third-party partners.Moreover, the Code of Professional Ethics and Conduct delineates the following responsibilities of all employees towards the Compa-ny, customers, and the market:
Respect for every employeeProhibit using one's position forpersonal gain, accepting unrea-sonable hospitality from suppli-ers, purchasing to achieve sales,or making payments for specialfavorsProhibit using company assetsfor activities unrelated to workAdhere to safety and health-re-lated rules and policies tomaintain workplace safety
Professional Ethics
Bloomage Biotech is resolutely opposed to all forms of corruption, bribery, and other unethical behaviors. The Company strictlycomplies with national policies and regulations such as the Anti-unfair Competition Law of the People's Republic of China and hasformulated systems including the Anti-Corruption and Anti-Fraud Regulations and the Anti-Commercial Bribery Compliance Guidelines.These systems cover anti-corruption, anti-fraud, anti-unfair competition, and con?ict-of-interest management guidelines. In 2024,Bloomage Biotech conducted internal audits focusing on anti-bribery, anti-fraud, and anti- corruption across key areas like salesand purchasing within its domestic subsidiaries, to assess the implementation of relevant policies.
In terms of bribery risk management, the Company has identi?ed four key areas of concern: 1)Interactions with government o?cials; 2) Interactions with distributors, agents, and other transac-tion-in?uencing parties; 3) Interactions with medical institutions, hospitals, and other transac-tion-in?uencing entities; 4) Sponsorships and donations to hospitals or medical institutions. Toaddress these concerns, the Company has clearly outlined employee conduct guidelines in theAnti-Commercial Bribery Compliance Guidelines, covering both prohibited and permitted activitieswithin these areas.In 2024, the Company established a con?ict of interest declaration mechanism, requiring allemployees to regularly declare their personal con?ict of interest situations. During the reportingperiod, the coverage rate of employee con?ict of interest declarations at Bloomage Biotech was100%.
In our external collaborations, the Company includes compliance commitment letters (coveringclauses on good-faith cooperation, ?nancial compliance, and anti-commercial bribery) in allprocurement contracts, thereby establishing clear business ethics requirements and responsibili-ties with suppliers and other partners.
To build a culture of integrity and clean governance, we regularly provide anti-corruption andanti-bribery training to board members, management, and all employees. In addition, specializedtraining programs are provided for high-risk positions, such as marketing. In 2024, the Companyconducted three training sessions on compliance and anti-fraud requirements for all employeesand incorporated special lectures on anti-corruption and anti-bribery within the framework ofcriminal compliance training. Furthermore, the Company disseminates educational and aware-ness-raising materials on anti-corruption and anti-bribery through its internal journals, aiming tostrengthen all employees' commitment to ethical conduct and integrity.
The Company has established a comprehensive business ethics management system comprising the Board of Directors, AuditCommittee, and relevant departments. The Board of Directors assumes overall responsibility for overseeing and coordinating allaspects related to business ethics. To ensure the continuous and e?ective operation of our anti-bribery framework, we annuallyengage a third-party certi?cation agency to conduct an ISO 37001 Anti-Bribery Management System Certi?cation Audit.
Anti-Bribery Management
Bloomage Biotech's Business Ethics-Related Systems (Selected)
Excerpt from theManager's Red LineBehavior - 12 Articles
Keep con?dentiality of all clientinformationProhibit unauthorized disclosure;timely notify potential con?icts ofinterest to relevant partiesCarefully select business partnersand clients
Fairly trade with the Company'scustomers, suppliers, and compet-itorsProhibit manipulation, conceal-ment, damage, defamation, abuseof proprietary information, or falsereporting of signi?cant factsProhibit providing illegal, improper,or suspicious payments or promis-es to others for undue bene?ts
Responsibilitiesto the Company
Responsibilitiesto clients
Responsibilitiesto the market
Code of Professional Ethics and Conduct, Employee Compliance and Anti-Bribery Handbook, Compliance (Anti-Bribery)Management Regulations, Bloomage Biotech Anti-Corruption and Anti-Fraud Guidelines, Management Measures for Compli-ance Reporting, Investigation and Handling, Manager's Red Line Behavior - 12 Articles, etc.Anti-Commercial Bribery Compliance Guidelines, Sales Personnel and Sales Conduct Management System, Business PartnerCompliance Management Measures, Compliance Guidelines for Interactive Engagements (Including Conferences, Exhibitions,and Sponsorships), etc.Code of Ethics in Dealing with External Partners
Code of Ethics for Employee Personal Conduct
Falsi?cation
Misappropriation of company property
Misappropriation of public funds,private borrowing of funds,or unauthorized guarantees
Unauthorized loans or credit sales
Speculative use of enterprise funds
Disclosure of company trade secrets
Doing business with relatives that
harms company interests
Unauthorized part-time
work for remuneration
Provocation or causing troubles
Dereliction of duty or gross negligence
Spreading illegal or reputation-damag-ing remarks that a?ect the Company's
reputation, brand image, ororganizational unitySoliciting bene?ts from partners,customers, subordinates,or a?liated companies
In terms ofbribery riskmanagement
In terms ofcon?ict of
interestmanagementIn terms of theconstruction ofintegrity culture
In terms of
externalcollaborations
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
2024 Sustainability ReportAbout Us
2827
In 2024Key Performance
Bloomage Biotech encourages joint supervision and integritymaintenance among employees, clients, suppliers, and otherstakeholders. We've established a regular reporting and investi-gation mechanism for compliance violations through ourManagement Measures for Compliance Reporting, Investigation andHandling. Reportable matters include, but are not limited to,violations of laws and regulations, as well as breaches of businessethics such as acts of dishonesty, fraud, corruption, unfaircompetition, and other unethical conduct.We have established a wide range of complaint and reportingchannels, including telephone, email, and on-site complaints,which are publicized to all employees, distribution clients, andsuppliers. In 2024, Bloomage Biotech successfully managed theresponse to reports and executed special investigations with a100% handling rate.To protect the privacy and security of whistleblowers e?ectively,the Company has standardized the management of whistleblow-er information. This includes safeguarding personal details,reporting content, and communication methods. Any form ofretaliation against whistleblowers is strictly prohibited. A dedicat-ed reporting email address has been established for thispurpose. This email is maintained by designated personnel whoensure that all communication with whistleblowers remainscon?dential and limited to one-on-one interactions only. Forveri?ed reports that lead to substantiated ?ndings againstaccused parties or misconducts identi?ed through these reports,appropriate disciplinary actions will be taken. Furthermore, inaccordance with our reward system policies, we may providewhistleblowers with material or moral incentives as recognitionfor their contributions in identifying unethical behavior.
Whistle-blowing ManagementMechanism
Embezzlement lawsuitsinvolving Bloomage Biotech orits employees were ?led andconcluded
Conducted
company-wide anti-bribery riskassessment
Speci?cally
Specialized anti-briberytraining sessions were heldAchieving
100%
coverage of key position holders
Managers participated
The signing rate of theproduction materials suppliercompliance commitment letter
100%
Emailjubao@bloomagebiotech.comTel010-85670099-1503
Reporting Channels
Whistle-blowing Work?ow Process
Collect whistle-blowinginformationClassify whistle-blowing recordsAnalyze and sort out informationEstablish an investigation team
File a recordReconsider, respond and handle
Parties appealif there is any objectionHandle the investigation result
Maintaining robust information security measures and privacy protection is fundamental for fostering long-term cooperationbetween Bloomage Biotech and its business partners, customers, as well as employees. We are committed to continuouslystrengthening our information security management frameworks as well as our customer privacy protection mechanisms tocomprehensively safeguard the data security concerns related to all stakeholders involved.
Cybersecurity and Privacy
Bloomage Biotech strictly adheres to relevant laws and regulations and has developed comprehensive information security anddata protection policies, including the Information Security Risk and Emergency Management System and the Information SecurityControl Policy, in alignment with the ISO/IEC 27001 information security management standard. The Company is committed tocontinuously enhancing its institutional framework for information and data security, thereby e?ectively managing data protectionacross all business operations.
The Company has established an e?ective information security management system through ?ve key perspectives: organization,management, technology, training, and supervision. The Information Security Management Committee oversees and coordinatesthe Company's e?orts in this regard, with dedicated departments entrusted to execute information security protection strategiesand procedures. In 2024, Bloomage Biotech successfully obtained ISO 27001 certi?cation for its information security managementsystem. Annual reevaluations were conducted for two critical systems—the anti-counterfeiting and traceability system and the rawmaterials portal system—both of which passed a second-level information security assessment.
Furthermore, Bloomage Biotech has developed a Privacy Policy, which is published on our o?cial website. This policy outlines keyelements such as our usage authorization strategies, data retention periods, as well as individuals’ rights regarding accessing,correcting, or deleting their personal information. Moreover, in collaboration with third parties and business partners, the Compa-ny strictly adheres to laws and regulations, requiring third parties to sign agreements and implement necessary security measuresto handle relevant user personal data in accordance with privacy policy requirements. In 2024, no incidents involving violations ofinformation or data security were reported within the Company.
The Company actively encourages employees in relevant positions to pursue professional certi?cations in information security tocontinuously enhance their expertise. As of the end of 2024, three members of our information security team have obtainedCerti?ed Information Security Professional (CISP) national certi?cation while one member has achieved Certi?ed InformationSystems Auditor (CISA) international certi?cation.
Only open ports that are essential forbusiness functions to mitigateunnecessary network exposure.
Management System
Excerpt from the Management Regulations for Public
Internet Access of Information Systems
Ensure that users and services aregranted only the minimum privilegesnecessary to perform their tasks, thusreducing potential security risks.
Principle of Least Privilege Access
Conduct regular security assessmentsto identify and rectify vulnerabilitiespromptly, ensuring ongoing networksecurity.
Regular Security Audit Principle
Enhance authentication processes toguarantee that only authorized usersor services can access applications,thereby preventing unauthorized
access.
Strict Authentication Mechanism
Allow access requests solely fromtrusted sources or veri?ed IP address
ranges to strengthen network
perimeter defenses.
Trusted Source Access
Control Principle
Maintain comprehensive records of allapplication access activities, includingaccess time, source, and targetinformation for e?ective traceability
and auditing purposes.
Access Log Recording Principle
Essential Port-Opening Principle
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement2024 Sustainability ReportAbout Us
Bloomage Biotech has implemented a comprehensive array of measures to enhance information and data security protection,thereby solidifying the foundation of network security and ensuring the stability and security of our information systems.
We have established independent reporting channels for complaints that are managed by a dedicated team within the Company.Strict measures ensure the protection of personal information related to reporters/complainants with guarantees against retalia-tion:
Safeguard Measures
Bloomage Biotech strictly complies with laws and regulations such as the Measures for the Administration of Information Disclosureby Listed Companies issued by regulatory authorities. In 2024, the Company revised the Information Disclosure Management Systemand the Investor Relations Management System to continuously enhance information disclosure management capabilities andprotect the rights and interests of investors and other stakeholders.We adhere strictly to principles such as authenticity, accuracy, completeness, timeliness, and fairness when disclosing information,ensuring that investors can access timely updates about company activities. Multiple channels have been established, ranging fromlarge-scale public communication e?orts through strategy meetings organized by securities ?rms; receiving investor researchinput; conducting teleconferences; utilizing SSE e-interaction Platform; holding roadshows; all designed to foster robust communi-cation between investors and Bloomage Biotech while enhancing transparency regarding company operations.
Investor Rights Protection
In 2024
Publishedannouncements
Achieved the highest rating ofGrade A in the annual informationdisclosure evaluation conducted bythe Shanghai Stock Exchange
Participated in compiling the 2023 Annual ChinaListed Companies Investor Relations White Paper,jointly released by Roadshow China, IR ResearchInstitute, and other supporting institutions
Held earningspresentationmeetings
Hosted investor researchactivities or conferenceexchanges
Measures for Protection of Bloomage Biotech's Information Security
Use of Information-Security Technologies
Personal Information Protection Complaint and Reporting Channel: privacy@bloomagebiotech.comInformation Security Violation Reporting and Feedback Channel: CSIRT@bloomagebiotech.com
Internally, we utilize security center plugins provided by cloud service providers, which are deployed on our key serversWe conduct regular vulnerability scans with the assistance of external security operation and maintenance servicesWe employ web application ?rewalls to safeguard and reinforce websites that provide public services
Information Security Risk AssessmentWe conduct monthly penetration tests in critical plant areas, covering critical servers within our networkWe comprehensively identify and analyze risks and vulnerabilities across various aspects such as company networkinfrastructure, data storage, transmission and processing. Moreover, based on assessment results, we establishcorresponding plans and corrective measures to continuously enhance data security
Monitoring of the Information Security SystemWe ensure internal applications are deployed in strict isolation from those that provide public accessAccess to internal applications is granted only after rigorous identity veri?cation processes are completedPublicly accessible applications bene?t from protective measures implemented by cloud service providers
Information Security Emergency ManagementWe have established a Computer Security Incident Response Team (CSIRT) to coordinate responses to technical issuesrelated to computer security incidentsA reporting procedure is in place for individuals who discover violations; they can promptly report these issues tomanagement or the CSIRT
Promotion of Information Security AwarenessTraining on port-opening procedures including procedure requirements, operational guidelines, and best practicesis provided for network administrators and system administratorsIn November 2024, we organized an online “Data Security Awareness” training event tailored for all employees. Thistraining focused on key points regarding data protection practices applicable in daily work. Throughout the year,1,249 employees participated in information-security training sessions
Key Performance
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement2024 Sustainability ReportAbout Us
Driving Forces: R&D Innovationand Quality ManagementBloomage Biotech is committed to advancing in fundamental biologicalresearch, focusing on glycobiology and cell biology. By leveraging the advan-tages of industrial transformation in synthetic biology, we provide innovativescienti?c solutions for health and well-being. The Company initiates itsoperations from the upstream R&D of biomaterials, seamlessly integratingraw material production with brand development to establish a comprehen-sive transformation pathway for biomaterials. We rely on technologicalinnovation, the expansion of materials and solutions, achievement transfor-mation, intellectual property protection, and collaborative e?orts betweenindustry and academia to strengthen our scienti?c foundation. Simultane-ously, we conduct in-depth quality research while gaining insights intomarket demands to deliver high-quality products and services.SDGs Addressed in this Chapter
Major Material Topics of Sustainability Covered in this Chapter· R&D Innovation· Product Environmental Impact· Industrial Cooperation and Development· Research Ethics· Product Quality
· Healthcare Availability· Client Service· Information Security· Intellectual Property Protection
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement2024 Sustainability ReportAbout Us
Bloomage Biotech places a high value on independent research and development as well as the successful transformation ofinnovative outcomes. We have established a robust innovation system that prioritizes green and sustainable practices while adher-ing to scienti?c ethics. Our focus also includes protecting intellectual property rights and fostering industry collaboration topromote high-quality development within both our company and the broader industry landscape. Rooted in the foundationalscienti?c principles of glycobiology and cell biology, we are dedicated to achieving groundbreaking innovations in bioactivesubstances through cutting-edge technologies such as synthetic biology and regenerative medicine. Our goal is to diversify producto?erings while expanding application scenarios that meet consumers' personalized needs, realizing Smart Biomanufacturingacross six major categories of bioactive substances.
R&D Innovation
Bloomage Biotech has established an evolving product-planning-and-development management system that centers on marketdemands as well as customer needs. We have implemented an Integrated Product Development (IPD) management system aimedat shortening product development cycles, enhancing the e?ciency with which R&D results are transformed into market-readyproducts, and ultimately improving market performance by bridging gaps between market insights and research e?orts.
R&D Management System
Bloomage Biotech has built a global R&D platform, integrated innovative resources and established a system for key biomanufac-turing technologies. The Company focuses on the R&D, innovation, and production of 6 categories of biologically active substancesrelated to human health, including functional sugars, proteins, peptides, amino acids, nucleotides, and natural active compounds,covering the entire industry chain from cell construction to commercial applications.The Company places high emphasis on fundamental research and applied fundamental research, and has eight R&D platforms,including Synthetic Biology R&D Platform, Functional Saccharides R&D Platform, Cell Biology Research Platform, RegenerativeMedicine Research Platform, Pilot Conversion Platform, Application Mechanism R&D Platform, Material Functionalization Technol-ogy Platform, and Formulation Development Platform. Through AI-enabled functional integration and intelligent upgrades, theseplatforms span the full product lifecycle from cell construction to commercial applications. This establishes a full industry chainbusiness system covering bioactive materials, medical end products, innovative transformation of dermatology, and innovativetransformation of nutritional science, solidifying competitive advantages in core technology development and commercialization.
Innovation Platform Development
In June 2024, Bloomage Biotech completed the construction of its Pilot-Scale Results Transformation Center. This platform, with a totalinvestment of RMB several billion yuan, spans an area of 30,000 square meters and is equipped with 64 pilot-scale production lines. Itencompasses the entire process from fermentation and puri?cation to re?ning, enabling the Company to undertake pilot-scale andsmall-scale commercial production of various bioactive raw materials for pharmaceutical-grade, skincare-grade, and food-gradeproducts.The platform is characterized by its ?exibility, platform-based operation, and digitalization. It adopts an open cooperation modelfeaturing modularization and drawer-type approaches across the entire industry. Bloomage Biotech actively provides a range of services,including pilot-scale maturation, experimental validation, inspection, and testing, to universities, research institutions, enterprises,investment ?rms, as well as public service sectors, supporting the industrial and market transformation of research achievements.
Case
the Construction of the Pilot-Scale Results TransformationCenter Completed by Bloomage Biotech
As of the end of 2024
National HighTech Enterprises (NHTEs)
Provincial-Level Specialized,Sophisticated, Distinctive,and Innovative (SSDI) EnterpriseR&D Investment
466 million RMB
4.46 %
increase over last year
8.68 %
of R&D investment to revenue
invention patentsdirectly related to our corebusiness functions
of R&D professionals
20.70 %
of total employees
Bloomage Biotech Pilot Scale Results Transformation Center
Key Performance
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement2024 Sustainability ReportAbout Us
3635
Bloomage Biotech has established the R&D Management Committee led by our Chairwoman with participation from senior execu-tives and core technical managers. This committee oversees all aspects of our R&D system management and has created a globalR&D platform to facilitate business-oriented operations through the introduction of an Integrated Product Development (IPD)management system. This approach breaks down barriers between di?erent R&D units by establishing a project-oriented person-nel deployment mechanism that enables e?cient human resource utilization.
The Company strictly complies with laws and regulations including the Law of the People's Republic of China on Promoting theTransformation of Scienti?c and Technological Achievements, Safety Management Measures for Biotechnology Research and Develop-ment, Measures for Drug Registration, and Regulations on the Supervision and Administration of Cosmetics. We consistently update andimplement internal systems such as the Pilot-Scale Testing and Trial Production Control Procedures, R&D-to-Production TechnologyTransfer and New Product Introduction (NPI) Governance Framework, Design and Development Control Procedures, Patent ManagementRegulations, and Patent Incentive Measures. These e?orts contribute to establishing a robust and standardized R&D project manage-ment framework, continuously re?ning evaluation criteria for scienti?c achievements and talent incentive mechanisms. Further-more, the Company has developed a series of research project management regulations to ensure that relevant activities areconducted legally and compliantly throughout project initiation, development, review and other stages.
R&D Management Structure and Systems
In 2024
number of R&D projects
participated in national andprovincial key R&D projects
Grounded in a comprehensive and advanced R&D system, Bloomage Biotech prioritizes green sustainable innovation, integratingconcepts related to environmental protection, health, and safety in every phase involved in developing new substances, technolo-gies, materials, and processes. The Company actively explores profound synergies between biotechnology and sustainabledevelopment. This commitment aims to promote green transformations within industries while ensuring ecological harmony.
Sustainable Innovation
Bloomage Biotech leverages scienti?c principles and e?ective biomanufacturing technologies characterized by safety-focuseddevelopment. It aims to develop formulations/products that do not contain toxic elements and have low toxicity levels. Theseformulations exhibit lower impurity levels while maintaining high purity and meeting high stability standards. We integrate sustain-ability throughout our product development process.
Product & Solution Innovation
We implement source substitution and green processes by replacing virgin materials with recycled alternatives whenever feasible.Our commitment extends to prioritizing low-toxicity and environmentally friendly reagents and consumables in our operations. Weactively utilize biobased carbon sources and innovate packaging applications to minimize negative impacts on the environment,ecology, biodiversity, and human health throughout the entire product life cycle. In doing so, we not only contribute to environ-mental protection but also foster the development of new quality productive forces. Additionally, we harness arti?cial intelligencetechnology to predict substance e?cacy, screen potential active ingredients, develop di?erentiated products, unlock new function-alities, and expand solution scenarios.
Bloomage Biotech, focusing on environmental protection and quality enhancement, conducted a systematic study on the potentialissues of biodegradable material Bio-PE during prolonged contact with cosmetics. Through dedicated material modi?cation studies, theCompany successfully optimized Bio-PE for application in single-use packaging materials. This innovation signi?cantly reduces theconsumption of non-biodegradable plastics and advances the sustainable development of the beauty industry.
CaseResearch on Biodegradable Materials in Single-Use Packaging
In 2024, Bloomage Biotech developed an eco-friendly polyole?n ?lm packaging that complies with international standards. This packag-ing utilizes a single-material design, achieves over 90% recyclability, and generates no toxic or harmful emissions during incineration. Thesuccessful development of this packaging has accelerated the Company's sustainable innovation and development, enabled customersto embrace the green concept, and set an example of sustainable development for the industry.
CaseDevelopment of Eco-Friendly Packaging to Empower Customer Sustainability
Our upgraded emulsi?cation technology reduces energyconsumption by approximately 10% while cutting chemicalreagent usage (e.g., methylene chloride & ethanol) by over50%, further enhancing both product safety and environmen-tal sustainability.The introduction of COP pre-?lled syringes (a drug-devicecombination product) into our pharmaceutical production linehas completed pilot-scale testing. This innovation reducesmedical waste processing costs and achieves an approximately80% reduction in energy consumption during manufacturing.By adopting serum-free formulations with chemically de?nedcompositions, we have signi?cantly reduced reliance onanimal-derived materials, thereby mitigating potential ecologi-cal risks associated with traditional biopharmaceutical produc-tion processes.
Implementation and Contributions of Major GreenTechnology Innovations in 2024
R&D Management Structure at Bloomage Biotech
Insights and analysis of
new technologies &materialsExploring innovativebusiness models thatexpand commercialapplications
Insights and studies on
frontier science
R&D Management
Committee
Global R&D Platform
R&D Sharing CenterProviding technical services & support through a shared service delivery platformIntellectual Property (IP) CenterManagement of IP protection, utilization, and development e?orts
Responsible for the comprehensivemanagement of the Company's R&D system
Integrated Coordination and InformationCascading
Integrated Medical Device &Pharmaceutical R&D Center
Raw Material R&D Center
Skin Science Innovation
R&D Center
Innovation Research Institute
Frontier Research Institutefor Scienti?c Insights (FRISI)
Conducting R&D management and operations across business lines
Key Performance
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
2024 Sustainability ReportAbout Us
Bloomage Biotech Creates a Fully Production and Linked Unmanned Operation Production Workshop
The Company is committed to ongoing hazard identi?cation processes, implementing measures to reduce, substitute, or prohibitcontroversial ingredients and minimize the use of preservatives. These actions enhance the safety, sustainability, and biodegrad-ability of our ingredients, thereby signi?cantly reducing their negative impact on both human health and the environment. Toachieve a balance between e?cacy and safety, we select active ingredients based on scienti?c principles. Our approach focuses ondelivering precisely targeted solutions while minimizing unnecessary active additions, ensuring a superior combination of compre-hensive e?cacy with fewer components. In addition, Bloomage Biotech conducts radioactive substance testing on products fromour MedRepair brand that contain marine-sourced raw materials. This proactive measure ensures product safety for consumers.In 2024, the Company did not receive any penalties from regulatory agencies for non-compliance with chemical usage in products.
Bloomage Biotech strictly adheres to domestic and international regulations such as the Cosmetic Safety Technical Speci?cations andthe Regulation on Registration, Evaluation, Authorization, and Restriction of Chemicals (REACH Regulation), ensuring products areregistered or certi?ed for ingredient safety, mildness, e?ciency, and natural organic properties. The Company extensively referenc-es authoritative industry and market standards to develop systems such as the Chemical Use List for Research and Development.We have established comprehensive chemical use management mechanisms to standardize the selection of raw materials for ourproducts.
Ingredient Sustainability
Bloomage Biotech has established a re?ned technical system for biomanufacturing hyaluronic acid alongside green preparationmethods. Our commitment involves continuously enhancing production designs and processes, investing in state-of-the-art equip-ment, establishing e?cient process systems, and elevating digitalization & automation levels throughout production stages. Byintegrating sustainable principles, such as environmental protection & safety into every aspect of manufacturing operations, weensure that sustainability remains at the core of our practices. We are also dedicated to exploring & deploying technologies relatedto Industry 4.0. Our AI-powered platform for rapid screening of active ingredients is widely utilized across production lines. Byoptimizing work?ows and improving management models, we drive technological upgrades and innovations within product manu-facturing processes, thereby leading the advancement of intelligent manufacturing trends.
Manufacturing Innovation
Bloomage Biotech strictly complies with domestic and international regulations and guidelines for biomedical research, includingEthical Review Measures for Life Sciences and Medical Research Involving Human Subjects, Regulations on the Management of LaboratoryAnimals (aligning with the 3R principles of Replacement, Reduction, and Re?nement in animal studies), Good Clinical Practice (GCP) forDrugs, Guidelines for Registration and Review of Animal Testing in Medical Devices, Clinical Trial Guidelines for Sodium Hyaluronate-basedFacial Injectable Fillers. To ensure systematic compliance, we have developed internal governance documents such as the TechnicalGuidelines for Cosmetic Consumer Usage Testing. We also strictly adhere to the World Medical Association's Declaration of Helsinki andregion-speci?c ethical frameworks to ensure legal and regulatory conformity of testing activities, whether conducted internally orexternally. The Company’s R&D Management Committee oversees global R&D operations to coordinate issues related to technolo-gy ethics. Additionally, we have established the Cosmetic E?cacy Evaluation Ethics Committee responsible for reviewing and super-vising ethical concerns during e?cacy assessments of functional skincare products. In 2024, the Company did not incur ?nes fromregulatory bodies for violating ethical technology testing guidelines.
Ethics in Technology
Guided by the principles of scienti?c rigor, ethical integrity, and corporate accountability, we have established rigorous assessmentframeworks that leverage cutting-edge technologies and innovative alternative testing methodologies to ensure product safety ande?cacy. Our commitment extends to systematically minimizing and ultimately replacing animal testing and human trials. We havedeveloped AOF (Animal Origin-Free) medium technology that is serum-free with no animal-derived components, signi?cantlydecreasing our dependence on animal-sourced materials. We use cell testing, ex vivo skin testing, and 3D skin model testing.Additionally, we have a subject-testing model that is entirely based on voluntary participation with a freely exercisable withdrawalmechanism, which is used in place of animal testing for e?cacy trials on functional skincare products. When designing trials formedical device e?cacy, we prioritize alternative methods to minimize the frequency of conducting animal and human clinical trials.Bloomage Biotech does not directly conduct animal or human testing and therefore has no sta? involved in animal testing or anyrequirements for the management of care or welfare for test subjects. The Company conducts thorough in-vitro evaluations on keyraw materials related to product e?cacy to replace animal testing while enhancing overall product safety. All the Company's neces-sary animal and human clinical trials are entrusted to quali?ed Contract Research Organizations (CROs) or hospitals. Contracts arein place to stipulate compliance with national regulations on trial ethics and related measures for the welfare of human and animalsubjects. They also ensure compliance with the Company's management regulations for third-party animal-testing and inspectioninstitutions, thereby ensuring that the company's responsibilities of respecting life ethics and safeguarding welfare are e?ectivelyful?lled. In 2024, Bloomage Biotech conducted regular training sessions aimed at enhancing R&D personnel's awareness concern-ing experimental ethics.
Furthermore, the Company follows and implements requirements related to AI ethics and information ethics. We use AI responsi-bly in our business operations. When utilizing AI systems, we adhere to a human-centered approach. When adopting generative-AIsolutions, we implement manual controls and conduct comprehensive evaluations of the results. Moreover, we treat data as acrucial asset and install encryption software on the o?ce equipment for all R&D personnel to further enhance the full-processcompliance control of data and information. In 2024, the Company organized three training sessions related to information ethics.
Bloomage Biotech has developed a standardized reconstructed human epidermal model, speci?cally designed for functional evaluationof cosmetics and pharmaceuticals, serving as an alternative to conventional animal testing methodologies. This innovative modeladdresses ethical dilemmas associated with such practices while overcoming human-testing bottlenecks. It shortens evaluation cycleswith precise and highly repeatable data, thereby advancing skin irritation-related applications within China’s framework for reducingreliance on animals. Additionally, this model serves as an essential platform facilitating toxicological evaluations along with pharmacolog-ical studies alongside molecular biology research focusing both raw materials and ?nished products. This initiative signi?cantly enhancesthe safety assessments of raw materials and ?nished products while ensuring the e?ectiveness of cosmetics and pharmaceuticals.
Case
Standardization of Engineered Epidermal Models and Their Applica-tion as Alternatives to Animal Testing for Skin Irritation Assessment
3837
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
2024 Sustainability ReportAbout Us
Bloomage Biotech leverages its technological innovation capabilities and technical platform advantages to implement opencooperation, actively collaborating with governments, industry organizations, research institutions, etc., to promote joint scienti?cresearch, the establishment of standardized norms, and industry knowledge popularization, driving the sustainable and healthydevelopment of related industries.
Collaborative Development
The Company places signi?cant emphasis on the in-depth integration ofindustry, academia, and research for collaborative technological innovation.Through strategic cooperation agreements, joint establishment of researchcenters, the development of advanced pilot-scale conversion platforms, aswell as applied basic research and academic discussions in related ?elds oftechnology and manufacturing, Bloomage Biotech facilitates a seamlessconnection among industry stakeholders that accelerates the transforma-tion from R&D to commercial application. In 2024, we deepened our collabo-ration within the realm of industry-academia-research partnerships, result-ing in substantial achievements. We conducted 29 projects in collaborationwith 12 universities and research institutions across diverse areas such assmall-scale process development for substance creation, quality inspectionprotocols, and e?cacy studies on various applications involving functionalsugars and amino acids.
Industry-Academia-Research Collaboration
To promote the adoption of new materials, technologies, andprocesses, as well as advanced management concepts, and toremove technological barriers that hinder the transformation ofscienti?c and technological achievements, Bloomage Biotechtakes the initiative to attend various industry associations andlead and participate in the formulation and implementation ofnational, group, and industry standards. This not only enhancesits own in?uence and discourse power but also promotes theestablishment of clear guidelines and standards for the industryto follow. Bloomage Biotech has led or participated in the formu-lation of 8 industry standards and 48 group standards. Amongthese, 12 group standards were released in 2024, including theindustry standard QB/T 4576-2023 for Sodium Hyaluronate, whichwas led by Bloomage Biotech in its revision and o?cially came intoe?ect on July 1, 2024. Additionally, the Company is currentlyinvolved in the development of 16 national, industry, and groupstandards.
Standard Setting
Bloomage Biotech has established exhibition halls in its main o?ces, factories, and R&D centers to conduct science popularizationactivities for visiting groups. Additionally, the Company actively participates in industry exhibitions and exchanges and integratesinternal and external professional resources to conduct online public education. In 2024, the Company conducted 145 scienti?cpopularization campaigns focusing on bioactive ingredients throughout the year. Meanwhile, the Company jointly developed andpublished the 2024 Scienti?c Skincare Guidelines for Oily Skin in collaboration with academic institutions and dermatology experts.This initiative delivers comprehensive solutions for consumers while advocating science-based skincare principles.
In 2024, Bloomage Biotech inaugurated its Bio-Manufactur-ing 5.0 Science and Technology Museum in Tianjin, markingthe completion of three landmark industrial exhibitionhalls: the World Hyaluronic Acid Museum, the SyntheticBiology Science Pavilion, and the Bio-Manufacturing 5.0Science and Technology Museum. These facilities employcutting-edge interactive technologies such as simulatedmodels, three-dimensional holographic projections, anddynamic light-shadow installations. Through these technol-ogies, they o?er panoramic demonstrations of hyaluronicacid applications, synthetic biology innovations. They alsoshowcase the pivotal role of bio-manufacturing in advanc-ing carbon peaking and carbon neutrality strategies. Collec-tively, they serve as an educational portal for the public toexplore the scienti?c frontiers and industrial implications ofbiotechnology. Since their respective openings, these threemuseums have hosted over tens of thousands of visitors.
Industry Popularization andCommunication
The Bio-Manufacturing 5.0 Science andTechnology Museum Was Inaugurated in Tianjin
Bloomage Biotech integrates intellectual property management into the entire product operation process. The Company has builta standardized and e?ective intellectual property management system by clarifying management policies and objectives, improv-ing management structure and resource elements, and strengthening lifecycle management of intellectual property. The Companyhas been certi?ed by GB/T 29490 intellectual property management system. As of 2024, the Company has accumulated a total of587 authorized patents, and 580 valid patents.
Intellectual Property Protection
The Executive Director of the Company’s R&D Committee is responsible for overseeing the operation and continuous improvementof the intellectual property management system. The Intellectual Property Center is tasked with providing professional expertiseand implementing speci?c initiatives related to IP management. The Company reviews the suitability and e?ectiveness of theintellectual property management system every year.Bloomage Biotech strictly adheres to current laws and regulations, referring to standards such as the Intellectual Property Manage-ment System Standard for Enterprises to formulate and enhance its intellectual property protection policies and procedures. Thesemeasures are e?ectively implemented in all aspects of IP management activities. The Company has clari?ed its principles anddivision of responsibilities for intellectual property management in patents, trademarks, copyrights and business secrets. We haveestablished clear procedures for the application, registration, utilization, management, transfer, and protection of intellectualproperty rights.
4039
Bloomage Biotech's Measures on Strengthening Intellectual Property Protection
Risk Identi?cation and Management
Bloomage Biotech has implemented a comprehensive patent search and competitor patent monitoring mechanism toconduct systematic analyses, including Freedom to Operate (FTO) at various stages such as project initiation, R&Dprogression, project completion, and pre-market launch. This mechanism enables the Company to proactively identifyand mitigate infringement risks throughout the entire product lifecycleWe have paid attention to the regional characteristics of intellectual property protection and have actively applied forinternational patents to fully protect our intellectual property and enhance our ability to respond to supply chain risks.We allocate necessary budgets every year to respond to possible intellectual property risks
The Company carries out intellectual property training activities for its employees every year, such as professionalinternal training and bi-weekly sharing sessions. In 2024, the Company carried out 9 intellectual property-relatedpublicity and training sessions, with more than 1,800 participants and more than 18 training hoursIn addition, we have actively participated in relevant external exchange activities and received investigations andresearch from relevant supervisory and management departments on our intellectual property management. Wehave also been involved in various seminars, training classes, and other activities
Awareness-raising Training and Exchange
We have clearly de?ned the requirements for rewarding and penalizing intellectual property-related matters anddecomposed the intellectual property management objectives and conducted regular assessments. In 2024, theCompany provided intellectual property-related performance incentives to 240 employees, with a total bonusamounting to RMB 1.49 million
Performance Evaluation
We have actively cooperated with police and judicial authorities in many places by assisting in handling cases ofcounterfeit production and sale to protect intellectual property rightsWe have entrusted professional third-party organizations to follow up on infringements of our trademarks, patentsand other intellectual property rights. In 2024, the Company ?led 16 rights protection litigation cases. The Companyhas not been punished by relevant competent authorities or held liable by court judgments for infringement ofothers' intellectual property rights. There have been no major infringement litigation cases of intellectual property(including abuse of a dominant position, counterfeiting and piracy)
Protection of Rights and Interests
Bloomage Biotech participated in the “2024 China-KoreaCutting-edge Biotechnology Exchange and Cooperation Symposium”,co- hosted by the Chinese Embassy in South Korea and the Korean
National Institute of Green Technology
A delegation comprising the Deputy Chair of the International Federation of
Societies of Cosmetic Chemists (IFSCC) and faculty members from theUniversity of S?o Paulo, Brazil, conducted an o?cial visit to Bloomage
Biotech World Hyaluronic Acid Museum
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement2024 Sustainability ReportAbout Us
Additionally, the Company respects the outcomes and spirit of the Declaration on the TRIPS Agreement and Public Health, and abidesby compulsory licensing requirements for public interests, public health and other purposes in the Patent Law of the PRC. Weinvoluntarily transfer relevant patents when necessary to popularize and promote technologies. In this way, the Company canbene?t more people with its innovative achievements.
Bloomage Biotech follows the quality management policy and principles of "leading technology, standardized management, safeand reliability, and professional service" with product quality always prioritized. Bloomage Biotech enhances its “OperationalExcellence and Lean” globally aligned quality management system through lifecycle management, by establishing quality standardsand objectives that surpass national regulatory requirements and industry standards, with an unwavering commitment to deliver-ing premium-quality products for global consumers. Each year, we set goals related to product inspection pass rates, ?rst-inspec-tion pass rates for ?nished products, customer satisfaction with product quality, ex-factory pass rates, and on-time delivery rates.In 2024, the Company successfully achieved all these established goals.
Quality Management
Quality Management SystemThe Chairwoman of Bloomage Biotech holds overall responsibility for product quality and safety. This includes strategic planning,the formulation of quality policies, review of quality objectives, and oversight of their implementation. Relevant quality manage-ment departments and employees collaborate closely within the Company to ful?ll their respective responsibilities e?ectively.Together, they form a robust quality assurance network that safeguards product quality and safety.
Quality Management Structure
Bloomage Biotech strictly adheres to comprehensive legal frameworks including the Law of the People's Republic of China on ProductQuality, the Drug Administration Law of the People's Republic of China, the Food Safety Law of the People's Republic of China, the Regula-tions for the Implementation of the Food Safety Law, the Good Pharmacovigilance Practices (GVP), the Cosmetics Production QualityManagement Standards, and the Medical Device Operation Quality Management Standards. The Company has established and imple-mented a systematic quality governance system encompassing the Quality, Food Safety, and HACCP (Hazard Analysis Critical ControlPoint) Integrated Management Manual and Product Monitoring & Measurement Control Procedures. This system enforces full life-cyclequality management spanning product design, R&D, manufacturing, and post-market surveillance, with clearly de?ned qualityaccountability across all stages to ensure regulatory compliance, safety, and e?cacy of products.
Quality Management Systems, Processes, and Measures
4241
Board of Directors
Monthly Reporting
Supply Chain Platform
Quality Center
Monthly Reporting
Bloomage Biotech's intellectual property licensing
Bloomage Biotech's annual trademark status
Bloomage Biotech’s Architecture for Integrated Product Quality & Safety ManagementTotal patents
Domestic trademarksTrademark rightsOverseas trademarks
???
???
?
?
???
??
???
??
???
??
??
??
??
???
Domestic patentsOverseas patentsPatentsfor invention
Number of inventionpatents applied to core
business operations
Utility model
patents
Design patents
Number of licenses in ????Number of applications in ????
Number of licenses in ????Number of applications in ????
Unit: Item
???
???
??????
???
???
Quality System Management
Department
R&D Quality ManagementDepartment
Supplier Quality Management
Department
Customer QualityManagement Department
Quality ManagementDepartments across All
Production Bases
Unit: Item
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
2024 Sustainability ReportAbout Us
Bloomage Biotech has established and continuously improved aproduct life-cycle quality management system, with the constructionof a quality management information system to drive the implemen-tation and application of digitalized and intelligent systems across allproduct lines. This initiative aims to advance comprehensive qualitymanagement practices, ensuring end-to-end quality control andsafety throughout the product life cycle.Bloomage Biotech has established a dedicated Quality Inspection &Audit Team that standardizes quality review processes, includingself-inspections and preparations for external audits. This teamsystematically conducts internal audits of the quality managementsystems at production facilities. Alongside rigorous product testingprotocols and actively collaborates with external regulatory authori-ties, accredited certi?cation bodies, and customer audits. Throughcontinuous improvement, the Company has received exemp-tion-from-inspection evaluations from some customers and haspassed MDR audits conducted by certain customers with zerodefects. In 2024, Bloomage Biotech completed a total of 147 custom-er-factory inspections and third-party audits organized by custom-ers. All of these were successfully passed, with no major quality risksdetected. General defects were promptly recti?ed.The Company has obtained the following certi?cations: ISO 9001Quality Management System, ISO 13485 Medical Devices QualityManagement System, ISO 22716 & GMPC (US) Cosmetic Good Manu-facturing Practices, EFfCI GMP Standard for Cosmetic Ingredients,Kosher Certi?cation, Halal Certi?cation, HACCP Food Safety Manage-ment System, FSSC 22000/ISO 22000 Food Safety ManagementSystem, and Laboratory Accreditation. Its high-standard productionlines comply with the requirements of US Current Good Manufactur-ing Practices (cGMP), China's GMP, and ICH Q7 Guidelines for ActivePharmaceutical Ingredients. Additionally, the Company has success-fully passed quality audits and on-site inspections conducted byregulatory authorities including the EU Medical Device Regulation(MDR), US Food and Drug Administration (FDA), South Korea'sMinistry of Food and Drug Safety (MFDS), Japan's Pharmaceuticalsand Medical Devices Agency (PMDA), and China's National MedicalProducts Administration (NMPA) for GMP compliance.
Quality Audits and Certi?cations
Bloomage Biotech establishes internal product quality and safety management procedures and systems in accordance withapplicable laws and regulations. We implement quality risk assessment and control measures to e?ectively address and managequality risks, thereby enhancing Bloomage Biotech's brand reputation through high-quality standards. The Company consistentlyidenti?es, assesses, controls, communicates, audits, and minimizes quality risks throughout its product's lifecycle to decrease thelikelihood and impact of risks to an acceptable level while protecting consumer safety, health, and rights. The Company conductscomprehensive quality risk assessments annually and recti?es any defects identi?ed.In 2024, the Company did not experience any signi?cant safety or quality-related liability incidents concerning our products orservices. There were no fatalities linked to the use of Bloomage Biotech products, nor were there any enforcement actions takendue to violations of the current Good Manufacturing Practice for Pharmaceuticals (cGMP).
Life-Cycle Quality Control
In 2024, the CompanyKey Performance
Carried out over120,000
product tests
Conducted internal audits of theproduction-based quality manage-ment system at least
1 a year
Undergone
o?cial and customer audits,with no major quality risks ordefects identi?ed
Obtained
new drug/API (ActivePharmaceutical Ingredient)registration certi?cates
Obtained
Domestic class III medicaldevice registration certi?cates
Obtained
Class II medical deviceregistration certi?cates
4443
Bloomage Biotech’s Lifecycle Quality Control
Supplier quality is rigorously assessed during the onboarding process. We sign quality assurance agreements with quali?edsuppliers, establishing clear quality standards.In addition, from mold development, sampling, testing to mass production, we work collaboratively with suppliers toaddress bottlenecks as well as any quality or safety issues that may arise. On-site communication is employed whennecessary for the immediate resolution of issues. We implement monthly tracking management processes that ensurenon-compliance issues are resolved in a closed-loop manner.Supplier Quality
For more detailed information regarding supplier quality management practices, please refer to the “Achievements:
Sustainable Value Chain” section.A comprehensive mapping of the R&D platform's quality management system has been developed with an establishedframework for R&D documentation. A total of 66 speci?c quality control requirements and management procedures havebeen formulated to standardize our product development process e?ectively.We have established a robust cross-departmental communication mechanism that enhances collaboration across six keysystems: quality assurance, materials management, equipment facilities oversight, analytical laboratory control, and R&Dproduction/preparation processes. This holistic approach ensures stringent adherence to quality control throughout everystage of product development.
R&D Quality
Bloomage Biotech implements strict controls through various measures including raw material testing, equipment manage-ment, standardized operations, process and ?ow optimization, lean production techniques, and environmental controls.We have established comprehensive regulations such as the Product Monitoring and Measuring Control Procedure tostandardize the acceptance and inspection processes for materials, water usage, intermediate products, and ?nishedgoods. Additionally, we ensure meticulous management of device calibration. Throughout each stage of production, weconduct thorough performance evaluations as well as functionality assessments alongside comprehensive quality testing.This integrated approach enables us to achieve all-around control over product process quality.After production, products are subject to internal or external quality testing. Quali?ed products are cleared for releasebased on an inspection report. Otherwise, an unquali?ed inspection report is issued, and non-conforming products arehandled under company regulations. This ensures the quality, e?cacy, and safety of products before they leave the factory.
Production
Quality
Monitoring and Auditing Management: We conduct at least one routine audit for all products each year and collaborate withregulatory authorities, customers, and other parties for special and routine supervision and inspection. In 2024, no majorproduct quality defects were identi?ed, indicating manageable quality risks in the operational phase.Product Traceability Management: Bloomage Biotech has established and updated the Product Identi?cation and TraceabilityControl Procedures in line with ISO 9001 and ISO 22000 standards, creating a comprehensive product traceability system.This system ensures that product outer packaging is intact and clearly labeled. Records are kept truthfully, accurately, andstandardly for easy access, review, and traceability of product information. Regular simulations are conducted to quicklytrace products using batch numbers and labels.Non-Conforming Products Management: Bloomage Biotech has set up regulations like the Non-Conforming Products
Management Rules and Cosmetics Quality Release Procedure. Non-conforming products are clearly labeled, stored separately,and undergo investigation, handling, correction, and inspection. Products that can be reworked are corrected to meetquality standards, while those that can't are disposed of under supervision to prevent them from entering the market.Quality Emergency Management: Bloomage Biotech has developed management systems including the Emergency
Preparedness and Response Control Procedures and the Food Safety Emergency Response Plan to e?ectively manage productsafety incidents. These measures aim to prevent product safety incidents proactively and ensure quick control if they occur.The Company continuously re?nes its handling processes for product safety incidents by incorporating monitoring, earlywarning systems, reporting mechanisms, emergency response protocols, post-incident handling procedures, andsafeguard measures. An annual emergency drill focusing on drug and food safety incidents ensures relevant departmentscan respond promptly, protecting public health.
Management
Quality
Aftersales Tracing: Bloomage Biotech has established the Product Release Authorization Procedure and the After-Sales
Monitoring and Governance Procedure to ensure only quali?ed products leave our facilities. A Customer Quality ManagementDepartment has been set up for front-line quality management, collecting feedback on business quality issues and trackingtheir resolution e?ectively. This department ensures timely market feedback for necessary product adjustments.
Products Recall: Bloomage Biotech has implemented regulations like the Product Recall Management Standard OperatingProcedure, Returned Product Control and Handling Procedure, and Medical Device Mock Recall Management Standard OperatingProcedure. Recall management is executed based on product categories, with defective items handled appropriately. Asummary of recall situations is documented with corrective actions to prevent recurrence of issues identi?ed during recalls.Separate recall plans exist for pharmaceutical and non-pharmaceutical product lines, with at least one mock recall drillconducted annually in each category. In 2024, no recalls were required due to safety or health concerns related to sold ortested products.After-Sales
QualityManagement
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
2024 Sustainability ReportAbout Us
Internal E?ortsExternal strategiesLaunching the “Quality Month” initiative, featuring 33themed activities such as: Quality Culture Campaign,Quality Control Team Competitions, Visual StorytellingPhotography Competition, “Innovative QualityExcellence in My Eyes – Bloomage” Essay SeriesImplementing a series of training and awarenesscampaigns, including: Job-speci?c knowledge training;Quality process dissemination; Thematic training onquality enhancement; Compliance-focused training("Strengthening Quality and Compliance"); Monthlytraining on quality regulations and proceduresCollaborative Training on Hands-On and ProfessionalSkills for Compliance Risk ManagementOrganizing the “Building the Great Wall of Quality”Knowledge Contest 2024: Adapting to IndustryTransformationConducting Quality Scenario Simulation and TechnicalSkills CompetitionInteractive Quality & Safety Engagement Campaigns:
Gami?ed Learning for Operational ExcellenceNarratives of Resilience: Quality-driven ProductionRecovery and Employee Dedication
Bloomage Biotech has established a vigilance system covering products such as pharmaceuticals, medical devices, and functionalskincare products, along with procedures for reporting and handling adverse reaction events. Monthly literature research relatedto product adverse events is regularly conducted, and relevant regulations are collected. Internal training and health-and-safetyawareness campaigns are organized periodically. The Company also maintains communication with regulatory agencies and otherstakeholders to continuously enhance pharmacovigilance and product adverse reaction management, thereby safeguarding publichealth and safety.
Pharmacovigilance and Adverse Reactions
Bloomage Biotech clearly de?nes quality management goals, promotes lean production, and encourages cross-site collaborationand empowerment. Additionally, the Company advocates quality training and education, values practical drills on quality manage-ment, and implements quality assessments and incentive mechanisms. All these e?orts contribute to building a distinct qualitymanagement culture. At Bloomage Biotech, we actively nurture our employees' quality concepts and awareness by organizingquality monthly activities, providing quality training and promotion, participating in the construction of quality standards, maintain-ing cooperation and communication with external parties, etc. In 2024, we conducted hundreds of o?ine/online trainings relatedto quality control and product safety, covering all relevant personnel involved in product quality management.
Cultivation of Quality Culture
The Chairwoman of the Board of Directors leads drug safetymanagement and has established the Drug Safety Committeeand a leading group for monitoring medical device adverseevents. Other committee members are managers from depart-ments related to drug safety, including pharmacovigilance,quality management, production, sales, R&D, and registration.We ensure pharmacovigilance and adverse reaction manage-ment throughout the product lifecycle.Bloomage Biotech strictly follows national, local, and internation-al pharmacovigilance regulations and guidelines. In line withexternal policies, regulatory directions, stakeholder expectations,and internal compliance requirements, the Company continuous-ly revises a series of pharmacovigilance and medical-devicevigilance management mechanisms, procedures, and standardoperating procedures covering the entire product life-cycle,including the Drug Safety Committee Operating Bylaws and thePharmacovigilance Quality Management System. In 2024, BloomageBiotech revised and implemented 21 procedural documentsrelated to its pharmacovigilance system and the medical deviceadverse event monitoring system.The Company actively participates in training sessions organizedby regulatory authorities to enhance vigilance awareness andimprove management capabilities. Additionally, we disseminateprofessional knowledge internally to strengthen employees'understanding of pharmacovigilance and their skills in handlingadverse reactions. Throughout the year, Bloomage Biotechorganized and completed seven internal audits and self-inspec-tions of the pharmacovigilance system. The Company also under-went nine o?cial inspections related to pharmacovigilancepractices, speci?cally focusing on medical device adverse eventmonitoring. Furthermore, we received one audit from a customerrelated to our pharmacovigilance systems and conducted 15internal and external training sessions on pharmacovigilance andmedical device adverse reactions.Bloomage Biotech is committed to continuously optimizing itspharmacovigilance risk management system. We formulatecomprehensive pharmacovigilance plans that involve monitoringand analyzing drug safety signals. Regular risk assessmentsconcerning adverse reactions are conducted, leading to insightfulreports that inform us of our control measures. To enhancestakeholder engagement, we have established accessiblefeedback channels that allow for the active addressing offeedback regarding adverse events. We maintain close communi-cation with provincial/municipal drug reaction monitoringcenters as well as other regulatory agencies. Adverse events arereported promptly, enabling collaborative e?orts in testingprocedures and risk assessments.In 2024, the Company received and handled 171 reports ofadverse drug reactions and 65 reports of adverse medical devicereactions. There were no product-related deaths or violations ofthe current Good Pharmacovigilance Practices.
Pharmacovigilance
Bloomage Biotech adheres to the management principles of“safety ?rst, openness and transparency, scienti?c valida-tion, and risk noti?cation” in developing and continuouslyre?ning its adverse reaction management system forfunctional skincare products. In compliance with relevantlaws, regulations, and industry standards, the Companyregularly updates and revises the Cosmetic Adverse ReactionMonitoring and Reporting Standard Operating Procedure (SOP).This process optimizes information collection, monitoringand analysis, emergency response procedures, andfeedback mechanisms to safeguard consumer rights whileenhancing product quality and safety control capabilities.The Company conducts relevant tests during productdevelopment based on industry standards as well as internalprocedures, including the Human Skin Patch Testing Protocolfor Cosmetics, In Vitro 3T3 Neutral Red Uptake PhototoxicityAssay, and Skin Sensitization Assessment: Direct PeptideReactivity Assay (DPRA). These measures help mitigate poten-tial adverse reactions on human skin caused by functionalskincare products. The Company has analyzed and evaluat-ed reports and monitored data of adverse product reactionsbefore and after marketing, which have been actively andpassively collected, and ensured product traceability.Through internal audits, external inspections, trainingsessions, and e?ective communication channels, we ensurethat assessments related to suspected or con?rmed adversereactions are conducted in a timely manner while remaininge?cient and compliant with legal standards. In 2024, Bloom-age Biotech was subjected to four external audits concern-ing the monitoring of adverse cosmetic reactions whilehosting ?ve internal training sessions focused on managingthese reactions related speci?cally to functional skincareproducts. Notably in that year, one case of a suspectedadverse reaction was reported concerning our functionalskincare line. In accordance with our established regulationson cosmetic adverse reaction monitoring management, wecarried out thorough collection processes alongside report-ing measures. And analysis evaluations were conductedswiftly followed by an investigation into this occurrence.E?ective risk control measures were implemented ensuringthat no widespread adverse reaction events occurred.
Adverse Reaction Management for Func-tional Skincare Products
0531-82685091
4645
Bloomage Biotech’s e?orts to foster an atmosphere of quality culture
Participating in the “2024 Cosmetics IndustryHigh-Quality Development Symposium” organizedby the Shandong Provincial Medical ProductsAdministrationParticipating in the “Quality Month” Campaignorganized by Hainan Provincial Medical ProductsAdministrationAttending external workshops and trainingactivitiesAttending Jinan City quality typical exchangespeechShowcasing smart factory practices through videopresentations by the Provincial Medical ProductsAdministrationShowcasing exemplary works from Shandong'squality - driven brand storytelling campaignsOrganizing media tours to promote regionallycerti?ed products under the "Quancheng GoodProducts" initiativeParticipating in the “2.25 Skin Care Day” eventAttending the Second Medical Device Innovationand Development ConferenceInviting regulators and industry associations tobase their training courses in the BloomageBiotechParticipating in the construction of international,national, industrial and group quality-relatedstandards actively
Synergized Internal-External Strategies
for E?ective Implementation
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
Adverse reaction feedbacktelephone number of the Company
2024 Sustainability ReportAbout Us
Driven by making products and services of better quality, more accessible, more inclusive, safer and longer-lasting, BloomageBiotech has always been expanding product application areas and consumption scenarios, to bring healthy, beautiful and happylife experiences to mankind. The Board of Directors remains actively engaged in making informed decisions regarding issuesimpacting enterprise development within the context of healthcare accessibility among other relevant considerations.
Product Accessibilityand A?ordability
Bloomage Biotech is committed to expanding applications for hyaluronic acid products across various ?elds while enhancingaccessibility for diverse populations globally. The Company continuously explores broader applications for medical sodiumhyaluronate beyond dermatology into areas like gynecological health while progressively increasing application areas formicro-crosslinked hyaluronic acid extending from facial applications to body areas such as hands or necks.Our range which includes various bioproducts featuring hyaluronic acid is distributed across over 70 countries worldwide promot-ing both industry growth and enhanced market penetration e?orts thereby facilitating safe and e?ective solutions accessibleglobally. In 2024, Bloomage Biotech established a Southeast Asia Regional Centre, formed a localized team, and actively developedand expanded emerging markets.The Company is committed to improving drug accessibility and medical levels in underdeveloped areas. We have actively cooperat-ed with sectors of society, such as governments, medical institutions, and non-governmental organizations, to carry out the PatientCare Charity Campaign. For example, the Chairwoman leads her charity walk campaign to help solve the health problems of peoplein underdeveloped areas.
Product Accessibility
Bloomage Biotech strives to provide customers and consumers with high-quality raw materials and terminal products at reason-able prices. To continuously improve the a?ordability of our products in the global market, we fully consider the level of economicdevelopment in each region in product pricing.While abiding by the market pricing mechanism, the Company has considered factors such as the a?ordability and amountpurchased from di?erent countries and regions for all its products. Adhering to business ethics rules such as anti-monopoly andanti-unfair competition, the Company has priced fairly in accordance with the local market, industry pricing, and regulatory require-ments.At present, the Company owns one ophthalmic pharmaceutical product and one orthopedic drug, both of which have been includ-ed in the medical insurance to bene?t the whole country, reducing the economic burden of patients and bene?ting more patients.
Product A?ordability
Genitourinary syndrome of menopause (GSM) signi?cantly impacts women's health and quality of life. Hyaluronic acid, recognized for itsexcellent biocompatibility, o?ers potential advantages in enhancing tissue hydration and lubrication. Bloomage Biotech, in partnershipwith Beijing Hospital, has pioneered a clinical trial to evaluate the use of hyaluronic acid in treating GSM. This research aims to assess thesafety and e?cacy of this treatment approach within the Chinese population. The ?ndings will provide valuable guidance for cliniciansand o?er technical support in developing safe and e?ective treatment options for menopausal patients.
Case
A Clinical Trial on the Treatment of Genitourinary Syndrome ofMenopause with Hyaluronic Acid Conducted by Bloomage Biotech
Bloomage Biotech has established a dedicated service team committed to responsible marketing practices. The Company hasdeveloped diverse communication channels that enable prompt responses while addressing customer feedback and inquiriesaccurately. Through rigorous quality control measures and reliable after-sales support, we e?ectively safeguard consumer rightsand interests, thereby fostering positive relationships with customers over the long term.
Customer Services andRights Protection
Bloomage Biotech rigorously complies with laws and regulations in terms of responsible marketing, such as the Law of the People'sRepublic of China on the Protection of Consumer Rights and Interests, the Advertising Law of the People's Republic of China. The Companyhas devised policies like the Code of Conduct for Advertising Release, Compliance Guidelines for Live Streaming Promotion, SensitiveTerm Base for Cosmetics and Daily Chemical Products to regulate marketing and communication practices. Additionally, we establishmarketing compliance procedures and regularly organize internal training. The Company's legal center conducts a comprehensivereview of product promotion information and related marketing language to ensure legal compliance. In 2024, Bloomage Biotechdid not face any legal disputes related to false marketing claims.
Responsible Marketing
Bloomage Biotech closely monitors the latest regulatory developments regarding product manuals, labeling, and packaging. TheCompany promptly updates its internal management procedures and conducts regular self-audits to rectify any discrepancies.Committed to the principle of information transparency, Bloomage accurately labels product ingredients, usage instructions,contraindications, and shelf life to ensure full compliance with applicable laws and regulations. All claims regarding product e?cacyare substantiated by results from external authoritative testing and validation processes. To further enhance transparency, theCompany clearly communicates product ingredients and their sources during promotional activities. Comprehensive ingredientinformation is publicly disclosed across multiple platforms, including the Company's o?cial website. Moreover, ingredient explana-tion seminars are organized for interested parties. This approach fosters an open environment where customers and consumerscan provide oversight. Additionally, Bloomage Biotech regularly educates consumers about product shelf life and proper usagemethods through various channels such as social media platforms, advertising campaigns, and customer service hotlines.
Enhancing Product Information Transparency
In its external marketing collaborations, Bloomage Biotech incorpo-rates marketing risk clauses in its promotional contracts. Theseclauses require partner agencies and in?uencers to sign a Commit-ment Letter for Marketing Compliance, ensuring strict adherence tolaws, regulations, company policies, and the guidelines of promo-tional platforms related to internet marketing activities. Prior toinitiating partnerships, we conduct comprehensive backgroundchecks and audits of online in?uencers and major V-streamers. Weprovide training to ensure they are well-versed in relevant regula-tions and prohibited terms, as well as review the promotionalcontent they intend to use for product advertising. Duringlive-streaming events, we implement manual monitoring acrossmultiple platforms to closely track any negative public sentiment inreal-time.
Compliance in Marketing
Bloomage Biotech responsiblemarketing training overview
15,312
training hours
22,243
participants
4847
Key Performance
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
Online platform stores and e-commerce livestreams serve as the primary sales channels for Bloomage Biotech's functionalskincare and food products. To raise employees' awareness of responsible marketing and ensure compliance during the salesprocess, the Company conducts training on compliance in promotion and advertising practices for key marketing employees,promptly summarizing and sharing regulations and policies related to compliant product promotion and advertising. Externalexperts are occasionally invited to conduct compliance promotion training for sales personnel. Furthermore, the Company regular-ly reviews prohibited marketing keywords and other online sales risks, reinforcing the compliance and operational capabilities ofrelevant personnel through post-event analysis, weekly exchanges and special training so as to avoid providing consumers withnegative experiences due to violations.
2024 Sustainability ReportAbout Us
Bloomage Biotech has established management documents such as theOperating Procedures for Customer Satisfaction Survey and Analysis, whichclearly de?ne customer service objectives. The Company continuouslyconducts training programs aimed at enhancing customer servicecapabilities while establishing quality inspection standards linked direct-ly to customer service sta? performance assessments. BloomageBiotech has established a dedicated consumer research team thatcollaborates with external data analysis ?rms to conduct satisfactionsurveys regarding product quality and company services both beforeand after product launches. The results of these surveys are analyzed indepth, enabling timely updates and iterations of our products whilecontinuously optimizing our operational methods and content. Inaddition, Bloomage Biotech promotes awareness of its products whilebuilding trust among customers through various outreach initiatives,such as publishing scienti?c articles and white papers, organizingskincare-related seminars, providing online educational content, hostingsessions featuring industry experts, and partner training workshops.In 2024, we established a centralized customer feedback collection mechanism alongside standardized monitoring processes forservice delivery. By integrating information from multiple channels into clear standards at each interaction step, we e?ectivelyaddressed issues related to information fragmentation or processing delays while signi?cantly boosting response times. We alsoenhanced technical support by assembling a specialized expert team capable of conducting targeted training that re?ne usagescenarios, enriching our knowledge base while updating raw material labeling standards to comprehensively improve customerexperience.
Improving Customer Satisfaction
Bloomage Biotech places a high priority on customer privacy and security. To safeguard customer information and trade secretswhile preventing privacy breaches, the Company encrypts data related to user privacy and enforces strict permission isolation atthe original layer of its Operational Data Store (ODS). We have established a hierarchical access system for customer informationbased on departments, job levels, and positions, accompanied by a rigorous data access approval process. This structure ensuresthe secure and compliant use of customer information. Bloomage Biotech has required employees to strictly control and managedocuments and other materials according to relevant provisions and administrative regulations. It is forbidden to arbitrarily leakany documents and materials of the Company to outsiders. In addition, the Company organizes special training on trade secretprotection on an irregular basis to enhance employees' con?dentiality awareness.The Company strictly protects the privacy and data security of B2B customers. We have con?dentiality clauses in all contractssigned with customers. We do not disclose privacy without his or her knowledge and consent. The Company abides by the PersonalInformation Protection Law of the People's Republic of China and the data protection policies of online shopping platforms. We havestrengthened our internal self-discipline and autonomy. Based on legality and compliance, the Company has handled B2C consum-ers' personal information, following the principle of personal information noti?cation and consent. Regarding medical aestheticproducts and services, Bloomage Biotech has implemented management measures such as the Image Rights License Agreement andthe Facial Injectable Treatment Informed Consent to protect the privacy rights of distributors and patients.The Company continuously develops speci?c processes for identifying, assessing, prioritizing, monitoring, and managing risksrelated to customer privacy protection. These measures provide comprehensive safeguards for securing customer privacyinformation. In 2024, Bloomage Biotech did not experience any incidents involving leakage of customer privacy or veri?edcomplaints related to invasion of privacy or loss of customer data. Furthermore, there were no complaints arising from inadequatemanagement of customer data security.
Customer Privacy Protection
To respond to customer feedback on time and handle customer complaints e?ciently, Bloomage Biotech formulated the CustomerComplaint Handling Standard Operating Procedure as well as Customer-Related Processes and Closed-Loop Feedback ManagementProcedure. Also, we have established handling and feedback procedures, customer service standards and speci?cations, andemergency handling procedures. We have optimized its service quality through daily inspections, research and analysis, and timelytraining for relevant employees.Upon receiving feedback and complaints, the Company conducts thorough cause investigations along with risk assessments whereapplicable. The company may take actions such as sampling or initiating product recalls based on the ?ndings, and the companydevelops corrective action plans accordingly and implements preventive measures aimed at e?ectively resolving various types offeedback. We have established distinct handling procedures based on the nature of customer feedback. If a complaint pertains toproduct quality, the customer complaint handling process is initiated. Feedback involving adverse reactions triggers the AdverseEvent (AE) support process. For feedback related to product usage experiences or consumer demands, our Product ManagementDepartment will assess the possibility to develop new products and services.The Company welcomes feedback from B2B customers via WeChat, email, phone calls, and interviews. In 2024, the Companyreceived a total of 38 complaints from B-end customers through various channels, with a response rate of 100% and a complaintresolution rate of 100%.The Company welcomes queries, requests and suggestions from B2C consumers via online or o?ine channels. The Company hasprovided online customer service on e-commerce platforms, such as Tmall, JD.com and TikTok, and participated in the “Hassle-FreeReturn Protection” program promoted by the platforms. If consumers have any questions or complaints, they can contact usthrough customer service channels. Furthermore, we consistently engage private-domain fans alongside recruiting public-domainconsumers by inviting them into trial runs featuring new products to gather valuable perspectives covering diverse aspects likeuser experience, e?cacy, weight packaging material and fragrance. In 2024, the Company received a total of 53 complaints fromB2C consumers via various channels, with a response rate of 100% and a complaint resolution rate of 100%.
Customer Feedback and Complaints
In ????
with a satisfaction rate of
99.4 %
achieving the 2024 satisfactiontarget
The Company has conducted asatisfaction survey on
935 customers
Additionally, the Tmallcustomer service teamsassociated with our majorbrands have been recognizedwith “Golden Wangwang”&“Silver Wangwang” titles
5049
In 2024, all brands under Bloomage Biotech maintained high DSR1 scores on major mainstream online platforms such as Tmall,JD.com, and TikTok without content moderation alerts, comment suspension and serious violations.
Key Performance
1DSR score is the detailed evaluation score given by buyers on e-commerce platforms tosellers, re?ecting the performance of sellers in aspects such as product description,logistics service, communication, and transaction experience.
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
2024 Sustainability ReportAbout Us
2024 Sustainability Report
SDGs Addressed in this Chapter
Major Material Topics of Sustainability Covered in this Chapter· Employee Rights· Employee Development· Occupational Health and Safety
Growth: TalentEmployment and DevelopmentBloomage Biotech ?rmly believes that talent is a crucial cornerstone for theCompany's sustainable development. We are dedicated to fostering anequitable, diverse, inclusive, and safe working environment for all employ-ees. Our commitment includes providing a comprehensive, full-cycle talenttraining system that supports professional development and broadenscareer advancement opportunities while facilitating the personal growth ofour employees. We will continue to enhance our occupational health andsafety management practices, ensuring the safeguarding of our employees'occupational safety as well as their physical and mental well-being. By doingso, we aim to collectively achieve our goals for sustainable development.
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagementAbout Us
5453
Bloomage Biotech adheres to the principles of legal and equal employment. The Company is committed to comprehensivelyrespecting and protecting human rights, as well as safeguarding laborer rights and interests, through standardizing employeerecruitment and hiring processes, continuously improving employment management systems, and clarifying ethical codes ofconduct.
Fair and Standardized Employment
Bloomage Biotech is committed to upholding the principles outlined in the Universal Declaration of Human Rights and strictlyadheres to national and local laws and regulations, including the Labor Law of the People's Republic of China, Labor Contract Law ofthe People's Republic of China, and Regulations on the Prohibition of Child Labor, in all its operational regions. In alignment withstandards such as the SA 8000 Social Responsibility Standard, ISO 26000 Social Responsibility Management System Standard, andEthical Trading Initiative (ETI) Base Code, we have developed and implemented an Employee Handbook along with several associat-ed management policies. The Company is dedicated to treating all employees fairly and equitably, regardless of their race, skincolor, ethnicity, gender, age, religious beliefs, or cultural background. We have a strict zero-tolerance policy towards child labor inany form. Additionally, forced labor, including any use of violence, threats, or illegal restrictions on personal freedom, is expresslyprohibited. Corporal punishment, intimidation, harassment, abuse, or any form of discrimination against employees is likewisestrictly forbidden.
Compliance in Employment
We have made employee recruitment and management standards, including but not limited to:
The Company strictly prohibits the use of child labour. We have established and implemented work management procedures forthe prohibition of child labour and the protection of underage workers. Identity and background checks are carried out on employ-ees, and the following measures are taken to ensure e?ective management:
The Company categorically prohibits all forms of forced labour and abuse, including sexual coercion, sexual assault, threats,unwarranted body searches, maltreatment, humiliation, exploitation, and harassment. A comprehensive management system hasbeen established. This system clearly outlines employees' rights and interests, sets explicit requirements for management person-nel, and provides a well-de?ned complaint channel. A dedicated department is responsible for conducting investigations to ensuree?ective supervision and continuous improvement of management quality.Bloomage Biotech continues to expand its talent pool and build a well-structured talent pipeline. By the close of the reportingperiod, the Company had a workforce of 4,444 employees. The labour contract signing rate reached 100%, and the employeeturnover rate stood at 28.75%. All employees were adults above 18 years old. There were no incidents of child labour employment,forced labour, or other severe human rights violations such as debt-bondage labour, labour tra?cking, or transfer.
In the event that child labour is detected, immediate action is taken. The child's work is halted without delay, and a compre-hensive health check is arranged. Subsequently, the child is safely escorted home, and both the child's guardian and relevantauthorities are promptly noti?edChild Labour Rescue ProceduresThe Company has formulated the Recruitment Management Regulations. Recruitment is carried out under the principle of “openness andfairness”, ensuring that recruitment decisions are not in?uenced by discrimination based on factors such as ethnicity, religion, disability,gender, or marital statusNecessary background checks are conducted with the informed consent of candidates to prevent issues such as identity fraud and con?ictsof interest
Recruitment Process
Bloomage Biotech has established the Attendance and Leave Management Policy to implement standard working hour systems and compre-hensive time-keeping procedures. This ensures the smooth operation and production order of the Company while safeguarding employees'legal rights to rest and time o?During Employment
Employee-Initiated Termination of the Labor Contract:
The Company respects employees' voluntary decisions to resign and adheres to established resignation procedures
Company-Unilateral Initiation of Position Changes or Termination of Employment Contracts:
Compliance with Law and Labor ContractBloomage Biotech is committed to complying with local employment laws, regulations, andlabor contracts, ensuring that termination or layo? procedures are conducted legally and fairlyUnimpeded Communication and TransparencyEmployees are informed in advance about terminations. The speci?c reasons fortermination, along with detailed processes and follow-up arrangements, are clearly conveyedSupport and CompensationEmployees' rights are fully respected throughout this process. Appropriate ?nancial compensation isprovided in accordance with legal requirements. Additionally, Bloomage Biotech o?ers support for re-employment through various meanssuch as career counseling, training opportunities, internal referrals, and job transfer options
Position Changes, Terminations, and Resignation
The Company ?rmly opposes any form of child labour use and will never collaborate with suppliers who knowingly employchildren
Statement and Principle
Prior to employee onboarding, we employ a multi-tiered veri?cation approach that combines third-party background checkswith manual reviews. Personnel ?les are meticulously created, and we conduct in-depth veri?cation and authentication ofemployees' true identity details. This comprehensive process is designed to prevent the inadvertent recruitment of childlabour, especially in cases where employees might submit false informationRecruitment and Hiring
For underage workers between the ages of 16 and 18, we strictly adhere to legal and ethical guidelines. They are not permittedto engage in, nor will they be assigned to, work in high-risk environments such as high-altitude jobs, underground operations,radioactive, highly toxic, ?ammable, and explosive work areas. Additionally, they are excluded from tasks involving thefourth-level physical labour intensity as de?ned by national regulations and other internship work with inherent safety risks.In compliance with legal requirements, regular health examinations are arranged to safeguard their well-being
Protection of Underage Workers
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
2024 Sustainability ReportAbout Us
?,?????.??%
?,?????.??%
MaleFemale
?,?????.??%
?,?????.??%
??
?.??%
Aged 51 or aboveAged 31 to 50Aged 30 or below
EmployeeGender Structure
EmployeeAge Structure
?,?????.??%
????.??%
??.??%
Senior managementMiddle managementGeneral sta?
?????.??%
?,?????.??%
?,?????.??%???.??%
Doctor’s degreeMaster's degreeBachelor's degreeBelow bachelor's degree
EmployeeEducationStructure
5655
Bloomage Biotech respects employees of di?erent ages, races, genders, nationalities, and physical conditions. To ensure thefairness and justice of the Company's procedures and processes in recruitment, salary incentives, training, and promotion, we haveformulated and implemented the Professional Code of Ethics and Conduct and other systems. In this way, we ensure that employeesenjoy equal rights, prohibiting any form of discrimination and accepting employees' complaints when necessary.
Diversity and Inclusion
“True gender equality should transcend the over-emphasis on gender. Gender equality is not only an indicator of social progress butalso a linchpin for the sustainable development of enterprises. Bloomage Biotech is committed to doing its part to assist morewomen in realising their self-worth, enabling them to shine with wisdom and radiance, and contributing to the creation of a moreequitable social environment.” Zhao Yan, Chairwoman and CEO of Bloomage BiotechIn May 2024, Bloomage Biotech o?cially became a signatory member of UN Women's Women's Empowerment Principles (WEPs). Thisinitiative aims to empower women in the workplace, marketplace, and community, thereby promoting the realization of gender equality.The signing of the WEPs also signals international recognition of Bloomage Biotech's commitment and e?orts in promoting genderequality and women's empowerment. Looking ahead, Bloomage Biotech will further deepen its practices in gender equality and women'sempowerment. By establishing a high-level leadership mechanism and strengthening education and training for female employees, theCompany aims to enhance the personal and social values of its female workforce.
Case
Bloomage Biotech's Signing of the United Nations Women's EmpowermentPrinciples (WEPs)
“
”
The Company has provided equal opportunities for all employees. We have fully utilized the respective advantages of genderdi?erences and capability di?erences at work. In 2024, awareness training on diversity, discrimination and harassment, and forcedand abusive labour was newly developed and incorporated into the Employee Onboarding Guidebook for new employees.
We respect and protect the rights and interests of female employees and clarify the scope of work for female employees:
- We forbid arranging female employees in super labor-intensive positions- We prohibit arranging pregnant and lactating female employees to engage in any work that may endanger their and theirchildren's health and safety- Provide diversi?ed care to our female employees by setting up a dedicated lactation room in the Company and organizingregular care activities
Female Employees
We are highly attentive to the lives of employees from diverse racial and ethnic backgrounds, showing full respect fortheir emotions, cultural, and dietary customs. In our company cafeteria, we make distinctions in food o?eringsaccording to the religious beliefs of ethnic-minority employeesIn 2024, Bloomage Biotech has employed a total of 9 foreign employees and a total of 120 minority employeesEmployees of Di?erent Races and Ethnicities
We have formulated the Management Regulations on Retirement and Re-employment. We have not restricted theopportunities for employees to develop old employees' abilities. Oriented to personal expertise and industryexperience, we fully protect the rights and interests of re-employed employeeIn 2024, Bloomage Biotech has had 11 re-employed employeesRetired and Re-employed Employees
The Company supports the employment of special groups such as people with disabilities. We have prohibiteddiscrimination against the disabled in the recruitment and appointment process. When conditions permit, we providesuitable positions for such individuals to protect their legitimate rights and interestsIn 2024, Bloomage Biotech has employed a total of 17 disabled employees
Disabled employees
As of the end of the reporting period, the proportion of female employees at Bloomage Biotech was as follows:
48.96 %
of the total number ofemployees
50.00%
in senior management
41.45%
in middle management
62.72%
among R&D sta?
EmployeeHierarchical
Structure
Employee Structure of Bloomage Biotech in 2024
Key Performance
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement2024 Sustainability Report
Unit: person/%
About Us
General sta?Management
General sta?Management
5857
Bloomage Biotech attaches great importance to attracting and retaining talents. We have striven to make career developmentchannels smooth, continuously optimized employee training systems, and built a complete performance incentive mechanism. Bydoing so, we provide a broad platform for employee development.
Talent Development
Bloomage Biotech approaches talent development and management from a strategic perspective. The Company has establishedan e?cient talent recruitment management mechanism and scienti?cally forecasts talent development requirements. We prompt-ly engage external human resources service agencies to assist in building our talent pool in technology, management, and profes-sional ?elds. We conduct social and campus recruitment activities on mainstream social and recruitment platforms. Additionally,the Company has drawn attention to talent acquisition by actively participating in industry activities, conducting training withschools, promoting employer brands, and providing competitive bene?ts.When recruiting talent, Bloomage Biotech adopts a diversi?ed talent acquisition strategy. The Company has established a scienti?c,objective, and comprehensive evaluation system. By utilizing diverse assessment tools such as scienti?c evaluations and situationalsimulations, and integrating professional and systematic interview processes, we thoroughly assess the capabilities of candidates,thereby strengthening our talent development strategy. Furthermore, Bloomage Biotech continuously re?nes the Internal ReferralManagement Regulations. For referrers who successfully recommend management-level candidates for employment, the Companyo?ers bonuses to encourage employees to continuously support the Company in attracting high-quality talent.In recent years, Bloomage Biotech has received prestigious employer awards such as the ECHO 2023 King’s Ark·Most Talent-CentricEmployer Award and the China HR Venus Grand Awards: Talent Management Benchmark Enterprise. These recognitions signify theCompany's continuous exploration of employee development pathways and the achievements it has attained.
Talent Introduction
Bloomage Biotech has improved employee qualities and fueled their career development through training. The Company hasestablished talent cultivation systems such as the Training Management System and the Internal Job Posting System, which clearlyde?ne its talent cultivation strategy. By developing diversi?ed promotion channels and establishing an open developmentplatform, we have provided employees with more opportunities for training and further study.
Talent Cultivation
Bloomage Biotech has built a systematic talent training system framework. To facilitate the internal talent pipeline development,we have provided multi-?eld and multi-level training programs covering management training, professional training, new sta?training, and general skills training. In addition, we provide rich academic resources and platforms, such as various AI o?ce toolsand CNKI accounts, to help employees make e?cient use of o?ce and learning resources and support their development.
Employee Training System
Training participationrate by hierarchical level??.??%
??.??%
Training participation rate by gender??.??%??.??%
Female employeesMale employees
Female employeesMale employees
Training hours byhierarchical level??.????.??
Average training hours by gender??.????.??
In 2024
Traning sessions
6,279 participants
Training hours per employee
26.61 hours
Overall investment in employee training 2.67 million RMB
For all managersDesign tiered leadershipprograms tailored tomanagement hierarchiesInclude leadershiptraining for seniormanagers and middlemanagers, as well asmanagement skillstraining for juniormanagers and newlypromoted managers
Diversi?ed Promotion ChannelsManagement track
Lecturer Resources
Management Talent PipelineInternal job competition systemJob Rotation SystemManagement trainee systemProfessional trackR&D track
Management training
For all employeesFor each professionaltrack covered bymarketing, R&D,production and functionsProvide professionalskills training courses,including three stages ofbeginners, intermediateand advanced levels
For new hiresProvide training oncorporate culture,company system, jobbasics, knowledge andskills, enabling new hiresto integrate into newpositions and grasp thebasic knowledge requiredby the position in a shorttime
For all employeesProvide training onknowledge that allemployees of di?erenttracks are required tomasterInclude training courseson general management,general qualities, generalskills and other relatedknowledge and skills
For R&D platform members
For R&D personnel,establish a learningplatform that enhancesthe exploration of newsubstances, technologies,materials, and processes,enabling them to quicklyembrace cutting-edgeperspectives andstimulate R&D motivation
OpenDevelopment Platform
Internal lecturers, external experts
O?ine CoursesCovering various categories such as management,technology, operation, and general knowledge.
Online Platform (E-learning)
Case videos, learning courseware,knowledge base resources, etc.
Sharing of educational resources
Professional TrainingNew Employee TrainingGeneral trainingGeneral training
Employee training performance of Bloomage Biotech in 2024
Bloomage Biotech's all-round employee training system
Key Performance
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
2024 Sustainability ReportAbout Us
In 2024, the Company organised 7 vocational skills training sessions, with around 500 participants. These trainings employed thematicinstruction alongside group competitions and situational interactions to assist employees in clarifying their thought processes from userneeds to improving business performance. This approach deepened employees' understanding of market dynamics and enhanced thesuccess rate of new product development as well as market promotion.
CaseVocational Skills Training Conducted by Bloomage Biotech
This year marks Bloomage Biotech formally initiated the Reserve Cadre Nomination Process for Tier 1 (Including 1.5) and HigherManagement Team. Managers are encouraged to nominate candidates who demonstrate exemplary character and performancewhile aligning with organizational development needs. This e?ort lays a foundational framework for systematic long-term talentreserve within the Company’s talent management strategy.The Company has continued to enhance the Implementation Rules for Learning and Growth Welfare, which encompasses vocationalquali?cation training projects and educational programs for all employees, including part-time and contract workers. The initiativeencourages employees to pursue relevant professional quali?cation certi?cates or upgrade their academic education. It also clearlyoutlines reimbursement policies for personal academic advancement expenses and provides subsidies for obtaining certi?cates. In2024, the Company invested a total of RMB 196.4 thousand in subsidies to support employees in achieving educational quali?ca-tions and professional certi?cates.
Bloomage Biotech 2024Vocational Skills Training
Bloomage Biotech conducts a comprehensive 5-day onboarding training program for newly hired employees. This training integratesvarious formats, including classroom lectures, group discussions, on-site visits, outdoor team-building activities, and practical drills. Theprogram aims to impart essential knowledge regarding corporate culture, product information, and quality and safety management. Thisapproach not only deepens employees' identi?cation with the corporate culture but also enhances their professional skills and fosters aspirit of teamwork, thereby facilitating the smooth integration of new employees into the workplace.
CaseBloomage Biotech’s New Employee Onboarding Camp
New Employee Onboarding Camp, Jinan Production Base
In 2024, the Company organized 4 leadership training sessions across di?erent business lines, engaging approximately 200 participantsin total. The training adopts a thematic approach combined with situational interaction to promote in-depth and amicable collaborationamong departments. This initiative contributes to the optimal allocation and e?cient utilization of resources.
CaseBloomage Biotech has launched diversi?ed leadership training programs
Active Ingredient Business Line & Pharmaceutical &Medical Device Business Line: “Driving Growth through Development”
Management Leadership Training
Personal Health Consumer Goods Business Line & Global R&D Platform -Personal Care R&D Center: “Boundary-less Communication: Win-Win
Cooperation” Horizontal Leadership Training Project
Global R&D Platform - Raw Material R&D Center & ActiveIngredient Business Line: Specialized Horizontal Leadership Training Centered on
“Value Linkage: Synergy for Win-Win Results”
Global R&D Platform - Raw Material R&D Center: “Fusion-Innovation”
First Phase Project Management Capacity-Building Training Camp
6059
Concepts and Plans in theDevelopment for theSecond SessionBiomanufacturingPilot-Scale Platform
Flagship Products MarketStrategy ProgramHRBP Strategic Partner-ship Boot campPMP Certi?cation &Project ManagementExcellence InitiativePresentation Skills
Training Program on theDevelopment Plan for theSecond SessionBiomanufacturingPilot-Scale PlatformConsultative MarketingTraining Camp
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement2024 Sustainability ReportAbout Us
Bloomage Biotech continuously expands its talent development models including internal tutoring, external expert teaching, andcollege-enterprise cooperation. Besides, the Company has continued to enrich the existing teaching resource library to meetemployees' diverse growth needs.In 2024, the Company further re?ned internal documents, such as the Interim Regulations on the Management of Tutoring New andInterim Regulations on the Management of Internal Trainers. By doing so, we have clari?ed the tutoring process, tutor quali?cationsand appointments, teaching responsibilities, and assessment methods. We have regulated internally established tutorial systemsand apprenticeship to build a stable and high-quality team of trainers.Additionally, Bloomage Biotech improved employee development paths in terms of three directions: “experiential and practicallearning”, “feedback and instruction” and “courses and skills training”.
This year, the Company has initiated a pilot rotation program designed to cultivate mid-to-senior-level composite leadership talentsand enhance cross-functional management competencies, thereby building a robust talent development ecosystem.
Employee Training Model
Bloomage Biotech actively explores innovative talent - cultivationmodels and promotes the transformation of scienti?c andtechnological achievements. In 2024, the Company continuouslyre?ned the innovative talent management model. The R&DManagement Committee takes the lead in overall planning,supervision, and guidance, while various departments collabo-rate in management, each performing its own duties. BloomageBiotech places signi?cant emphasis on attracting innovativetalent and optimizing the structure of its talent pool. The Compa-ny actively encourages R&D personnel to engage in internaltransfers and job rotations, thereby establishing pathways for thecultivation and development of innovative talents. We regularlyformulate and update our talent assessment and incentive mech-anisms to align with best practices. In doing so, we continuouslyenhance our model for the cultivation and management ofinnovative talents. Currently, we boast a multidisciplinary, profes-sionally structured, industry-experienced, deeply capable, ande?ciently collaborative talent team, providing fundamentalsupport for the Company's technological innovation.Bloomage Biotech places a strong emphasis on providing varioustraining opportunities for R&D personnel to empower innovativeresearchers. In 2024, the Company conducted a total of 43training sessions focused on innovative talent development, with2,931 participants accumulating 128 hours of training. Amongthese, seven sessions were speci?cally designed for core sta?and team leaders, engaging a total of 382 participants. Addition-ally, the Company arranged for relevant personnel to attendexternal technical training programs to enhance industry techni-cal exchanges.
Innovative Talent Cultivation
In 2024, the Company organized 6 training sessionsthemed “R&D Personnel Understanding BusinessOperations” for all R&D sta? involved in raw materials andpharmaceutical and medical device research. A total of 952person-time participated in these sessions. The trainingaimed to enhance capabilities in knowledge transfer,management cognition, organizational awareness, projectmanagement, and self-growth among R&D personnel.Through thematic instruction, case studies, interactivediscussions, and simulated problem-solving scenarios, theprogram improved employees' business awareness as wellas their problem-solving skills and collaborative thinking,supporting the continuous optimization of the Company'sR&D system in alignment with its strategic objectives.
Case
Conducted Business CompetencyTraining Conducted by Bloomage Biotech
In 2024, Bloomage Biotech
represents about
20.70%
of our total workforce
experts enjoying specialgovernment subsidiesfrom the State Council
Provincial Experts with Outstand-ing Contributions
Taishan Industry Leading Talents
Municipal Leading Talent
Key technical personnel in critical?elds such as senior/deputyengineers and pharmacists.
The Company employsapproximately
920R&D professionals
around 50% hold postgraduate degreesor higher
Training rate of ourinnovative talent
6261
Talent training practices of Bloomage BiotechLeveraging its training system and learning platform, the Company has provided teaching resources andonline and o?ine courses in management, professional, general, and other knowledge
Courses andskills training
Tutorial systemestablish an internal teaching mechanism, develop a team of internal lecturers, andprovide personalized instructionDaily communicationeach department holds regular meetings to encourage communication andlearning between old, middle-aged, and young employees, between current employees and new employ-ees, and between employees in relevant departments. This aims to pass on excellent experience and helpemployees independently access to training resources neededFeedback andinstruction
Job-speci?c learning: match suitable positions according to personal abilities, and continue to accumulateskills and management experience at workJob rotation mechanism: provide three-year rotation opportunities for the head of ?rst-line business topromote internal mobility of talentsPersonal improvement: provide learning subsidies to encourage employees to improve their academiclevel or professional and technical abilities, and obtain relevant quali?cations and academic certi?cates
Experiential andpractical learning
Key Performance
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement2024 Sustainability Report
100%
About Us
Talent Development
Bloomage Biotech provides a growth framework that aligns with job require-ments and career planning objectives while establishing scienti?c evaluationcriteria for employees' promotion pathways. The Company has implemented aPerformance Management System that standardizes key performance manage-ment processes, including setting performance indicators, conducting perfor-mance communication and coaching, evaluating performance, and facilitatinginterviews with feedback. This system combines quarterly and annual evalua-tions to regularly assess employee performance while providing a basis for salarydistribution as well as talent promotion and development decisions. We arecommitted to eradicating any form of discrimination during career advancementprocesses to ensure equal promotional opportunities for all employees.In 2024, Bloomage Biotech initiated the Personal Business Commitment (PBC)performance assessment across all employee levels. Additionally, we havecontinuously optimized our Employee Performance Evaluation Grievance RedressMechanism. Employees who have questions or concerns regarding their perfor-mance results can initiate an appeal at any time, and we guarantee that respons-es will be provided within 2-3 days.In 2024, Bloomage Biotech issued the Interim Regulations on Internal Job PostingManagement V2.0. This update introduced an evaluation mechanism for theadaptation periods of Tier 1 Organizational Unit Leaders, Senior Management,and Core Technical Personnel through a Dual-Tier Evaluation process comple-mented by a 360-Degree Assessment approach. These mechanisms comprehen-sively evaluate the compatibility between employees and their roles whileencouraging individuals to seek more suitable career development opportunitieswithin Bloomage Biotech. Furthermore, the establishment of standardizedinternal job posting processes enhances our ability to e?ectively allocate andmanage talent resources across the organization.
Promotion Mechanism
In 2024
100 %
employees receivedperformance evaluations
internal promotionsInternal promotion rate
7.25 %
In 2024, Bloomage Biotech imple-mented the Management Measures ofHonors and Recognition V2.0 for allemployees, further enhancing ourselection mechanism for honors andrecognition. Additionally, we estab-lished an assessment and incentiveframework that focuses on “productdevelopment projects as individualunits”, guided by the “goal of meetingmarket and customer demands”. Byleveraging project-based perfor-mance evaluations along with bonusstructures, we aim to enhanceemployees' motivation for progressand accelerate high-quality, innova-tive research and development ofproducts.
Incentivesand Recognition
In celebration of our anniversary in 2024, Bloomage Biotech honored benchmarked model employees at our celebration event byawarding a total of 16 prizes (eight categories) comprising individual awards such as 1 Chairwoman's Special Award, 7 ExcellentTeamwork Award, and 8 Outstanding Contribution Award. This not only expresses gratitude towards our dedicated workforce but alsoaims to motivate outstanding performers to continue achieving excellence alongside us.
CaseCommendation activities on Bloomage Biotech's anniversary
Group Photo of the Commended Employees at the Company Anniversary Celebration
In 2024
Employee stock ownershipplan (ESOP) covered
4,800,000
shares issued under this plan
Representing1%
of the total stock value
Forms ofrecognition
Spiritual Incentives: We enhance employees' sense of honor and achievement throughawards such as medals of honor or prestigious titlesMaterial Incentives: We conduct annual evaluations to identify outstanding projects,providing bonus incentives to both teams and individuals recognized for their contri-butionsTalent Development Incentives: Key accomplishments are documented in personaldevelopment ?le. Include employees in the core reserve echelon for special trainingopportunities. Provide promotion opportunitiesEquity Incentives: We implement long-term incentive measures for the Company’sdirectors, senior management, and key personnel. Outstanding individuals are givenpriority access to equity and other medium-to-long-term incentive programs
Objects ofrecognition
Teams or individuals excelling in our quarterly recognition programBenchmark Models: Recognized role models within each business lineEmployees who have made signi?cant contributions to critical projects or tasksEmployees involved in key milestone events for the Company
Recognitionfrequency
Awards will be given in the annual/quarterly summing-up meetingAwards will be given timely after important projects/tasks are completed
Honor and recognition system of Bloomage Biotech
6463
Key Performance
Key Performance
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
2024 Sustainability ReportAbout Us
Bloomage Biotech places paramount importance on employee occupational health and safety. The Company adheres strictly tolegal regulations such as the Work Safety Law of the People's Republic of China and the Law of the People's Republic of China on Preven-tion and Control of Occupational Diseases. We have established a comprehensive work safety management system alongsideoccupational health protocols that focus on enhancing safety practices across all operations, ensuring compliance with work safetyregulations while safeguarding employee well-being.
Safety and Health
By benchmarking against ISO 45001 standards and international best practices, we have further re?ned our policies governingsafety and health management, including the Work Safety Management System and Occupational Health Management System. As ofthe end of this reporting period, Bloomage Biotech's production bases in Jinan, Tianjin, and Dongying have all achieved ISO 45001certi?cation for their occupational health and safety management systems. Regular internal audits are conducted alongsideexternal audits to ensure adherence across all production bases.
Safety Management
Bloomage Biotech emphasizes standardized development for work safety through a top-down organizational approach thatdirects, coordinates, and implements safety tasks across subsidiaries while regularly convening meetings focused on work safety.The Company's Work Safety Committee serves as the supreme authority for safety-related a?airs. The Chairwoman and CEO of theCompany assumes the role of director, while the heads of various departments and safety heads of production bases aremembers.In 2024, Bloomage Biotech newly established the Safety and Environmental Protection Management Center. This center is taskedwith formulating and implementing the Company's safety and environmental protection strategies, ensuring the e?ective opera-tion of the safety and environmental protection systems. The Group has set up an internal safety expert panel and collaboratedwith a third-party to form an external expert panel. By conducting audits alternately between the internal and external expertpanels, the Company further strengthens the foundation of its safety system management and continuously improves its safety -management standards. This approach supports activities such as formulating work safety regulations, conducting safety audits,and engaging in academic discussions on work safety.
Security Structure
Bloomage Biotech sets goals related to occupational health and work safety every year, as a guide to promote various work safetymanagement tasks. In 2024, the Company adjusted the safety production goals of 2024 by combining the safety audit recti?cationopinions and national laws and regulations related to safety production. We have ?nally developed 19 annual goals and distributedthem to each subsidiary and branch, ensuring their implementation at each production base. In 2024, all of the Company's safetyobjectives were successfully achieved.
To achieve its safety production targets successfully, the Company has broken down the targets and delivered them to subsidiaries,departments, manufacturing workshops, teams, and individuals. We have completed the targets from top to bottom by standardiz-ing the production system, improving the safety management structure, developing a safety culture, and assessing safety perfor-mance.
Based on its realities, each production base has formulated its management measures for performance appraisal, which arerelated to vocational health and safety. These measures stipulated safety performance appraisal standards and procedures cover-ing all relevant employees. We also require general managers of all production bases and employees to sign a safety target respon-sibility letter. In 2024, the signing rate of employee safety target responsibility letters in all production bases of Bloomage Biotechreached 100%. Besides, the work-related injury insurance purchase rate also stood at 100%.
Safety Goals
10.82 million RMB
Invested in work safety and occupational health
135.2 thousand RMB
allocated to employees' work safetyliability insurance
100%
related positions' work safetyliability insurance
The number of accidents is ?
Number of work-related deathsNumber of work-related injuriesNumber of working days lost dueto work-related injuriesWork-related accidents per millionwork hours
Indicators
personcountday/
Unit
2024
0.32
2023
Employees' occupational health and safety conditions of Bloomage Biotech
2 The statistical scope encompasses the entire Bloomage Biotech Group, including safety investments, employee health check-ups, occupational diseasecheck-ups, detection of occupational disease hazard factors, and other occupational health and safety investments, as well as investments in employees' worksafety liability insurance and work-related injury insurance.3 This is not a mandatory requirement for the industry in which Bloomage Biotech operates.
Production Safety Committee
Departments
Production Safety Committee O?ceSafety Expert Group
Production bases
Workshops
Safety production management structure of Bloomage Biotech
Minor injury rate ≤ ?%
Completion rate of the “three simultaneous”requirements for new, renovated, and expanded
projects: ???%The pass rate of occupational hazard
factor detection: ???%Coverage rate of safety audits
(inspections): ???%Establishment of the Group's professionalauditing standards for occupational health and
environmental protection
Number of major incidents: ≤
The pass rate of hiddenhazard recti?cation ≥ ??%Timely reporting rate ofaccidents/incidents: ???%
Key Performance
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
In 2025, Bloomage Biotech will continueto centre its e?orts on the developmentof the safety system, aiming to compre-hensively enhance the Company's safetymanagement level. Through systematicmanagement and continuous innovation,we strive to elevate its safety manage-ment to a higher standard. The Compa-ny's work safety objectives for 2025 areas follows:
2024 Sustainability ReportAbout Us
Bloomage Biotech has formulated and continuously re?ned a comprehensive set of regulations, including the Hazard Identi?cation andRisk Assessment System and the Safety Inspection and Hidden Danger Investigation Management System. These systems encompass all aspectsof work safety management, such as risk identi?cation, safety hazard investigations, chemical management, occupational health manage-ment, equipment management, contractor management, operational safety management, emergency response protocols, and incidentmanagement. Additionally, we integrate safety culture development with safety monitoring and internal/external audits to consolidateour achievements in safety management.
Work Safety
Bloomage Biotech Safety Management System (Selected):
Work Safety Responsibility Management SystemManagement System for the Withdrawal and Use ofWork Safety Expenses
Work Safety Meeting Management SystemSafety Performance Appraisal Management SystemSafety Management
Management System for the Classi?cation and Control of Work Safety RisksIdenti?cation of Hazards and Risk Analysis of Operational Activities
Risk Assessment and Control
Management System for Safety Inspections and the Investigation and Treatment of Hidden Dangers
Hidden Danger Investigation
Safety Management System for Hazardous ChemicalsSafety Management System for Precursor and ExplosiveChemicals
Safety Management System for Major Hazard SourcesChemical Management
Management System for Labour Protection EquipmentOccupational Health Management System
Occupational Health Management
Safety Management System for Contractorsand SuppliersContractor Management
Management System for SpecialEquipmentSafety Management System forProduction FacilitiesEquipment Management
Management System for SpecialOperationsSafety Management System for Con?nedSpaces
Operation Safety Management
Incident Management SystemEmergency Rescue Management System
Emergency Response andIncident Management
Work Safety System
The Company implements a dual-prevention system that combines theclassi?cation and control of work safety risks with the investigation andmanagement of accident hazards. Safety education and training activitiesare carried out regularly. Through annual internal and external safetyaudits, the Company sorts out the list of safety risk factors each year andimplements safety management measures, thus achieving standardisedclosed-loop management throughout the entire production life cycle.Each production base of Bloomage Biotech has established a risk classi?-cation and control system and a system for the investigation and manage-ment of accident hazards. These systems are reviewed annually to ensuretheir e?ectiveness. The production bases have established risk controllists, including risk ledgers, records of hazard identi?cation and analysis.They also organise comprehensive inspections, seasonal inspections,special inspections, holiday inspections, monthly inspections, and irregu-lar daily inspections. Potential hazards discovered during inspections arepromptly issued to the responsible parties via the OA system for recti?ca-tion within a speci?ed time limit, and the relevant responsible parties areevaluated.The Company also attaches great importance to the safety managementof engineering contractors and other suppliers within the productionbases. It strictly implements the Safety Management System for Contractorsand Suppliers. Compliance checks are carried out on contractors' quali?ca-tions. Before the entry of all engineering contractors, safety requirementsand the responsibilities of both parties are clearly de?ned. Safety training,assessment, and technical disclosure are provided for external construc-tion workers. Safety supervision and management are carried outthroughout the process to promptly identify and rectify potential safetyhazards of contractors, preventing safety risks during the contractors' andsuppliers' operations within the park. In 2024, all production bases ofBloomage Biotech conducted a total of 467 safety education sessions forsuppliers, contractors and other personnel, with 27,823 participants. Inaddition, we care about the safety of employees' daily lives. Systemdocuments such as the Canteen Management Regulations and the EmployeeApartment Management Regulations have been formulated to ensure thesafety and hygiene of employees' food and accommodation.
Work Safety Management
In 2024
The internal safety auditcoverage rate of BloomageBiotech was100%Covering
elements such as work safetyobjectives and indicators,organisational structure andresponsibilities, productionequipment and facilitiesmanagement, operationsafety, risk classi?cation andcontrol, hazard investigationand management, in alldepartments and productionworkshops.The recti?cation completionrate was
100%.
The Company also actively promotes the automation and digitisation of work safety and strengthens safety monitoring in thefollowing ways:
Con?gure automatic alarm systems, including combustible gas detectors, automatic ?re alarms, temperaturedetectors, and audible and visual alarms.
Production bases have built security integration platforms equipped with intelligent systems. Real-time dynamicmonitoring is obtained through electronic maps, achieving comprehensive safety monitoring of the park.In daily management, we issue, rectify, and eliminate hazards through the OA system to improve work e?ciency.
6867
Key Performance
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
2024 Sustainability ReportAbout Us
To prevent hazardous chemical accidents, Bloomage Biotech adheres to relevant laws and regulations such as the Work Safety Lawof the People's Republic of China and the Regulations on the Regulations on the Safety Management of Hazardous Chemicals. TheCompany has developed a series of internal regulations, including: Safety Management System for Hazardous Chemicals and Precur-sor Chemicals; Management System for Highly Toxic Chemicals; Safety Management System for Explosive and Drug Precursor Chemicals.These regulations clarify departmental responsibilities and management approaches throughout the entire life cycle of hazardouschemicals. The Company standardizes the management process for hazardous chemicals, including procurement, storage, loadingand unloading, transportation, usage, disposal, and accident handling. Regular emergency drills are conducted based on estab-lished plans such as the List of Hazardous Chemicals and the Special Emergency Response Plan for Accidents of Hazardous Chemicals(Major Hazard Sources).
Chemical Safety
As Bloomage Biotech's core to promote its continuous innovation and development, the laboratory also serves as a centralizedplace for hazardous chemicals. To standardize laboratory safety management, the Company has formulated and implementedstrict laboratory safety procedures, clarifying standard operating procedures for the management of chemicals, biological materi-als, and laboratory equipment. We have taken multiple measures to ensure the safe operation of the laboratories.
Laboratory Safety
In 2024, production bases in Jinan, Dongying, and other places simulated hydrochloric acid leakage scenarios and carried out emergencyresponse plan drills. After the hazardous chemical keeper discovered the leakage, he noti?ed the members of the disposal team to wearacid- and alkali-resistant chemical protective suits, gas masks, goggles, and other personal protective equipment. Then, the leakedhydrochloric acid was adsorbed with sand, and the adsorbed sand and the damaged containers were transferred to the waste chemicalwarehouse. Finally, the hydrochloric acid containers were replaced. This drill helps improve employees' ability to coordinate scienti?con-site disposal when there is a chemical leakage, reducing the possible impact of leakage incidents.
Case
Drills for On-site Disposal Plans of Hazardous Chemical and HazardousWaste Leakage Conducted at Production Bases in Jinan, Dongying, etc.
Safety measures of Bloomage Biotech's laboratories (partial)）
We have assigned safety commissioners responsible for preparing laboratory emergency plans and conducting drillsEmergency preparedness
In the development of the institutional system for the global R&D platform, the Company has drafted and continuouslyre?ned the general guideline, including Global R&D Platform Laboratory Management Procedures, and issued specialsystems such as the Global R&D Platform Hazardous Chemicals Management Regulations, the Global R&D Platform Hazard-ous Waste Management Regulations, and the Equipment and Facilities Safety Management SystemFor the ?rst time, the R&D platform has established platform-level management systems, a safety performance manage-ment mechanism, and a safety mutual-inspection mechanism to boost the participation of all employees
System construction
We regularly maintain and inspect all laboratory equipment to ensure it is in good condition
Facility and equipment managementWe provide necessary personal protective equipment, such as lab coats, safety glasses, gloves, and masks, and ensurethat employees can use them correctly
Personal Protection ManagementWe properly classify, label, store, and dispose of all biological materials and chemicals to reduce the risks of cross-con-tamination and accidental exposures
Hazardous chemicals managementIdentify safety risks in R&D laboratories and rectify them in a timely manner to reduce the exposure of personnel to risks
Risk Identi?cation and Control
We regularly organized training on laboratory operations and equipment useIn 2024, the R&D platform organized a total of 7 EHSand safety training sessions, with 541 participants in total and acumulative training duration of 19 hours
Personnel training
Conduct physical examinations for R&D personnel to screen for occupational diseases promptlyIn 2024, a total of 191 occupational health examinations were carried out for R&D personnel in the platformOccupational Health Examination
7069
Chemical Safety Management MeasuresIdentify chemicals before warehousing and establish chemical labels and Safety Data Sheets (MSDS)Classify and store hazardous chemical storage cabinets in separate warehouses as required, and manage them with adouble-lock system by two personsIdentify high-risk chemicals and reduce or replace their usageObtain safety technical speci?cations from suppliers when purchasing chemicalsDetermine the inventory with the warehouse before procurement to reduce storage risksReduce the risk of exposure to hazardous chemicals by installing explosion-proof cabinets, accident fans, and combus-tible gas detectorsRegularly train employees on the properties, storage, retrieval, use, protection, and emergency response of chemicalsConduct a comprehensive survey of hazardous chemicals and establish an inventory of hazardous chemicals.Provide employees with labor protection equipment such as protective gloves, protective face shields, goggles, acid-and alkali-resistant clothing, and ?ltering gas masks according to the properties of the chemicalsSet up safety warning signs, hazardous chemical information cards, and operating procedures for positions involvinghazardous chemical operations, testing, and inspectionFormulate emergency response measures for hazardous chemical leakage and equip accident emergency facilitiessuch as chemical adsorption cotton, ?re sand, boric acid, and drenchers
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
2024 Sustainability ReportAbout Us
Bloomage Biotech is dedicated to creating a safety culture atmosphere through measures such as strengthening safety trainingand drills, building safety culture demonstration workshops, releasing safety knowledge posts, and organizing safety knowledgecompetitions. Moreover, Bloomage Biotech encourages employees to put forward reasonable safety suggestions and activelyparticipate in the Company's safety construction.
Safety Culture
Bloomage Biotech formulates and implements internal documents such as the Safety Training and Education System. The safetytraining plan is updated regularly every year. The main responsible persons, safety management personnel, and employees onspeci?c positions of each production base are required to receive safety education. Special operators and operators of specialequipment must hold relevant professional quali?cations. New employees must receive three-level training for work safety.
Safety Training
In 2024, Bloomage Biotech has optimized comprehensive emergency plans, special emergency plans and on-site disposal plans,such as the Work Safety Incident Emergency Response Plan, the Special Emergency Plan for Fire and Explosion Accidents, MechanicalInjury Incident Response Plan, Typhoon Preparedness Special Emergency Plan, On-site Response Plan for Heatstroke in High-TemperatureEnvironments, Earthquake (Evacuation) Special Emergency Plan. The plans cover a total of 13 categories, including ?re, vehicle injuries,electric shocks, alcohol accidents and scalding accidents, and the relevant plans have been registered for the record. We carry outsafety emergency drills in various production bases and o?ces every year based on relevant emergency response plans to helpemployees apply the knowledge and skills learned in safety training to practice.
Safety Emergency Drills
In 2024, Bloomage Biotech regularly educated and trained employees on safety and health regulations. Diverse training methods wereadopted, including classroom training, simulation drills, and case analysis, to enhance the training e?ect by combining theory andpractice. Additionally, each production base established a question bank of essential safety knowledge and urged departments toregularly assess employees to ensure that every employee masters the necessary safety knowledge.
CaseSafety Training Conducted by Each Production Base of Bloomage Biotech
In June 2024, several production bases of Bloomage Biotech launched “Work Safety Month” activities with the theme of “Safety for All,Emergency Ready, Clear Lifelines Always”. Activities such as emergency evacuation drills simulating ?re and earthquake scenarios, onlinepublic classes on risk avoidance and escape, and quizzes on risk avoidance and escape were organized to enhance employees' ability torespond to emergencies and avoid risks.
Case
“Work Safety Month” Activities Carried Out by BloomageBiotech in Multiple Locations
In 2024, to continuously improve the Company's design review level regarding the safety and operability of facilities, Bloomage Biotechorganized special training on Hazard and Operability (HAZOP) analysis at the group level. This training enhanced employees' ability toidentify and analyze potential hazards in engineering projects or production facilities in advance, ensuring safety from the perspective ofthe overall equipment system.
Case
Special Training on Hazard and Operability (HAZOP) Analysis Conducted byBloomage Biotech
Indicators
timesparticipantshour
1,75534,08036,629
16,67523,533
Occupational health and safety training of Bloomage Biotech
4 The statistical caliber covers all of Bloomage Biotech's all operating production bases in China.
In 2024, each production base of Bloomage Biotech carried out various types of drills, including comprehensive emergency drills, specialemergency drills for major hazard sources, and special emergency drills for ?res and special equipment accidents. The themes of thesedrills covered aspects such as ?res, simulated leakage in ethanol tank areas, abnormal boiler conditions, con?ned space operations, ?redrills, and emergency responses during the ?ood season. These activities comprehensively enhanced employees' emergency responsecapabilities to safety incidents.
CaseA Variety of Safety Drills Conducted by Each Production Base of Bloomage Biotech
Fire Drill at the Production Base
7271
Unit20232024
Number of occupational healthand safety trainingNumber of employees trained onoccupational health and safetyTotal hours of occupationalhealth and safety training
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement2024 Sustainability ReportAbout Us
Bloomage Biotech strictly complies with laws and regulations such as the Law of the People's Republic of China on the Prevention andControl of Occupational Diseases. During this year, we updated and implemented occupational health-related managementsystems, including the Occupational Health Management System and the Management System for Labour Protection Equipment. TheCompany regularly hires external institutions to detect occupational hazard factors at production bases and provides comprehen-sive protection against occupational disease risks for employees from aspects such as personal safety protection, environmental,and engineering measures. This is to address the Company's major occupational disease risks, such as dust, high temperatures,noise, and chemicals. During this reporting period, the health examination coverage rate of Bloomage Biotech employees hasreached 100%.
Occupational Health
The Company has adopted a series of measures to reduce or eliminate occupational disease hazards:
Personal ProtectionProvide employees and other personnel entering the production site with a full set of labor protectionequipment for free, and guide and supervise employees to use and wear them correctly
In 2024, Bloomage Biotech provided education and training on occupational health for employees. The training covered topics such asthe Company's occupational health management system and operating procedures, the use of occupational disease prevention facilitiesat their positions, the wearing of labour protection equipment, and the knowledge and skills of emergency response to occupationaldisease hazards. By combining theoretical learning with practical operations, the training e?ectiveness was enhanced.
Case
Occupational Health Training Conducted by Each ProductionBase of Bloomage Biotech
Practical CPR Training at the Hainan Production BaseOccupational Disease Knowledge Training at the Tianjin Production BaseIn addition, Bloomage Biotech attaches great importance to preventing the risk of repetitive strain injuries that may be caused toemployees during daily operations. By improving the working environment and operation methods, such as using robotic arms,automated guided vehicles (AGVs), and electric vehicles, and upgrading manual packaging processes to automatic or semi-auto-matic packaging machines, the Company reduces the pain or injuries that employees may su?er from repetitive movements andoveruse of muscles. We also install fans to exchange air, alleviating the impact of high temperatures in the workshop and prevent-ing negative health e?ects on employees during their work.
7473
Engineering Control and Equipment ManagementMinimize employees' exposure to occupational hazard factors through measures such as isolation, zonedoperations, ventilation, dust removal, noise reduction, and the sealing and piping of production equip-ment
Regular Occupational Health ChecksOrganize occupational health examinations for employees engaged in work involving exposure tooccupational disease hazards before taking up their posts, during their employment, and upon leavingtheir posts. Inform employees of the results of the occupational health checks and the suggestionsprovided by the occupational health examination institutions
Management MeasuresIn terms of risk prevention, identify the risks of occupational hazards in the workplace and formulatepreventive and control measuresImplement management control measures, such as reducing working hours and improving operationmethods, to control the extent of employees' exposure to harmful factors and mitigate the potentialhealth impactsSet up warning signs and instructions in prominent locations in workplaces, job positions, equipment,and facilities where occupational hazards exist or are generatedSet up the “Hazard Snap” Mini Program in the OA system, enabling employees to report any discoveredoccupational health and safety hazards, risks, and issues at any time, and ensuring that these reports arepromptly addressedConduct regular occupational health training and organize a series of emergency drills to enhanceemployees' awareness and capabilities of health protection
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement2024 Sustainability ReportAbout Us
7675
Bloomage Biotech has continued to re?ne its compensation and bene?ts system and establish standardized management policies.The Company provides employees with excellent working conditions, ensures smooth communication and complaint channels,and strives to create a respectful, fair, and friendly work atmosphere. These e?orts are aimed at continuously enhancing employ-ees' sense of happiness and belonging.
Employee Rights and Bene?ts
Bloomage Biotech adheres to the principle of equal pay for equal work. This year, the Company updated the Salary ManagementSystem and the Performance Management System and introduced a broadband salary model for the ?rst time. To match salary withemployees' contributions and performance and to boost their motivation, we have optimized the income distribution structureand clari?ed the salary incentive orientation. The Company pays salaries on time and in full and provides pay stubs to employees,enabling them to understand the details of their compensation structure, bonuses, and bene?ts. Each year, the Company usesannual performance ratings as the basis for salary adjustments, combining individual salary levels in the market, performanceratings, and total compensation to form a salary adjustment plan.
Employee Compensation
In 2024, Bloomage Biotech continued to optimize the Bene?ts Management System, enhancing the employee bene?ts system tocover three categories: statutory bene?ts, supplementary bene?ts, and position-based bene?ts. Based on employee feedback, were?ned our bene?ts structure to meet diverse employee needs. Moreover, the Company strengthened its care for employees byestablishing a lactation room for female employees, and a gym, and organizing activities such as holiday celebrations, periodiccondolences, and team-building events to help employees balance work and family life. Additionally, we have made the o?ceenvironment more comfortable to provide employees with a more pleasant and humane workplace.
Employee Bene?ts
The Company's remuneration payments are based on the following principles:
Bloomage Biotech bene?ts system
The Company's salary structure includes the following components:
Principle of jobvalue payment
Principle of perfor-mance results payment
Principles of openness,fairness, and transparency
Fixed cash incomeVariable cash incomeOvertime payAllowances and subsidies
Salary type
Base salary, position salary, and seniority salaryMonthly performance bonus, quarterly performance bonus, project bonus, salesbonus, annual bonus, and special bonusOvertime pay for hours beyond standard working hours and holiday overtime payGeneral subsidies such as meal allowance, transportation subsidy, and high-tempera-ture allowance, as well as subsidies for employees stationed in other locations
Contend
In 2024
The social security contribution ratefor all employees100 %
The coverage rate for supplementary medical insuranceand physical examination for regular employees100 %
Provide meal allowances based on job nature and support employees in advancing their education:
Transportation allowancesCommunication allowancesShift allowancesLearning and growth allowances (for education advancement)
Position-based
bene?ts
Provide bene?ts to employees to meet national statutory requirements based on the Leave and AttendanceManagement System and the Bene?ts Management System:
Social insurance (medical insurance, pension insurance, unemployment insurance, work-related injury insurance, maternityinsurance)Housing provident fundStatutory holidays, annual leave, sick leave, marriage leave, maternity leave, parental leave, nursing leave, paternity leave,and funeral leaveLabor protectionEducation and training
StatutoryBene?ts
Provide additional bene?ts to all regular employees to enhance welfare bene?ts and satisfaction, including:
Care bene?ts: commercial insurance, annual physical examinations, high temperature subsidiesWarmth bene?ts: holiday gifts, condolence allowance, birthday bene?tsEconomic bene?ts: lunch allowances, overtime meal allowances, transportation allowances, work-type residence permit,employee purchase programLearning and growth bene?ts (for professional quali?cations and certi?cations)Supplementary
bene?ts
Key Performance
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
2024 Sustainability ReportAbout Us
In March 2024, BloomageBiotech's subsidiaries andbranches held Women's Dayactivities themed "Achieving aBetter Self", featuring ?owerarranging, ?ower gifting, and DIYhandicrafts for femalecolleagues. These activitiespromote employee happinessand work-life balance.
CaseBloomage Biotech carried out Women's Day activities
Besides, to promote employee health, the Company has implemented diverse measures, including organizing sports activities, fun sports meets, andbuilding a gym. Additionally, the Company has organized free medical activities to help employees monitor their health in a timely manner.
Workplace gymFree medical services provided by hospital sta?Fun sports meets
Bloomage Biotech's health bene?ts
Bloomage Biotech attaches importance to communicating with employees and has established multiple and open channels,including face-to-face activities like employee meetings and departmental meetings, as well as online feedback channels such asemail and suggestion boxes. In 2024, the Company further democratized its systems and processes by publicizing new policies oninternal communication platforms and soliciting suggestions.To protect employees' legitimate rights, interests, and privacy, the Company has established an anonymous complaint and report-ing channel and kept employees' complaints and reporting information con?dential. Employees can anonymously report anyviolations, workplace misconduct, or health and safety issues to their superiors or the Human Resources Department. Then, therelevant responsible departments conduct follow-up investigations and handling based on employees' complaints or reports.
Bloomage Biotech regularly conducts employee satisfaction surveys anonymously, covering ?ve dimensions: job duties, manage-ment process, working environment, career development, salary, and bene?ts. We have also analyzed data with a third-partyprofessional research platform to ensure objective and professional survey results. Currently, the Company's employee satisfac-tion score stands at 85 points. Additionally, Bloomage Biotech has conducted surveys on the hygiene, meals, environment, andservice quality of the company cafeteria, with satisfaction rates exceeding 97%. Based on the survey analysis, the Company has anunderstanding of employees' work conditions, thus providing care and developing plans to improve employee satisfaction.Furthermore, Bloomage Biotech fully respects employees' rights to freely associate and refrains from interfering with the legalestablishment, operation, or management of collective bargaining, thereby facilitating e?ective communication between labor andmanagement. Each of Bloomage Biotech's production bases has established its trade union. According to the Trade Union Manage-ment System, we listen to employees' opinions, safeguard their legitimate interests and democratic rights, and regularly carry outunion welfare activities to improve their lives.In 2024, all major production bases of Bloomage Biotech signed the Collective Labor Agreements with the company’s trade union.The agreements cover principles of diversity, non-discrimination, and non-harassment, as well as working hours, salaries, occupa-tional safety and health, women's rights, employee insurance, bene?ts, and training, ensuring the protection of employees' legalrights and reasonable treatment.
Employee Communication
hr@bloomagebiotech.comBloomage Biotech’s employee channel for rational suggestions and opinions:
In June 2024.Bloomage Biotech helChildren'sDayactivities to strengthenthe bond betweene-mployees and theirchildren and enhancethesense o?denti?cation ofemployees'familieswith the workplace,further fosteringaharmonious and warmworking environment.
CaseBloomage Biotech's Children's Day activities
Bloomage Biotech's family fun activities on the Children's Day
Bloomage Biotech has launched its "Happiness Proposal" plan, o?eringcongratulations and gifts to employees on holidays and birthdays, and otherkey dates. In 2024, the Company organized various activities, including funsports meet, dumpling-making activity, and the Loong Year celebration, toconvey care and gratitude, enhancing employees' sense of belonging andhappiness.
CaseBloomage Biotech's "Happiness Proposal" plan
Bloomage Biotech’s employees and their children
attended the Loong Year celebration
Bloomage Biotech’s ?ower arranging and ?ower gifting activities on the Women's Day
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
2024 Sustainability ReportAbout Us
2024 Sustainability Report
SDGs Addressed in this Chapter:
Major Material Topics of Sustainability Covered in this Chapter· Environmental Compliance Management· Environmental Permits and Certi?cations· Pollutant and Waste Management· Product Environmental Impact
· Water Management· Response to Climate Change and Energy Management· Biodiversity
Symbiosis: Green, Low-Carbon,and ResilienceThe genes of green technology have been deeply embedded in every aspectof Bloomage Biotech's operations. The Company actively practices theconcept of green manufacturing, continuously improves its environmentalmanagement system, re?nes product design and processes, in an e?ort toreduce resource consumption and pollutant emissions. To address climatechange, we proactively drive green production through technologicalinnovation and the adoption of clean energy. Furthermore, we focus onresource recycling and reuse to advocate for a green and low-carbon lifestylein society.
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagementAbout Us
Production andoperations optimization
Product upgrades
Supply chain
enhancement
Strategic measures
Optimize energy and resource usein production
Continue to focus on sustainableproducts and technology R&D
Supply chain ESG management
Speci?c measures
Conduct greenhouse gas accountingContinuously implement energy-savingtechnological upgradesConstantly build a low-carbon corporate cultureDeploy renewable energy infrastructureParticipate in green electricity markettransactions
Perform greenhouse gas (Scope 3) accountingacross the value chainEncourage suppliers to improve their greenhousegas management levels
8281
Bloomage Biotech actively explores the development path of green manufacturing. The Company has been less dependent onfossil-based materials and continuously reduced resource consumption and GHG emissions. While reducing its own emissions, theCompany strives to provide green manufacturing solutions.To scienti?cally and e?ectively disclose the Company's e?orts in addressing climate change, we follow the recommendations of theTask Force on Climate-related Financial Disclosures (TCFD) and disclose our climate change risk management system and actionsfrom four dimensions: governance, strategy, risk management, as well as metrics and targets. The Company continuously seekssolutions to address climate change and strives to achieve sustainable, low-carbon development goals through emission reductionplanning, energy-saving technology applications, and renewable energy utilization.
Addressing Climate Change
Bloomage Biotech has established a top-down sustainable development management mechanism and assembled a dedicatedteam with professional knowledge, industry background, and experience. Regular specialized training was conducted to empowerthe organization to e?ectively drive climate change and energy-saving initiatives. Additionally, the Company has incorporated ESGperformance evaluation requirements, including climate change, into the annual personal performance commitments of relevantsenior executives, department heads, and specialized positions. To e?ectively implement relevant initiatives, we have utilized asalary-based incentive mechanism.
Bloomage Biotech has integrated climate change response into its sustainable development strategy and conducted carbonemission accounting from dimensions of both organization and product. We have set a special budget for greenhouse gas manage-ment and implemented low-carbon transition along two paths: energy conservation and emission control.Additionally, the Company proactively discloses its climate change management and performance on platforms like CDP, demon-strating its determination to address climate change and contributing to the mitigation of global warming.
Climate Strategy and Goals
Aware of the urgency and necessity to accelerate low-carbon transition, the Company aims to reduce total group-wide carbonemissions (Scope 1 + Scope 2) by 50% by 2030 (compared to that in 2023). We strive to scienti?cally and e?ciently reduce emissionsto the best of our capabilities.
During the reporting period, in order to strengthen its management of product sustainability, Bloomage Biotech conducted life cycle
assessments (LCAs) on multi-category products, including pharmaceutical-grade, cosmetic-grade, and food-grade Sodium Hyaluronate,
as well as cosmetic-grade Ectoine and BIOHYALUX HA Barrier Conditioning Single Use Essence. The Company calculated key indicators
such as product carbon footprint, resource consumption, and water consumption, and engaged authoritative auditing institutions to
conduct veri?cations, obtaining compliance statements in accordance with ISO 14040, ISO 14071, ISO 14064, ISO 14067 standards.
Case
Conducting life cycle assessments (LCAs) on multi-category products toevaluate their environmental impactsReview and supervise the identi?cation and assessment of risks and opportunities related to climatechange, as well as the completion of speci?c projectsESG Committee under the Board of Directors
Tasked with overseeing the daily management of climate change issues, conducting policy researchand training, developing climate change strategies and targets, leading the implementation andmonitoring of climate-related projects, and supervising carbon management and information disclo-sureESG Management
Center
Follow the Company’s climate strategy and targets, implement climate-related action plans, strength-en energy resource management, and regularly report progress on these actionsESG Working Groups
Oversee and make decisions on climate-related matters, such as formulating strategies related toclimate change, setting emission reduction targets and pathways, managing climate risks, andmonitoring progress toward emission reduction goalsBoard of Directors
Bloomage Biotech’s climate strategy framework
Bloomage Biotech’s climate governance structure
Carry out life cycle assessments (LCAs) onproducts to evaluate their environmental impactsPay attention to sustainable ingredients andpackaging innovation
ESG
ESG
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
2024 Sustainability ReportAbout Us
Bloomage Biotech places great emphasis on identifying and managing climate-related risks and opportunities. Under the reviewand guidance of the Company’s Board of Directors and the ESG Committee, the ESG Management Center has led the developmentof risk and opportunity assessment and response plans and coordinated with functional teams such as production, procurement,energy, and ?nance to implement speci?c tasks. Additionally, during this reporting period, we incorporated climate risk manage-ment into the Company’s overall risk management system, conducting quarterly risk assessments and reporting.
Risk and Opportunity Management
Climate Risk and Opportunity Management Process
We have conducted the scenario analysis based on the two Representative Concentration Pathways (RCPs) of the Intergovernmen-tal Panel on Climate Change (IPCC), namely RCP4.5 (low carbon emissions scenario) and RCP8.5 (high carbon emissions scenario).We have comprehensively identi?ed our potential physical risks in the short, medium, and long term as follows:
List of Climate Risks and Opportunities
Acute Risks
Chronic Risks
RiskType
Medium
Medium
RiskLevel
Short,medium,and longtermsShort,medium,and longterms
ExpectedOccurrenceTime
Possible damages or faults to devices and infrastruc-ture, resulting in production interruption and reducedproduction e?ciency, as well as more additional costsin device maintenance and replacementAn increase in short-term wastewater disposalburdens leads to larger external drainage volumesand severer water pollution risks, a?ecting productionstabilityThe normal operation of logistics and supply chainmay be a?ected with logistics delays, inventoryshortages, and overdue delivery, incurring a big threatto business continuity and client satisfaction
Potential Impacts
Develop the Preparedness Plan to Respond to NaturalDisasters, the Emergency Plan for EnvironmentalEmergencies, and the Production Safety AccidentResponse, combined with regular drills to continuouslyimprove emergency response mechanismsPre-emptively stockpile ?ood control materials,optimize water supply and drainage facilities, andinstall cuto? valves at discharge points
Short,
medium,
and long
terms
A need produced to equip more refrigerationequipment in an increased operational costSome raw materials and products go bad duringstorage and shipment, a?ecting the quality andmarketability of productsFire and explosion risks rise in the warehousing
Develop the Preparedness Plan to Respond to NaturalDisasters, combined with regular drills to continuouslyimprove emergency response mechanismsKeep the ventilation, temperature, and humidityunder control at a reasonable level in storage andtransportationStrengthen ?re prevention, including regularinspections and maintenance of ?re-?ghtingequipment and facilities, and ?re drills
Low
Short,
medium,
and long
terms
An increase in short-term wastewater disposalburdens leads to larger external drainage volumes andseverer water pollution risksPossible damage or faults to devices and infrastruc-ture, resulting in production interruption and reducedproduction e?ciency, as well as more additional costsin device maintenance and replacement
Develop the Preparedness Plan to Respond to NaturalDisasters, combined with regular ?ood drills tocontinuously improve emergency responsemechanismsPre-emptively stockpile ?ood control materials,optimize water supply and drainage facilities, andinstall cuto? valves at discharge points
Medium
Short and
medium
terms
Long-term drought may cause a water shortage inproduction and a?ect production stability
Stick to optimization of production processes, andemploy water-saving devices instead of old ones forhighly e?cient water resource utilizationScienti?cally arrange production plans and strictlyimplement water usage plans
Long term
Seawater intrusion in coastal areas can damageinfrastructure and production equipment, and causeerosion and ?ooding of factories, warehouses, ando?ce buildings, leading to production suspension andrelocationDamage to coastal ports and transportation channels,resulting in supply chain disruptions or logistics delays
Strengthen the resilience of buildings andinfrastructure to disasters, such as a design of higherbuilding foundation and more e?cient drainagesystemsAssess risks related to sea-level rise in coastal sites soas to adjust investment and development plans in atimely manner that potential risks are addressed
Response
Physical Risks
8483
Based on our production andoperational insights, we identifyclimate-related risks and opportunitiesby integ rating industry trends,domestic and international policylandscapes, and benchmarking againstbest practices, ultimately forming acomprehensive list
Identi?cation
We develop response plans for risksand opportunities, including but notlimited to formulating low-carbontransition plans and implementing aseries of adaptive measures appro-vedby the management
Response
We continuously engage in communi-cation with relevant parties andregularly conduct reassessments toensure that the risks, opportunities,and response measures are suitablefor the Company’s actual situation
Monitoring
In combination with our actualbusi-ness operations, we evaluate theapplicability and importance of eachrisk and opportunity and comprehen-sively determine the risk level andmaterial opportunities from perspec-tives including the probability ofoccurrence, business development,?nancial impact, and reputationalimpact
Evaluation
The climate risks and opportunity management process of Bloomage Biotech is as follows:
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
ExtremePrecipi-tation
High
TropicalCyclone
Extreme
Heat
Floods
WaterShortage
Sea-Level Rise
Low
2024 Sustainability ReportAbout Us
We analyze climate-related transition risks and opportunities facing the Company with two shared socio-economic pathways (SSPs)of the Intergovernmental Panel on Climate Change (IPCC), namely SSP1-1.9 (low carbon emission scenario) and SSP2-4.5 (highcarbon emission scenario).
During this reporting period, the Company e?ectively managed the above risks, which did not have a signi?cant impact on normaloperations and development. Additionally, the Company remained committed to low-carbon transition and continuouslyenhanced the low-carbon competitiveness of the organization and its products.
Transition Risks and Opportunities
Potential ImpactsResponseRisk/Oppor-tunity Type
Technological cost in low-carbon transitionInvestments in low-carbon technology failed and theCompany lagged behind peers in low-carbon transition
Monitor the rationality and applicability assessment of relatedtechnologiesTechnologies
Raw material costs may rise due to the climate- a?ectingquality and quantityClient/consumer demand for low-carbon products andgrowing ESG requirements for suppliers may reduceproduct demandClimate change may trigger regional power and waterrestrictions, or increased electricity prices, leading tohigher production and operating costs
Monitor raw material markets to anticipate price ?uctuationsStrengthen supply chain management by developing diversesuppliers and promoting suppliers’ carbon reductionEngage in energy conservation and emission reduction, increasethe use of clean energy, and communicate with stakeholders in atimely mannerIntegrate the concept of sustainability into product R&D,production, and sales to meet the demand for green products
Market
As the Company's ESG performance remains a focus forstakeholders, failure to address climate change risks orful?ll environmental responsibilities may damage itsreputation, leading to a deterioration of its brand imageand market positionIf emission reduction targets are not met, the Companymay need to purchase carbon o?set products to ful?llvoluntary emission reduction commitments, resulting inincreased operating costs
Engage with stakeholders on climate-related concerns throughvarious meansPlan carbon o?set transactions strategically and controltransaction costs
Reputation
Incentive policies involving carbon reduction subsidies andsupport are formulated by the government
Actively engage in the development and implementation ofcarbon reduction projects and timely apply for relevant subsidiesDeploy renewable energy applications, access green electricitysupply, and construct distributed photovoltaic and biogas powergeneration facilities at production and operational sites
Policies
The Company can count on new ?nancing channels andsupport policies attributable to the development of green?nancing and sustainable investmentThe demand of clients for green products increases
Build the capability of advancing green transformation andexpand funding sourcesAchieve non-hazardous disposal and low-carbon production ofproducts by means of R&D innovation, process optimization, etc.and try to obtain product carbon footprint certi?cation andenvironmental declaration for higher product competitivenessMarket
Opportunities are provided by industrial energy- savingtechnologies and equipment for companies to reducecosts and increase production e?ciency
Employ high-e?ciency production equipment to improveresource recovery and utilization, and further reduce costsrelated to energy and resource consumptionTechnologies
Type
Risk
Energy conservation and emission reduction emerge as key measures to address climate change. Bloomage Biotech has continu-ously carried out low-carbon transition initiatives from three aspects: improving energy management capabilities, enhancingproduction and operational energy e?ciency, and promoting value chain carbon reduction.Low-Carbon Transition and Emission Reduction Achievements
Bloomage Biotech actively advances the institutionalization of energy management to lay a solid foundation for ongoing energye?ciency improvements and energy consumption reduction. The Company sets annual energy management targets and hasformed a multi-level, full-production-base energy management network. The energy management network comprises leadinggroups at each production base, the Engineering and Equipment Department, related departments, workshops, and teams, all ofwhom have worked together to implement these targets. In 2024, we updated several procedural documents, including the EnergyManagement, Energy Saving and Consumption Reduction Regulations and the Energy Management Implementation Plan, to achievescienti?c, standardized, and procedural energy management.During the reporting period, Bloomage Biotech pursued ISO 50001Energy Management System certi?cation. The Jinan and Tianjin production bases successfully obtained the certi?cation.
Energy Management System Improvement
In July 2024, the Tianjin production base conducted a self-inspection based on relevant regulations, covering the Company's energymeasurement organizational structure, objectives, personnel, and relevant instrument management and calibration, as well as themanagement system, energy utilization, and energy ?ow. This ensured that the entire process remained under control, resulting in theSelf-inspection Report on Energy Measurement for Key Energy-Consuming Units. Based on the self-inspection results, the Tianjin productionbase achieved a 100% equipment rate for energy measurement devices, and all energy measurement sta? passed their job trainingassessments.
Case
Energy measurement audit at Tianjin production base tofurther strengthen energy management
8685
Energy management measures of Bloomage Biotech mainly include:
Forbid the use of equipment phased out by the state and use the latest energy-saving products recommended by the stateCarry out regular equipment maintenance, repair, and optimization to ensure that equipment operates at optimal conditions overthe long termEnergy-consuming equipment management
Establish and improve energy measurement systems. Equip with certi?ed measuring instruments and professionally quali?edmeasurement personnel as required, and conduct regular energy statistics to meet the requirements for energy classi?cation,grading, and itemized measurementBuild an energy management platform to continuously enhance digital energy management capabilities of the organizationEnergy metering statistics
Engage professional agencies to assist production bases in energy auditsImplement daily energy management inspections and a joint inspection system. Reward and punish individuals and departmentsbased on their performanceEncourage employees to put forward rationalized proposals and participate in technological transformations of energy-saving andconsumption- reducing. Provide positive incentives based on cost savings when the proposals are implemented and evaluated tobe e?ective
Energy performance management
Collect steam and thermal energy from the fermentation process and apply for factory heating, hot water supply, and thermalenergy consumption in the employee cafeteriaEnergy cascading utilization
Conduct energy audits regularlyEnergy audits
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
Oppor-tunity
If the Company is included in the national or regionalcarbon market, the associated compliance operating costsmay increaseAs stricter national policies and regulations are enacted tomitigate climate change, enterprises are faced with morecompliance pressures and related litigation risksThe Company's exported products may face policiesrelated to carbon tari?s and carbon footprint and otherrestrictions in the future
Pay close attention to global market conditions and changes inlaws, regulations, and policies involving carbon emissions. Carryout annual organizational carbon inventories and audits alongwith product carbon footprint certi?cationsStrengthen internal management by setting low-carbontransition targets and plans and implementing a series of actionsPolicies andregulations
2024 Sustainability ReportAbout Us
Purchase high-e?ciency o?ce equipmentProhibit the use of lighting and air conditioning in unoccupied areas. In occupied areas, only necessary lightingand air conditioning facilities will operateSet summer air conditioning temperatures at 26°C and winter temperatures at 23°CEncourage employees to turn o? power sources when not in use, cut o? power to certain areas during statutoryholidays, and post energy-saving slogans at lighting switch locationsArrange for dedicated personnel to conduct inspections and promptly address wasteful practices
Energyconservation
Replace o?ce fuel vehicles with hybrid or electric vehiclesInstall charging stations in parking areas
The energy use of Bloomage Biotech is as follows:
Energy Use
In 2024, Bloomage Biotech continued to expand and deepen e?orts in emission reduction actions based on two pillars: “improvingenergy e?ciency” and “advancing energy transition”.Production and Operational Energy Use Optimization
Unit20232024IndicatorsNatural gasGasolineDiesel oilPurchased heat from fossil fuelsPurchased heat from biomass fuelTotal electricity consumption Purchased electricity (thermal power) Purchased renewable electricity(wind power) Self-generated renewable electricityTotal comprehensive energyconsumptionComprehensive energy consumption intensity
cubic meter
litre
litre
GJ
GJ
kWh
kWh
kWh
kWhtons of standard coalton of standard coal/revenue in
RMB 1,000,000
15,686,836
21,7068,939174,331.7338,282.6970,453,12366,931,210/3,521,91335,071.79
5.77
13,073,45330,1127,934245,503.80153,263.0594,746,87477,625,77113,375,6183,745,48535,346.54
6.58
Energy Use of Bloomage Biotech5
8887
The statistical caliber covers all of Bloomage Biotech's wholly-owned operational production bases in China. In 2024, multiple production bases purchasedrenewable electricity (wind power) and biomass heat. "/": Not applicable.
Bloomage Biotech set goals to continuously enhance operational energy e?ciency. Production bases actively explore and analyzeenergy-saving potential and encourage all employees to provide suggestions for energy conservation and consumption reduction. In2024, the Company focused on the usage optimization and upgrade of energy-consuming equipment to improve energy e?ciency.Improving Operational Energy E?ciency
Bloomage Biotech has accelerated the transition to renewable energy, increasing the proportion of renewable energy usage.Building on existing distributed photovoltaic and biogas power generation facilities, the Company constructed new biomass boilersin 2024 and introduced purchased renewable electricity (wind power) and biomass heat, and achieved an equivalent emissionreduction of approximately 26,913.24 metric tons of carbon dioxide equivalent (CO2e).
Bloomage Biotech organizes annual training programs on energy conservation and environmental protection, and conductsenvironmental activities during National Low-Carbon Day (May 15), World Environment Day (June 5), and National Energy Conserva-tion Week. These activities convey to employees the contributions of water conservation, reduced detergent use, electricity savings,paper reduction, decreased single-use products, waste sorting and recycling, low-carbon travel, and green diet to resource conser-vation and environmental protection. The Company encourages and guides employees to start with themselves and practice greeno?ce and low-carbon living.
Advancing Energy Transition
Bloomage Biotech actively promotes low-carbon operations in o?ce settings through various measures, including energy manage-ment, consumables management, and digital o?ce practices, to enhance resource e?ciency in o?ce operations.
Advocating Green O?ce
Indicators
Purchased renewable electricity (wind power)Self-generated renewable electricity Photovoltaic electricity generation Biogas electricity generationPurchased heat from biomass fuel
Unit
kWhkWhkWhkWh
GJ
2023
/3,521,9132,401,7251,120,18838,282.69
2024
13,375,6183,745,4852,312,1921,433,293153,263.05Renewable heat
Renewable Energy Consumption of Bloomage Biotech6
Production basesEnergy e?ciency improvement measures (partial)
Greentransportation
5 The increase in total consumption of fossil energy heat and electricity this year was attributable to increased production capacity at the Tianjin production bases,leading to higher total comprehensive energy consumption. The Jinan production base increased its purchase of biomass heat, resulting in reduced total naturalgas consumption. Multiple production bases purchased renewable electricity (wind power) in 2024; The total comprehensive energy consumption calculated intons of standard coal only includes fossil energy consumption. “/”: Not applicable.
Chaohuproduction base
We optimized warehouse temperature and humidity control settings, arranged warehouse layouts more e?ciently, reducedarti?cial lighting, and replaced traditional light sources with LED lamps to lower energy consumption
Implement digital o?ce platforms and encourage electronic reporting and online meetingsPromote fully electronic invoicing and paperless operations, achieving online and paperless approval processesRequire double-sided and black-and-white printing, set up A4 paper recycling bins, and repurpose printed wastepaper for secondary usePaper conservation
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
We implemented a compressed-air networked operation project for pharmaceutical machinery air compressors, refrigerantdryers, and instruments. By optimizing equipment operation modes, energy e?ciency was improved, and energy consumptionwas reduced, with an estimated annual electricity savings of around 470,000 kWh and approximately RMB 370,000 in electricitycostsWe set ?xed stirring times for dissolving tanks to avoid unnecessary electricity consumption from ine?ective stirring, with anestimated hourly electricity savings of close to 45 kWh and annual electricity cost savings of RMB 20,000–RMB 50,000Jinan production base
We upgraded sedimentation tanks to save ethanol usage while achieving estimated savings of approximately 330,000 kWh ofelectricity and 6,000 tons of steam annuallyWe modi?ed the outlet pump of the bu?er tank by adding an exhaust port and enhancing valve control to avoid repeatedoperations, resulting in electricity savings of 1,485 kWh
Tianjinproduction base
Renewable electricity
2024 Sustainability ReportAbout Us
The statistical caliber of the Company's Scope 1 and 2 GHG emission data covers all of Bloomage Biotech's wholly-owned operational production bases in China.GHG emissions include emissions from natural gas consumption, diesel fuel, gasoline, fugitive methane from wastewater, refrigerant charge, ?re extinguishers,purchased electricity, and purchased heat; and Scope 3 data include emissions from purchased goods and services, capital commodities, fuel and energy relatedactivities, upstream transportation and distribution, business trips, and sold and sold products transportation and distribution. The Company conductsgreenhouse gas accounting in accordance with the requirements set forth in the Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard as wellas the ISO14064-1:2018 Greenhouse gases—Part 1: Speci?cation with Guidance at the Organization Level for Quanti?cation and Reporting of Greenhouse Gas Emissionsand Removals. “/”: Not applicable.
The statistical caliber covers all of Bloomage Biotech's wholly-owned operational production bases in China, including waste disposal costs, environmentalmonitoring costs, and renewable energy costs.
While focusing on energy conservation and emission reduction in its own operations, Bloomage Biotech also pays attention toenergy use and energy-saving achievements in the upstream and downstream of the value chain, striving to work with suppliersand consumers to jointly promote the carbon reduction process across the entire value chain.Promoting a Green and Low-Carbon Transition across the Value Chain
In 2024, Bloomage Biotech continued to conduct greenhouse gas emissions review and performed accounting for emissions acrossthe value chain (Scope 3) for the ?rst time.
Emission Performance
We urge suppliers to payattention to the risks andopportunities brought by climatechange, take conservation andsubstitution measures, activelyintroduce green energy, reduceconsumption of energy, water,and natural resources, anddecrease greenhouse gasemissionsWe have collected and assessedsuppliers' greenhouse gasemission information andreduction measures throughquestionnaires
Suppliers
We have promoted low-carbonlifestyles among consumersthrough initiatives such as emptytube recycling programs, productre?ll core designs, supplementarypacks, and large packaging toreduce small packaging usageWe have disseminated BloomageBiotech's sustainable developmentconcepts and practices toconsumers through mediareleases and exhibitions, guidingthem to practice sustainableconsumption behaviors
Consumers
We have optimized the layout of cloud warehouses,shortened transportation distances throughmulti-warehouse shipping models, increased vehicleload factors, and improved transportation e?ciencywhile reducing carbon emissionsWe choose carriers that use renewable energy andcollaborate with them on emission reductionmeasures in the transportation process, promotinga shift from traditional air transport to sea transportfor overseas businessWe have optimized the packaging space design toreduce void ratioWe use recyclable insulation boxes and ice packs
Logistics and packaging
IndicatorsTotal GHG emissions (Scope 1 + Scope 2) Location-based Market-basedScope 1 EmissionsScope 2 Emissions Location-based Market-basedGHG emissions per unit of revenue(Scope 1 + Scope 2) Location-based Market-basedScope 3 Emissions
Unit
tCO2etCO2etCO2etCO2etCO2etCO2e/revenue in RMB 1,000,000tCO2e/revenue in RMB 1,000,000
tCO2e
2023
100,902.09/43,554.7357,347.36/
16.61
//
2024
GHG emissions of Bloomage Biotech
9089
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
113,510.99109,785.9437,412.2776,098.7272,373.66
21.14
20.44
183,852.39
Upholding the concept of green manufacturing and the management policy of "preventing accidents, complying with regulations,protecting the environment and continuously improving", Bloomage Biotech has established and continued to improve the environ-mental management system to ensure environmental compliance while reducing the impact of operations on the environment.
Environmental ComplianceManagement
Environmental Management System
Wastewater discharge compliance rate100 %
Air emissions compliance rate
100%100%100%
National Green Factory(Jinan production base)
Provincial Green Factory(Tianjin production base)
Key Performance
Bloomage Biotech strictly complies with laws and regulations including the Environmental Protection Law of the People’s Republic ofChina and the Law of the People's Republic of China on Environmental Impact Assessment. With reference to the standards and require-ments of ISO 14001 Environmental Management System, we have revised internal environmental management systems, includingthe Environmental Protection Management System, the Environmental Factor Identi?cation and Evaluation Process, as well as manage-ment regulations on air emissions, wastewater, and waste discharge, in accordance with its own environmental managementstatus. Through systematic management, the Company aims to enhance its performance in environmental protection.In 2024, allmajor production bases of Bloomage Biotech (Jinan, Dongying, and Tianjin) obtained ISO 14001 Environmental ManagementSystem certi?cation.During this reporting period, the Company optimized its environmental management organizational structure. At the group level,the newly established Safety and Environmental Protection Management Center is responsible for setting overall EHS goals, annualtargets, and work plans, and for cascading, implementing, and evaluating these goals to ensure their achievement. At the produc-tion base level, the Safety and Environmental Protection Department is tasked with identifying and assessing environmentalfactors, determining signi?cant environmental factors and related targets and indicators, and formulating and supervising theimplementation of management plans. At the workshop level, environmental protection managers are appointed to implementregional environmental responsibilities and ensure the smooth progress of environmental protection e?orts.To further clarify the responsibilities of relevant departments, standardize employees' environmental protection and energy-sav-ing behaviors, and ensure that rewards and punishments are well-founded, we have formulated the Safety, Environmental Protec-tion, and Occupational Health Performance Appraisal Management Procedures and an energy e?ciency incentive mechanism. Wemonthly assess employees of each level based on rationalized suggestions, environmental protection and energy-saving technolo-gies, operations against regulations, and relevant penalties.
46.74 million RMB
Total investment in low-carbonenvrionmental protectiton
Number of environmental pollution incidents
Hazardous waste disposal compliance rate
2024 Sustainability ReportAbout Us
Environmental Risk Management and ControlTo step up its daily environmental risk management and control, Bloomage Biotech identi?es and evaluates environmental factorsinvolved in the Company’s production, R&D, and business operations one by one and controls them e?ectively. We keep track ofupdates in laws and regulations and the demands of interested parties and regularly identify environmental factors from 3 tempo-ral perspectives, 3 states, 8 types, and 2 aspects to form an environmental factor list. Additionally, we regularly evaluate thee?ectiveness of control measures for important environmental factors.
Daily Risk Management and Control
Bloomage Biotech strictly implements the "three simultaneous" system of environmental protection (environmental protectionfacilities and the main project must be designed, constructed, and put into use simultaneously). We conduct timely environmentalimpact assessments before project construction to obtain approval and organize acceptance of environmental protection afterproject completion to ensure that new projects meet environmental compliance requirements. We regularly conduct internal andexternal audits to discover problems and de?ciencies in environmental management. We also take timely corrective measures toprevent potential environmental accidents and pollution incidents and to protect environmental and public interests.The Company conducts at least 1 internal environmental audit every year, covering all operational sites and business types.Through personnel interviews, document reviews, and on-site visits, we conduct inspections and develop our Audit Report onenvironmental management policies, documented information, pollutant prevention and control measures, and emergencypreparedness and response. For problems discovered in the internal audit, the audited department analyzes the causes of thenon-conformities and prepares a report. Subsequently, the department makes its recti?cation plan based on the Corrective andPreventive Control Procedures and completes recti?cation within a time limit. Internal auditors are responsible for con?rming therecti?cation results.The Company regularly invites external third-party agencies to conduct ISO 14001 Environmental Management System audits toensure the applicability and e?ectiveness of the management system. The Company also takes the initiative to accept externalaudits from regulatory authorities and clients to continuously improve resource utilization and pollution prevention and control.
Environmental Supervision and Audit
Bloomage Biotech regularly conducts environmental knowledge training and provides in-depth interpretations of environmentallaws, regulations and standards for all employees to enhance their environmental awareness and create a company-wide participa-tion atmosphere. Furthermore, the Company also actively participates in training organized by regulatory authorities to keepabreast of the latest environmental regulations and standards, ensuring compliance with operations. In addition, the Companydevelops detailed operating procedures and provides specialized training for personnel involved in environmental protection toenhance their professional capabilities in environmental management. These e?orts ensure compliance with operationalstandards and e?ectively prevent violations.
Improving Environmental Protection Capabilities
Process of environmental factor identi?cation
In 2024, the Dongying production base organized a total of 5 drills for environmental emergencies, including 2 drills for on-site hazardouschemical leakage, 2 drills for sewage workshop ?re accidents, and 1 drill for on-site hazardous waste leakage. These drills tested thepracticality and operability of emergency response plans and improved the coordination capabilities of various departments andworkshop front-line employees, ensuring their abilities to properly handle emergencies.
CaseDongying production base conducts a drill for environmental emergency
Audit typeEnvironmental compliance inspectionSystem certi?cation and oversight auditRegulatory and client audits
CoverageAll production basesJinan, Dongying, and Tianjinproduction basesAll production bases
Audit performance
571 timesCompleted the required ISO 14001oversight audit57 timesInternalauditExternalaudit
Bloomage Biotech’s environmental audit performance for 2024
Unit20232024Indicators
Number of training sessions on environmentalprotection and pollution prevention and controlNumber of employees trained in environmentalprotection and pollution prevention and controlTotal hours of training on environmental protectionand pollution prevention and control
timesparticipants
hour
3,6223,313
2,9874,806
Environmental protection training of Bloomage Biotech
?
The statistical caliber covers all of Bloomage Biotech's wholly-owned operational production bases in China.
9291
Conduct regular inspections of environmental protection facilities to check their operation and equipment wear. Carry outtimely maintenance to ensure the safe and e?ective operation of all kinds of environmental protection facilitiesDaily inspection
We have established and improved the response mechanism for environmental emergencies, regularly identi?ed andassessed environmental risks, and prepared documents, such as the Emergency Plan for Environmental Emergencies and theemergency plan for heavily polluted weather. We have carried out regular emergency drills to ensure that on-site responseto environmental emergencies can be conducted in a quick, orderly, and e?cient manner
Emergency management
Discharge to the atmosphereDischarge to water bodiesDischarge to land
Raw materials andnatural resource useEnergy emissions Energy releaseWaste and by-productsSpace occupation
Past, present, futureNormality, abnormality,and emergency
Environmental pollutionEcological damage andrational use of resources
In accordance with the Regulation on the Administration of Permitting of Pollutant Discharges and the requirements of the
pollutant discharge permit, we conduct regular environmental monitoring, including air emissions, wastewater, noise, and
groundwater, to e?ectively monitor the discharge of pollutants and disclose the environmental monitoring results in a
timely manner as required. The results are subject to review by regulators and public supervision
Environmental monitoring
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
2024 Sustainability ReportAbout Us
Bloomage Biotech adheres to the baseline of biodiversity conservation in production and operations, actively identifying, monitor-ing, and mitigating potential negative impacts on surrounding ecosystems. Based on potential risk sources, a?ected scope, proba-bility of occurrence, severity of impact, and risk levels, the Company formulates corresponding prevention and control measures.Besides, the Company integrates biodiversity conservation concepts into product R&D, manufacturing, and raw material procure-ment, leveraging its expertise in synthetic biology to reduce the impact of products on biodiversity.
On May 22, 2024, the International Day for Biological Diversity, Bloomage Biotech launched a knowledge-sharing activity aroundthe theme “Protecting Biodiversity to Promote Sustainable Development”. This initiative enhanced employees' understanding ofthe connection between the Company’s production & operations and biodiversity, motivating their participation in biodiversityconservation practices.
Biodiversity Assessment
Bloomage Biotech strictly complies with pollution prevention regulations and standards, including the Law of the People's Republicof China on the Prevention and Control of Atmospheric Pollution, the Law of the People’s Republic of China on Prevention and Control ofWater Pollution, and the Law of the People’s Republic of China on the Prevention and Control of Environmental Pollution by Solid Waste.The Company prioritizes pollution prevention as a key initiative of its environmental management, strengthens the operationalcontrol of environmental protection facilities, and establishes internal emission standards based on national, local, and industrystandards to ensure compliance with pollutant discharge limits.
Pollutant Emissions andWaste Management
Bloomage Biotech adopts advanced air emission treatment technologies to e?ectively manage both organized and unorganizedemissions of air pollutants. Each production base has established systems and management records, such as the Air EmissionTreatment Management Process and the Operation and Maintenance Procedures for Air Emission Deodorization Systems. Air emissionsare treated through methods including acid washing, alkaline washing, water spraying, activated carbon adsorption, and theinstallation of low-nitrogen burners. Dedicated personnel are assigned to maintain emission treatment facilities, and third-partytesting is regularly commissioned. During the reporting period, all environmental protection facilities operated normally andstably, e?ectively ensuring compliance with air emission standards.In terms of air emission reduction, the Company continues to improve treatment e?ciency and reduce emissions by upgradingprocess designs and transforming environmental protection equipment.
Air Emissions
9493
Product R&D
We adopt fermentation methods to replace traditional extraction methods forproducing various bioactive materials, reducing the consumption of rare plantresourcesWe have introduced green processes, such as membrane ?ltration and enzymatichydrolysis, to replace traditional chemical treatment methodsTechnologicalinnovation
Through measures like source substitution and process optimization, we e?ectivelyreduce the negative impact of the product life cycle on the environment andbiodiversityWe have researched the application of plant-based plastics and purchasedbiodegradable plastics and recyclable plastics to use more sustainable packagingmaterials
Packagingoptimization
We regularly carry out biodiversity assessments and investigate the surroundingecosystems, animal, and plant species. The Company has conducted biodiversityassessment, whose results have shown that there are no nature reserves, scenicspots, national and local key protected wild plants, and rare or endangered wildanimals within 1 km of the area where the Company is located. The Companycauses no signi?cant negative impacts on biodiversity while maintaining the normaland e?ective operation of environmental protection facilities and detecting anddisinfecting foreign objects. The Company will continue to conduct regularassessments and cautiously manage biodiversity risks
Daily productionand operations stage
We conduct environmental impact assessments and take necessary ecologicalprotection measures during construction
Project planning
and design stage
Activeconservationmeasures
Baselineconservationmeasures
Bloomage Biotech biodiversity conservation measures (partial)
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
Each production base has enhanced the management of odor-generating processes by enclosing odor-emitting areas such asanaerobic reactors, anoxic tanks, regulating tanks, and sludge thickening tanks in wastewater treatment facilities. Collected odorsare treated through the emission treatment system to reduce odors generated during production operations.
IndicatorsSulfur oxidesNitrogen oxidesVolatile organic compounds
Unittontonton
Total emissions in 2023
2.32
7.46
3.30
Total emissions in 2024
1.75
6.22
3.05
Emissions of major air pollutants of Bloomage Biotech
Bloomage Biotech's odor mitigation measures (partial)
Air emission reduction measures at Bloomage Biotech
-The Dongying production base has replaced valves and manhole covers in the wastewater treatment workshop's air
Ethanol collection and treatmentThe Jinan production base has added emission treatment facilities in the ethanolstorage area to collect, treat, and reuse ethanol emissions, reducing fugitive emissions
Boiler exhaust gas reductionThe Dongying production base has adopted natural gas boilers (equipped with low-nitro
-gen burners) to lower air emissions
The Company has replaced diesel forklifts with electric forklifts in bulk to reduce emissionsfrom diesel combustion
The Company monitors, collects, and treats air pollutant emissions in accordance with regulatory requirements, including particulate matterand other emissions which are insigni?cant in information disclosure. The statistical caliber covers all of Bloomage Biotech's wholly-ownedoperational production bases in China.
2024 Sustainability ReportAbout Us
Bloomage Biotech continuously strengthens the management of water pollution prevention and control facilities and e?ectivelycontrols various water body risks. The Company has formulated the Wastewater Treatment Management Process to strictly controlall aspects of wastewater discharge and treatment. Integrated wastewater treatment facilities are used to treat pollutants such aschemical oxygen demand (COD) and ammonia nitrogen. During the reporting period, all environmental protection facilities operat-ed normally and stably, e?ectively ensuring compliance with wastewater discharge standards.Production bases listed as key sewage discharge units have established wastewater treatment workshops within their parks toensure that wastewater treatment meets the requirements of the Wastewater Quality Standards for Discharge to Municipal Sewers(GB/T 31962-2015) before being discharged into the municipal sewage pipe network. Besides, in accordance with the requirementsof the Management Regulations on Pollutant Discharge Permits, they have installed wastewater online monitoring equipment andnetworked with the government's environmental protection department to achieve internal and external collaborative and dynam-ic supervision of wastewater discharge. The wastewater quality of other production bases is regularly tested by the governmentand can be directly discharged into the municipal sewage pipe network. 100% of such wastewater discharged into the municipalsewage pipe network meets the discharge requirements.The company comprehensively monitors wastewater discharge and the operation of wastewater treatment facilities by regularlyinspecting production equipment and pipelines to promptly identify and address any leaks or spills. The Company also sets upanti-seepage layers and emergency ponds in key areas such as chemical warehouses and uses enclosed pipelines to transportwastewater. Anti-seepage layers are installed in wastewater pipelines and treatment facilities to e?ectively prevent groundwaterpollution.In addition to strengthening water body pollution control, the Company reuses wastewater for biogas power generation and imple-ments wastewater reduction initiatives. In 2024, the Company further reduced wastewater pollutant emissions by timely mainte-nance and optimization of wastewater treatment processes. For example, the Dongying production base adjusted the CEAB+AAObiological treatment method for wastewater, increasing the treatment time in anaerobic tanks, thereby reducing COD and sludgeproduction.Bloomage Biotech has the business of producing pharmaceutical-grade products. The Company's products (hyaluronic acid andrelated products) may ?ow into the wastewater treatment system during production due to container cleaning and other reasons.Such products discharged meet the pollution discharge requirements. In addition, these products themselves are non-toxic,biologically inactive, and can be used as food ingredients, thus posing no substantial negative impact on the environment orhuman health.
Wastewater
9695
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
IndicatorsTotal volume of wastewater dischargedChemical oxygen demand (COD)Ammonia nitrogenTotal phosphorusTotal nitrogen
Unit
10,000 tons
tontontonton
Total emissions in 2023
123.85
54.01
2.03
0.79
10.10
Total emissions in 2024
171.54
102.52
0.80
1.04
11.23
Wastewater discharge of Bloomage Biotech
Waste
Waste Management Policies and Measures
Waste typeStorage
General solidwaste
waste perlite, waste activatedcarbon), sludge, waste plastics,waste cartons, etc.
Recycle or hand over todisposal and reuse afterDomestic waste
dormitory waste, etc.
A general solid waste storage area hasbeen built to store general solid waste,domestic waste, and kitchen waste in a
Entrust a municipal wastedisposal company fortransportation and disposal
Hazardous wasteChemical containers
for transportation and disposalin strict accordance with theHazardous Waste TransferManagement Measures
Kitchen wasteFood waste from cafeterias
Entrust a municipal wastedisposal company fortransportation and disposal
Disposal
Optimize production processes and improveproduct quality and productivity to reducesolid waste generationRecycle cleaning solution to reduce chemicalconsumption and hazardous wasteproductionOptimize the wastewater treatment processto reduce the amount of dosing and sludgegeneration
Source reduction
unrecyclable general industrial solid wastesand hazardous wastes
HarmlessnessBloomage Biotech's measures to reduce the generation of various wastes mainly include:
Non-hazard-ous Wastes
HazardousWastes
Bloomage Biotech adheres to the sustainable development concept of green operation and upholds the principle of "reduction,recycling and harmlessness" of solid waste to promote comprehensive solid waste management and utilization. The Company hasformulated systems, such as the General Solid Waste Management Process and the Hazardous Waste Management Process tostandardize the classi?ed management of waste. The Company formulates annual management plans for general solid waste andhazardous waste, and establishes records for the generation, transfer, and storage of various wastes, ensuring full traceabilitythroughout the waste management process.
A storage room for hazardous waste hasbeen built. In strict accordance with therelevant requirements of the Standardsfor Pollution Control on Hazardous WasteStorage and the Technical Speci?cationsfor Collection, Storage, Transportation ofHazardous Waste, ground anti-seepage,gas collection, and exhaust pipeequipment are installed to store varioushazardous wastes in a classi?ed manner,and prominent warning signs ofhazardous waste are set in the storagearea
The statistical caliber covers all of Bloomage Biotech's wholly-owned operational production bases in China. This year, the increased production capacity atBloomage Biotech's Tianjin production bases has led to a rise in total wastewater discharge and COD.
Bloomage Biotech focuses on waste reduction at the source and harmless treatment at the end of the waste stream. Each produc-tion base reduces waste generation through process optimization and consumables management. For example, the Dongyingproduction base has replaced solid alkali with liquid alkali, reducing hazardous waste alkali bags by approximately 700 kg.TheCompany aims to reduce the ?lter residue discharge per ton of pharmaceutical-grade bioactive products at its Jinan productionbase by 1% and the sludge discharge per ton of wastewater by 3% by 2025, compared to 2023.
2024 Sustainability ReportAbout Us
9798
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
Bloomage Biotech responds to the national call to accelerate the building of a waste recycling system, continuously improvingwaste resource utilization and recycling levels in production and product development. The Company explores new pathways forrecycling and reusing waste and expired products from production processes.Waste Recycling and Reuse
Waste typeResource recycling measuresScrap packaging materials
Classify and recycle by material type (e.g., cardboard, mixed paper, plastic, PET bottles) and hand over tospecialized agencies for processing into other recycled productsWaste perlite and sludgeSingle-use empty tubes
Carry out the "Empty Tube Recycling" program. From its initiation in 2020 to the end of the reporting period,more than 15.63 million empty tubes had been recycled, with a total of more than 140,000 participants and arecycled weight of 23.45 tons
Indicators
Hazardous waste
General industrial waste
Domestic waste
Kitchen waste
Hazardous waste intensity
Non-hazardous waste intensity
Recycled waste
Unittontontontonton/revenue in RMB 1,000,000ton/revenue in RMB 1,000,000
ton
Total emissions in 2023
85.01
9,599.45
581.09
658.00
0.01
1.78
7,331.00
Total emissions in 2024
144.22
10,521.681,184.42
354.12
0.03
2.25
Total wasteton10,923.5512,204.44
7,125.01
Waste discharge of Bloomage Biotech
Bloomage Biotech's resource recycling measures (partial)management, and implements water recycling measures, leveraging innovation to advance resource recycling and green alternatives.
Resource Utilization andCircular Economy
--Water Management
In the newly launched aseptic project, the Dongying production base uses idle storage tanks to collect chilled water used for cooling inthe production process. After re-cooling, the used chilled water can be supplied to the workshop for recycling, which is equivalent tosaving 5,000 tons of water each year.
CaseDongying production base promotes condensate recyclingpipes, water waste due to leakage and spillage was reduced by 10%.
Case
Bloomage Biotech’s improvement on water metering and statistical measures
The Chaohu production base has strengthened real-time measurement and monitoring of water consumption by installing8 IoT water meter monitoring devices, so as to identify and address water consumption issues in a timely manner
IndicatorsTotal water consumptionWater consumption intensity
Unit10,000 tonston/revenue in RMB 1,000,000
Consumption in 2023
149.33
245.77
Consumption in 2024
163.83
305.44
Jinan production base conducts water balance tests to optimizewater use e?ciency and reduce water waste
The statistical caliber covers all of Bloomage Biotech's wholly-owned operational production bases in China. This year, the increased production capacity atBloomage Biotech's Tianjin production bases has led to a rise in hazardous waste, general industrial waste, and total waste.
All of Bloomage Biotech’s o?ces and production are supplied by municipal water. The types of water used mainly include produc-tion water, make-up water for cooling circulating water, boiler replenishment water, water for environmental protection facilities,and domestic water. The Company has formulated the Energy Management, Energy Saving and Consumption Reduction Regulations,adding water consumption management indicators into the daily indicator management system of each workshop and team, andclarifying water metering requirements. Each production base formulates an annual water consumption plan based on local waterconsumption quotas, monitors and analyzes water consumption data in a timely manner, and commissions third parties to carryout water balance tests and industrial water conservation diagnoses. By doing so, we have laid a solid foundation for the long-termimprovement of water resource utilization e?ciency.The Company aims to continuously improve water e?ciency by increasing thereuse of condensate water and improving production processes.Bloomage Biotech focuses on building water-saving enterprises by improving water metering, identifying water managementweaknesses, promoting water-saving technologies and processes, and replacing old water facilities to prevent water waste, such asleakage and venting in the water supply pipe network. The Dongying production base has been honored as a Water-savingEnterprise of Shandong Province.
The statistical caliber covers all of Bloomage Biotech's wholly-owned operational production bases in China. This year, the increased production capacity atBloomage Biotech's Tianjin production bases has led to a rise in total wastewater consumption. The total water consumption for 2023 was recalculated to be 1.49million tons.
2024 Sustainability ReportAbout Us
10099
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
Packaging Material Management
Bloomage Biotech strictly adheres to relevant regulations, reducing packaging material usage and plastic consumption throughdesign optimization, process improvement, material substitution, and recycling initiatives. Additionally, the Company hasthe use of smaller packaging and glass materials.
Lightweight and Plastic-Reduced Packaging
Bloomage Biotech's brand QuadHA's new product CT50 Skin Dynamic Youth Cream abandons the previous hardcover pasting processand EVA lining, and adopts white cardboard boxes and corrugated folding inner supports, reducing packaging weight by nearly 60%. Theuse of single paper material facilitates recycling, lowers processing complexity, and reduces the production process, thereby reducingenergy consumption.
Case
reducing plastic shell usage by approximately 37.6g per unit (77% of total packaging weight). Bio-Meso Hydrating Cleansing Honey’ssupplementary packaging design reduces plastic shell usage by about 42.2g per unit (82% of total packaging weight)packaging weight)
CaseSaving energy and reducing plastic, starting from the "core"
Bloomage Biotech's key measures to reduce weight and plastic in packaging include:
Conduct research on the application of sugarcane-based plastics in disposable packaging materials. Compared withtraditional petroleum-based plastics, each ton of bio-based plastics can reduce carbon dioxide emissions by about 3 tonssubstances contained in PVC on the environment and employees' health
Green packaging design
Reduce the use of composite materials and use a single materialSelect degradable, renewable, or recyclable materials. For example, use paper-aluminum foil bags in facial mask packag-Material substitution
Process improvement
Recycle waste plastics, waste outer packaging cartons, and other waste generated during the production process tominimize the amount of waste packagingPackaging recycling
Supply chain enhancement
Reduce packaging for transportation
QuadHA CT50 Skin Dynamic Youth Cream uses card boxesinstead of hardcover boxes
Bloomage Biotech strictly follows the requirements of the Product Quality Law of the People’s Republic of China, the Food Safety Lawof the People's Republic of China, the Drug Administration Law of the People's Republic of China, the Regulations on Cosmetics Supervisionand Administration, the Regulation on the Supervision and Administration of Medical Devices, the Law of the People’s Republic of Chinaon the Prevention and Control of Environmental Pollution by Solid Waste and other laws and regulations to carry out packaging design,procurement, and disposal. Besides, we comply with national standards including the Requirements of Restricting ExcessivePackage—Foods and Cosmetics and the Sustainable Packaging Initiative for Cosmetics to practice sustainable packaging materialmanagement. We actively embrace the principles of the circular economy, implementing strategies focused on lightweight design,material substitution, and recycling. By reducing pollution and waste at the design stage, increasing the use of sustainable rawmaterials, and recycling and reusing packaging materials at the end of a product's life cycle, we promote resource circulation andsustainability.
2024 Sustainability ReportAbout Us
102101
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
Bloomage Biotech continuously explores and adopts biodegradable and recyclable packaging materials, avoiding unsustainablewood sourcing, high-energy-consuming, or high-pollution petroleum-based materials.Sustainable Packaging Material Usage
Bloomage Biotech incorporates recycling considerations into packaging design from the outset, upgrading multiple products tosingle-material options and implementing waste packaging and product recycling plans to promote material circulation.Packaging Recycling and Reuse
Material typeMaterial featuresProduct applicationPost-Consumer Recycled(PCR) Plastics
The generation of plastic waste is reduced byrecycling and reusing PCR. Compared withtraditional materials, the production of PCRmaterials lowers carbon dioxide emissions.
During the injection molding process of thebottle of the Bio-MESO Saccharomyces RiceVitality Purifying Balancing Milk, 30% of PCRrecycled materials were added, fully integrat-ing the concept of environmental protection
-ality of the product.Paper-Plastic Inner Supports
Paper-plastic is a natural packaging materialmade from recycled cardboard, wood, bagasse,and biodegradable.
BIOHYALUX's single-use packaging replacesXPE material inner supports with paper-plasticoptions.
FSC (Forest Stewardship Council)
that the product is sustainable and environmen-tally friendly throughout the supply chain.
FSC-COC (chain of custody), allowed to purchasepackaging materials.
IndicatorsTotal procurement of packaging materials
packaging materials
Unit
tonton
2023
5,270.00
846.00
2024
8,494.231,635.00
The packaging materials purchased by the Company mainly include paper, plastic, glass, and aluminum.
In 2024, the Bloomage Biotech brand MedRepair upgraded its products, including MedRepair Soothing Radiant Essence, MedRepairBarrier Repairable Hydragel Cream, and MedRepair Hydrating Gel Cream. The packaging now features single-material plastic pumps,with all pump components (including springs, beads, gaskets, and straws) made from PP material, facilitating recycling and reducingmanual sorting and disassembly costs. Additionally, MedRepair's Soothing Skin Essence Sample packaging uses single-material OPPplastic soft packaging, which is 100% recyclable.
Case
MedRepair uses a single material all-plastic pump and plastic soft packagingfor end-of-line recycling
brands. The recycling program encourages green and low-carbon consumption by issuingsecond-throw empty tubes will be sent to the recycling factory for processing and made intorecycled environmentally friendly peripherals. As of December 2024, over 140,000 participantshave joined the "Empty Tube Recycling" program, recycling over 15.63 million empty tubes with atotal weight of 23.45 tons. In 2024, BIOHYALUX expanded the recycling program to allowyear-round participation without brand restrictions, fully integrating sustainable and circularconcepts into consumers' daily lives.
CaseBIOHYALUX's "Empty Tube Recycling" program for single-use products
Bloomage Biotech actively practices the concept of resourcerecycling, customizes canvas bag souvenirs made of waste packag-ing materials, and conveys the concept of sustainable consump-tion and circular economy to business partners. Each canvas bag ismade from 25 recycled plastic bottles, transforming waste throughcircular regeneration technology. This not only reduces plasticpollution but also demonstrates the potential of resourcerecycling.
CaseTurning waste plastic bottles into eco-friendly gifts
front back
2024 Sustainability ReportAbout Us
SDGs Addressed in this Chapter:
Major Material Topics of Sustainability Covered in this Chapter:
· Supplier Management· Product Environmental Impact· Response to Climate Change and Energy Management· Product Quality
Achievements: A SustainableValue Chain
A stable and reliable supply chain is crucial for corporate sustainabledevelopment. Bloomage Biotech adheres to the principles of integrity,stable, high-quality biomanufacturing supply chain ecosystem. We consis-tently practice responsible procurement, aiming at a positive impact on theenvironment and society while product quality is guaranteed.
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
2024 Sustainability ReportAbout Us
106105
Bloomage Biotech is committed to building and maintaining a secure, stable, and sustainable supply chain network. We continu-supply chain's security.
Bloomage Biotech continues to improve its supply chain management system. This year, the Company comprehensively sorted outprocess, supplier access, and management.
Supply Chain Management System and Structure
In the reporting period, Bloomage Biotech has developed partnerships with 1,339 production suppliers, distributed as follows:
Ensuring Supply Chain Security
Mainland ChinaHong Kong, Macao, and Taiwan, China
Overseas countries or regions
Region
countcountcount
Unit
1,333
Quantity
Bloomage Biotech’s supply chain management initiatives (partial)
Supplier Access Flow ChartStandardize the formulation of medium- and long-term procurement plans and demand applica-progress of procurement activities
Manage procurement needs and plans
SampleEvaluation
On-site Review
QualityAgreementsTrial ProductionSupplier
ApprovalList ofSuppliers
Guide business personnel to formulate procurement category strategies in a systematic manner toreduce procurement costs, optimize the Company's operational management, and enhance theCompany's competitiveness and sustainable development capabilitiesDevelop procurement and category management strategies
Standardize the access process, selection principles, and access rules for various suppliers, clarifythe responsibilities of procurement, quality, production, R&D, and other personnel in the supplierselection process, and ensure that procurement activities are carried out in compliance andSupplier selection and contract management
Standardize the process from issuing purchase orders to material acceptance and reconciliation,chain, while ensuring that the quality, quantity, and price of the purchased materials are consistentwith the contract requirements to meet production and operation needs
Manage procurement execution
Standardize supplier registration, evaluation, selection, the establishment of cooperative relation-ships, performance management, exit management, and continuous improvement, and improvetransparency, stability, and procurement qualityManage suppliers
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
DocumentEvaluation
Application and
AssessmentRegardingChanges
Evaluation andTrial Production
Process ofSmall-batch
Samples
Supplementa-
ry List ofSuppliers (to
In 2024, the Company optimized its organizational structure by establishing the "Global Supply Chain Platform" and "Global SharedPlatform." These platforms integrate and optimize production bases, enhance the management e?ciency of functional depart-ments, coordinate with various business lines, ensure stable material supply and continuous product production, and boost supplychain resilience. The Company also strengthened the construction of dedicated teams for procurement, bidding, and suppliermanagement to solidify supply chain risk management capabilities.Additionally, the Company implemented systematized management of procurement and supplier access processes through theSRM system. This system incorporates supplier quali?cation review, archive information maintenance, and dynamic supplierprocesses (performance, suspension, exit) to improve supply chain management e?ciency.
Bloomage Biotech has established a rigorous supplier admission mechanism, conducting comprehensive assessments of potentialsuppliers based on basic quali?cations, quality assurance, scale, competitiveness, and other factors. Necessary on-site audits arecarried out to select suppliers that meet requirements and include them in the annual List of Quali?ed Suppliers.The Company implements classi?ed management of quali?ed suppliers, and the suppliers are classi?ed according to their procure-ment amount, importance of goods, and impact on the Company's products and production, and other dimensions. By stratifyingsuppliers according to these dimensions, we implement supplier management in a tiered manner, e?ectively controlling supplierrisks and ensuring high-quality, stable, and safe operation of the supply chain.As per the Company’s requirements, suppliers of raw materials, packaging materials, and other types must be quali?ed with certi?-cates for production and operation, necessary management system (eg. quality management system, GMP, etc.), and forpurchased items (such as production process description, safety assessment, quarantine certi?cates, toxicology and e?cacy studydata or inspection reports of raw materials, etc.), accompanied with appropriate production conditions. Besides, the Companyassesses the performances of suppliers in environmental protection, occupational health and safety, energy management, andlabor rights, and rewards additional credits to excellent suppliers with well-established management systems and certi?cations.
2024 Sustainability ReportAbout Us
Supplier Quality Supervision and Review
-ers continuously improve their quality management capabilities.Supplier Quality Improvement and Empowerment
Supply Chain Quality Management
In November 2024, the Bloomage Biotech brand BIOHYALUX, in collaboration with packaging R&D, supplier quality, procurement center,and other departments, formed a dedicated project improvement team for customized product projects. The team visited suppliers toconduct in-depth cooperation and communication on key aspects of customized product packaging quality and technology, jointlyexploring improvement and optimization solutions.
CaseSupplier quality support
108107
Bloomage Biotech recognizes that material stability is a key risk in the supply chain. Therefore, the Company has developed target-ed supply chain risk response strategies to ensure high-quality, stable, and secure operations. These strategies include:
Interdepartmental collaboration
forecasts and procurement plans to jointly ensure a stable supply of materialsMaterial strategy developmentFormulate annual material demand forecasts and analysis, and formulate supply and demand plans
Procurement Plans OptimizationFor new product procurement needs, increase the planned frequency and monitoring frequency ofprocurementIdentify and analyze procurement risks, and comprehensively judge the procurement lead time of materi-als based on material categories, supplier production capacity, procurement demand forecasts, suppliermaterial arrival time, and procurement inventory, and formulate appropriate procurement plansSupplier collaborationEstablish strategic partnerships with important suppliersPay attention to the overall inventory status or production plan of key material suppliers, or providesuppliers with forecast values to ensure stable and continuous supplyDetermine the delivery mechanism and strategy with upstream suppliers based on the supply andapplication characteristics of materials
Standardized procurementSimplify internal processes and promote standardization of procurement agreementsPromote standardization of packaging materials, reduce the types of purchased packaging materials, and
Strict inventory managementsecuritySet up safety inventory, strictly monitor inventory levels, and conduct statistics and analysis of deviationsbetween actual consumption and plans
Response to abnormal situations
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
Implement a diversi?ed supplier strategy, self-production substitution, and intervene in the R&Dprocess in advance to identify supply chain risks and improve response capabilities
Bloomage Biotech has established a comprehensive supplier quality management mechanism, referencing regulatory require-ments and standards to develop quality management systems for di?erent categories of suppliers. These include the Regulationsfor Sampling, Inspection, and Retention Management of Cosmetic Packaging Materials, the Regulations for Sampling and RetentionManagement of Raw and Auxiliary Materials for Cosmetics, the Nonconforming Product and Return Processes, the Outsourced ProcessingManagement Regulations, and the Quality Management Regulations for Class A Raw Material Suppliers. The Company also signs theQuality Assurance Agreements with suppliers to ensure the stability and reliability of the materials provided.Dedicated personnel are assigned to evaluate supplier admission quality, assess quality performance, and drive continuous qualityimprovement. The Company sets annual management targets for supplier delivery quality inspection pass rates, regularly collectsand analyzes target completion status, and promptly follows up on nonconforming situations to ensure closed-loop handling.
The Company has established a robust supplier quality audit mechanism, based on regulations such as the Cosmetics Supplier Entry,Supervision and Management Regulations, the Regulations on Selection, Evaluation, and Management of Raw Material Suppliers, theSupplier Entry, Supervision and Management Regulations, and the On-Site Supplier Audit Regulations. These documents standardize thesupplier audit process. Each year, we develop a supplier supervision and audit plan covering multiple aspects of supplier opera-tions, including business, production, logistics, and warehousing. For identi?ed nonconformities during audits, we assist suppliersin developing e?ective corrective action plans, regularly communicate the implementation status of these plans, and conductnecessary re-audits to con?rm the e?ective implementation of corrective actions until issues are closed.Based on the annual evaluation and assessment results, the Company provides feedback to suppliers on areas for improvementand urges them to enhance their performance. For suppliers identi?ed with critical disqualifying items or deemed "nonconforming"in the evaluation, the Company will no longer include them in the annual List of Quali?ed Suppliers. If such a supplier is to be reacti-vated, they will be assessed through the new supplier introduction process. During this reporting period, the Company conductedquality audits on 206 direct suppliers, 35 indirect suppliers, 146 raw and auxiliary material suppliers, and 41 contract manufactur-ers. No "nonconforming" suppliers were identi?ed in the annual evaluation and assessment.
2024 Sustainability ReportAbout Us
Promoting ESG management among suppliers is a crucial aspect of Bloomage Biotech's commitment to sustainable development.The Company has established a foundational ESG management system for the supply chain, covering policy development, internaland external empowerment, assessment, data management, and sustainable procurement. This system will continue to deepenand optimize in future operations, working with supply chain partners to advance industry progress.
Policy Development
Supply Chain ESG Management
110109
In 2024, Bloomage Biotech's procurement center, in coordination with the quality department, conducted supplier quality training andempowerment activities. The training conveyed the Company's quality standards to approximately 60 suppliers across categories suchCaseSupplier quality training
Additionally, the conference featured a roundtable forum inviting multiple guests to discuss the opportunities and challenges broughtby digitalization and ESG to enterprises. Bloomage Biotech also recognized outstanding supplier partners for their exceptionalperformance in product quality, innovation capabilities, and collaborative synergy. Seven awards were presented, including theStar Award, Innovation Pioneer Award, and Cost Leadership Award.
Case
Bloomage Biotech successfully hosts inaugural supplier conference,pioneering a new era of industrial collaboration
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
On December 14, 2024, Bloomage Biotech successfully held its ?rst supplier conference themed "Leading Revolution, EmbracingBrilliance." The event invited 36 suppliers, numerous partners, and industry experts to jointly explore new opportunities and challengesin supply chain collaboration. Chairwoman Zhao Yan delivered a speech titled Growing Together, Achieving Mutual Success—Building aHigh-Quality Biomanufacturing Supply Chain Ecosystem. She proposed three cooperation visions: quality, sustainable development, andinnovative collaboration. Bloomage Biotech aims to reach consensus on cooperation standards with supplier partners to jointly build arobust industrial supply chain ecosystem, contributing to the development of the biomanufacturing industry.
During this reporting period, the Company formulated and implemented a revised version of the Bloomage Biotech Supplier Code ofConduct. This code addresses labor rights and human rights protection, health and safety, environment, business ethics, andmanagement systems, requiring suppliers to sign and comply with the Compliance Commitment Letter (including clauses on integritycooperation, ?nancial compliance, and anti-bribery). As of the end of the reporting period, 100% of production material suppliershad signed the above regulations.
Bloomage Biotech Supplier Code of Conduct
2024 Sustainability ReportAbout Us
The Company places emphasis on training the internal procurement team and suppliers in ESG management awareness andcapabilities, aiming to continuously enhance the ESG capabilities of relevant personnel both internally and externally. Therefore,the Company conducts specialized empowerment sessions around ESG management systems, policy trends, low-carbon transi-tion, and labor rights through supplier conferences and internal seminars. Additionally, the Company guides internal and externalpersonnel in understanding these concepts through practical work in scope 3 greenhouse gas data collection and ESG manage-ment evaluation. During this reporting period, the Company conducted ESG training for 80% of procurement positions and 50% ofsuppliers.
Internal and External Empowerment
During this reporting period, the Company established a supplier ESG self-assessment management mechanism, aiming tomanage the ESG risks of major suppliers through annual inquiries and to encourage suppliers to focus on and strengthen their ESGcapabilities. The assessment content, in addition to covering the Bloomage Biotech Supplier Code of Conduct, has added require-ments for low-carbon management, sustainable supply chains, and information disclosure. This encourages suppliers to systemati-
-ness. In 2025, the company targets to conduct assessments for over 20% of its production material suppliers.
Assessment
suppliers. During this reporting period, the Company conducted organizational-level scope 3 greenhouse gas data accounting andlife cycle accounting (LCA) for several products, collecting data from major suppliers. In the project, the Company cooperated withsuppliers to jointly establish relevant data statistical capabilities to lay the foundation for future management optimization.
Data Management
Bloomage Biotech actively practices sustainable procurement, aiming to enhance the sustainability of products from multipleperspectives such as low-carbon, environmental protection, and circularity. We prioritize suppliers with sustainable characteristicsand advantages to build a sustainable supply chain from the source. In 2024, we deeply promoted the optimization of productionrecyclability. For more information, please refer to the Section “Packaging Material Management” under Chapter 5.
Sustainable Purchasing
112111
Management responsibilitiesPerformance evaluationsAssessment and auditCorrection and improvementEHS managementTraining and communication
Management System
Decent workProtection of juvenile workersWorking hoursHumane treatmentNon-discriminationFreedom of association and collectivebargainingGrievance redress and stakeholderengagement mechanisms
Labor Rights andHuman Rights Protection
Safe and hygienic working conditionsOccupational health and safety complianceOccupational health and safety manageIncident managementHealth and safety information communica-
-tionOccupational health and safetymanagement systemEmergency preparedness and responseWorkplace regulationsLiving conditions
Health and Safety
Environmental permits andreportingPrevention of environmentalpollutionChemicals managementEnergy conservation and emissionreductionGreen energyEnvironmental management system
EnvironmentIntegrity and complianceInformation disclosureIntellectual property protectionFair competitionWhistl-blower protection andanonymous teportingResponsible procurement
Business Ethics
The Bloomage Biotech SupplierCode of Conduct stipulates that
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
Risk Identi?cation, assessment,and management
ment
2024 Sustainability ReportAbout Us
Responsibility: CommunityCare and Contributioncorporate responsibilities, and is committed to developing the "In Cloud"and "Bloomage Health Tour" public welfare activities. We promote theorganic integration of science and technology and art, support the compre-hensive development of medical and educational undertakings, give full playto the Company's own advantages, work together with all walks of life, andlay a solid foundation for building a harmonious and beautiful society.
SDGs Addressed in this Chapter:
Major Material Topics of Sustainability Covered in this Chapter:
· Social Welfare and Community Relations
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
2024 Sustainability ReportAbout Us
Social Welfare andCommunity Relations
Xinjiang" thematic activity to assist in the inheritance and development ofXinjiang's national culture. While showcasing the beautiful natural sceneryof Xinjiang, the activity delved into southern Xinjiang to understand themusical intangible cultural heritage of ethnic groups such as the Tajik,Uyghur, and Kirgiz, and promoted it through promotional videos, publicaccounts, and video websites. Additionally, Bloomage Biotech hosted theminority compatriots in spreading the true and diverse culture of Xinjiangand promoting the profound inheritance of ethnic minority musicalculture and song and dance art.
Case
Bloomage Biotech’s “In Cloud” project launched the theme activity of"To See Xinjiang—Southern Xinjiang"
In 2011, Zhao Yan, Chairwoman and CEO of the Company, initiated the "In Cloud" project with a mission to protect China's originalcultures. This project explores how to preserve the intangible cultural heritage of various ethnic groups in China through art exhibitions,immersive experiences, singing and dancing performances, and culinary events. Additionally, it supports rural development by promot-ing the inheritance of ethnic cultures and improving local residents' living standards. In general, it contributes to rural prosperity.Since its establishment, "In Cloud" has conducted 14 series of activities, visiting more than 10 provinces, autonomous regions, andmunicipalities directly under the central government, and passing through over 60 ethnic minority settlements in cities, with a totaljourney of more than 160,000 kilometers. It has helped nearly 400 cultural and intangible cultural heritage inheritors from 41 ethnicgroups to take the stage in China and abroad. As of the end of 2024, "In Cloud" has launched 127 related series works in the form of shortand strive to preserve more brilliant national cultures, contributing to the continuity of Chinese culture.
Case
“In Cloud” has been ongoing for 14 years to help the development of ethnicand cultural inheritance
Bloomage Biotech's "In Cloud" Series of Thematic Activities
In 2024, Bloomage Biotech strengthened its support and care for children with autism. Its brands BIOHYALUX and BLOOMCARE collabo-rated with the “Light Up Action Charity Plan” to jointly create the "Vitality Gift Box," incorporating the paintings of children with autisminto BIOHYALUX’s product Collagen Vitality Boost Essence. A portion of the sales revenue was applied to the care for children with autismautism and providing more tangible help to these children and their families.
Case
"In Cloud" has lasted for 14 years, traveled across more than 10 provinces or autonomous regions, penetrated into ethnic minoritysettlements in more than 60 cities, and helped nearly 400 ethnic culture and intangible cultural heritage inheritors from 41 ethnic groups.In 2023, the project was included in excellent cases at the Pavilion, UN SDG Summit 2023 and ESG best practices for Chinese Listed Compa-nies 2023 by China Association for Public Companies"Bloomage Health Tour" has been carried out for 11 years, with volunteer medical activities covering Yexian County of Henan Province, SedaCounty of Sichuan Province, Yinchuan City of Ningxia Hui Autonomous Region, Zibo City of Shandong Province, Bole City of Xinjiang Province,and other areas. This project has facilitated the recovery of thousands of patients
“I have always believed that the essence of charity is to inspire passion, especially for the protection of national cultures. Only whenthe people of the ethnic group themselves are passionate can the inheritance and promotion be more powerful.”
Ms. Zhao Yan, Chairwoman and CEO of Bloomage Biotech, initiator of "In Cloud"
“
”
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
Over the years, we have continued to carry out two major public welfare activities, "In Cloud" and "Bloomage Health Tour", activelyexplored and practiced in the ?elds of medical popularization and cultural inheritance, and continuously enriched our publicwelfare initiatives to expand social in?uence.Additionally, Bloomage Biotech pays close attention to the welfare of veterans and rural revitalization projects, aiming to improvethe living standards of veterans and rural residents. In 2024, the company donated facial masks, moisturizing lotions, personal careproducts and case to charitable organizations such as the Jinan City Veterans Care Foundation and the High-Tech Zone CharityFederation. These donations were used to support social welfare and charity projects, with a total value of donated goods reachingRMB 9.61 million.
Bloomage Biotech collaborated with "Light Up Action Charity Plan"to care for autistic children
2024 Sustainability ReportAbout Us
Appendices
118117
CONTENTS
Chairwoman andCEO's Message
SafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesSustainableDevelopmentManagement
Index of IndicatorsSSE Sustainability Report Disclosure Guidelines
Dimension
Environment
Society
Governance Related toSustainable Development
Disclosure TopicsAddressing Climate ChangePollutant EmissionsWaste ManagementEcosystem and Biodiversity ConservationEnvironmental Compliance ManagementEnergy UtilizationWater UtilizationCircular EconomyRural RevitalizationSocial ContributionInnovation DriveEthics in TechnologySupply Chain SecurityEqual Treatment of Small and Medium-sized EnterprisesProduct and Service Safety and QualityData Security and Customer Privacy ProtectionEmployeeDue DiligenceStakeholders EngagementAnti-commercial Bribery and CorruptionAnti-unfair Competition
P81-85P94-97P96-97P93P90-92P86-88P95, P98P98-102P115P115-116P33-41P38P105-112P42-50P28-29,49P51-78P23-24,106,111P10P25-27P25
Index
GRI Index
GRI Standard
GRI 2: General Disclosures
GRI 3Material Topics
Disclosure2-1 Organizational details2-2 Entities included in the organization's sustainability reporting2-3 Reporting period, frequency and contact point2-4 Restatements of information2-5 External assurance2-6 Activities, value chain and other business relationships2-7 Employees2-8 Workers who are not employees2-9 Governance structure and composition2-10 Nomination and selection of highest governance body2-11 Chair of the highest governance body2-12 Role of the highest governance body in overseeing the management of impacts2-13 Delegation of responsibility for managing impacts2-14 Role of the highest governance body in sustainability reporting2-16 Communication of critical concerns2-17 Collective knowledge of the highest governance body2-18 Evaluation of the performance of the highest governance body2-19 Remuneration policies2-20 Process to determine remuneration2-21 Annual total compensation ratio2-22 Statement on sustainable development strategy2-23 Policy commitments2-24 Embedding policy commitments2-25 Processes to remediate negative impacts2-26 Mechanisms for seeking advice and raising concerns2-27 Compliance with laws and regulations2-28 Membership associations2-29 Approach to stakeholder engagement2-30 Collective bargaining agreements3-1 Process to determine material topics3-2 List of material topics3-3 Management of material topics
IndexP3-4About This ReportAbout This ReportP98N/AAbout This ReportP105-112P51-78P67-68,105-112P19P19P19P19P19P11, 19P25-26P10P19-P75P75-P9P19-30, 57, 90P19-30, 57, 90P27P27P20-24,37,38,40,42,48,53,65,90,94,99P39P10P78P11P12-14P11-14
During the reporting period, no instances of overdue unpaidamounts to small and medium-sized enterprises were found
2024 Sustainability ReportAbout Us
120119
GRI 201: Economic Performance
GRI 202:Market PresenceGRI 203: Indirect Economic Impacts
GRI 205: Anti-corruptionGRI 204: Procurement Practices
GRI 206: Anti-competitive Behavior
GRI 207: Tax
GRI StandardDisclosure
201-1 Direct economic value generated and distributed201-2 Financial implications and other risks and opportunities due to climate change201-3 De?ned bene?t plan obligations and other retirement plans201-4 Financial assistance received from government202-1 Ratios of standard entry level wage by gender compared to local minimum wage202-2 Proportion of senior management hired from the local community203-1 Infrastructure investments and services supported203-2 Signi?cant indirect economic impacts204-1 Proportion of spending on local suppliers205-1 Operations assessed for risks related to corruption205-2 Communication and training about anti-corruption policies and procedures205-3 Con?rmed incidents of corruption and actions taken206-1 Legal actions for anti-competitive behavior, anti-trust, and monopoly practices207-1 Approach to tax207-2 Tax governance, control, and risk management207-3 Stakeholder engagement and management of concerns related to tax207-4 Country-by-country reporting301-1 Materials used by weight or volume301-2 Recycled input materials used301-3 Reclaimed products and their packaging materials302-1 Energy consumption within the organization302-2 Energy consumption outside of the organization302-3 Energy intensity302-4 Reduction of energy consumption302-5 Reductions in energy requirements of products and services303-1 Interactions with water as a shared resource303-2 Management of water discharge-related impacts303-3 Water withdrawal303-4 Water discharge303-5 Water consumption
IndexP132P84-85P75-77-P75, 129P55-56N/AP115-116-P26P27P27P25P22P22P22N/AP99-102P99-102P99-102P87-88P89P87-88P87-88P86-89P98P95P125P125P125
GRI 301: Materials
GRI 302: Energy
GRI 303: Water and E?uents
GRI 304: Biodiversity
GRI 305: Emissions
GRI 306: Waste
GRI StandardDisclosure
304-1 Operational sites owned, leased, managed in, or adjacent to, protected areasand areas of high biodiversity value outside protected areas304-2 Signi?cant impacts of activities, products and services on biodiversity304-3 Habitats protected or restored304-4 IUCN Red List species and national conservation listspecies with habitats in areas a?ected by operations305-1 Direct (Scope 1) GHG emissions305-2 Energy indirect (Scope 2) GHG emissions305-3 Other indirect (Scope 3) GHG emissions305-4 GHG emissions intensity305-5 Reduction of GHG emissions305-6 Emissions of ozone-depleting substances (ODS)305-7 Nitrogen oxides (NOx), sulfur oxides (SOx), and other signi?cant air emissions306-1 Waste generation and signi?cant waste-related impacts306-2 Management of signi?cant waste-related impacts306-3 Waste generated306-4 Waste diverted from disposal306-5 Waste directed to disposal308-1 New suppliers that were screened using environmental criteria308-2 Negative environmental impacts in the supply chain and actions taken401-1 New employee hires and employee turnover401-2 Bene?ts provided to full-time employees that are not provided to temporary orpart-time employees401-3 Parental leave402-1 Minimum notice periods regarding operational changes403-1 Occupational health and safety management system403-2 Hazard identi?cation, risk assessment, and incident investigation403-3 Occupational health services403-4 Worker participation, consultation, and communication on occupational healthand safety403-5 Worker training on occupational health and safety403-6 Promotion of worker health403-7 Prevention and mitigation of occupational health and safety impacts directlylinked by business relationships403-8 Workers covered by an occupational health and safety management system403-9 Work-related injuries403-10 Work-related ill health
IndexP93N/AP89P89P89P89P89P89P94P96P96P96-97P97P97P111-112P112P54P75-77P76N/AP65P67-72P73-74P73-74P73-74P73-74P73-74P73-74P66P74-74
GRI 308: Supplier Environmental
Assessment
GRI 402: Labor/Management Relations
GRI 401: Employment
GRI 403: Occupational Health and Safety
P93
P93
CONTENTSSafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesChairwoman andCEO's Message
SustainableDevelopmentManagement2024 Sustainability ReportAbout Us
122121
GRI 404: Training and EducationGRI 405: Diversity and Equal OpportunityGRI 406: Non-discrimination406-1 Freedom of Association and
Collective BargainingGRI 408: Child Labor
GRI 411Rights of Indigenous Peoples
GRI 415Public Policy
GRI 409: Forced or Compulsory LaborGRI 410Security PracticesGRI 413: Local CommunitiesGRI 414: Supplier Social Assessment
GRI 416: Customer Health and Safety
404-1 Average hours of training per year per employee404-2 Program for upgrading employee skills and transition assistance programs404-3 Percentage of employees receiving regular performance and career development reviews405-1 Diversity of governance bodies and employees405-2 Ratio of basic salary and remuneration of women to men406-1 Incidents of discrimination and corrective actions taken407-1 Operations and suppliers in which the right to freedom of association and collective bargainingmay be at risk408-1 Operations and suppliers at signi?cant risk for incidents of child labor409-1 Operations and suppliers at signi?cant risk for incidents of forced or compulsory labor410-1 Security personnel trained in human rights policies or procedures411-1 Incidents of violations involving rights of indigenous peoples413-1 Operations with local community engagement, impact assessment, and development programs413-2 Operations with signi?cant actual and potential negative impacts on local communities414-1 New suppliers that were screened using social criteria414-2 Negative social impacts in the supply chain and actions taken415-1 Political contributions416-1 Assessment of the health and safety impacts of product and service categories416-2 Incidents of non-compliance concerning the health and safety impacts of products and services417-1 Requirements for product and service information and labeling417-2 Incidents of non-compliance concerning product and service information and labeling417-3 Incidents of non-compliance concerning marketing communications418-1 Substantiated complaints concerning breaches of customer privacy and losses of customer data
P128P57-62P63P55-56,131P129P53-55, 63P78P54P54P67-68N/AP115-116P115-116P111P111N/AP38P36-38P45, 48P48P48P49
GRI 417Marketing and Labeling
GRI 418: Customer Privacy
IFRS S2 Index
Suggested Disclosure
Governance
Strategy
RiskManagement
Directionsand Targets
Disclose the governing body (which may include the board of directors, committees, or equivalent bodiesresponsible for governance) or individuals responsible for overseeing climate-related risks and opportunities.Disclose the role of management in the oversight, management, and supervision of the governanceprocesses, controls, and procedures related to monitoring climate-related risks and opportunities.Disclose how climate-related risks and opportunities may reasonably impact the prospects of the entity.Disclose the current and expected impacts of climate-related risks and opportunities on the entity's businessmodel and value chain.Disclose the impact of climate-related risks and opportunities on the entity's strategies and decisions,including information on transition plans related to climate.Disclose the impact of climate-related risks and opportunities on the entity's ?nancial position, ?nancialperformance, and cash ?ows during the reporting period, as well as the expected impact on the entity'sshort-term, medium-term, and long-term ?nancial position, ?nancial performance, and cash ?ows,considering how climate-related risks and opportunities are incorporated into the entity's ?nancial planning.Consider the entity's ability to adapt to climate-related changes, developments, and uncertainties, anddisclose the entity's strategies and its business model's adaptability to climate-related changes.Disclose the processes and related policies used by the entity to identify, assess, prioritize, address, andmonitor climate-related risks.Disclose the procedures used by the entity to identify, assess, prioritize, and monitor climate-relatedopportunities, including whether and how the entity uses climate scenario analysis to identify climate-relatedopportunities.Disclose to what extent the processes for identifying, assessing, prioritizing, and monitoring climate-relatedrisks and opportunities are integrated into the entity's overall risk management process and how they areincorporated and reported.Disclose information related to cross-industry metric categories.Disclose industry-speci?c metrics related to speci?c business models, activities, or other commoncharacteristics of participating industries.Disclose the targets set by the entity to mitigate or adapt to climate-related risks or to leverage climate-relat-ed opportunities, as well as any targets required by laws or regulations for the entity to achieve, includingindicators used by the governing body or management to measure progress towards these targets.
Index
P81P81P82,84-85P82,84-85P82,84-85P82,84-85P82,84-85P83P84P83P125-126P125-126P82
Table of the Ten Principles of the United Nations Global Compact (UNGC)
CategoryPrinciplesHuman Rights
Labour
EnvironmentAnti-Corruption
Principle 1: Businesses should support and respect the protection of internationally proclaimed human rights; andPrinciple 2: Make sure that they are not complicit in human rights abusesPrinciple 3: Businesses should uphold the freedom of association and the e?ective recognition of the right tocollective bargainingPrinciple 4: The elimination of all forms of forced and compulsory labourPrinciple 5: The e?ective abolition of child labour; andPrinciple 6: The elimination of discrimination in respect of employment and occupationPrinciple 7: Businesses should support a precautionary approach to environmental challengesPrinciple 8: Undertake initiatives to promote greater environmental responsibility; andPrinciple 9: Encourage the development and di?usion of environmentally friendly technologiesPrinciple 10: Businesses should work against corruption in all its forms, including extortion and bribery
Index
P53-54P53-54P78P54P54P54P81-102P81-102P81-102P25-27
GRI StandardDisclosureIndex
CONTENTSSafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesChairwoman andCEO's Message
SustainableDevelopmentManagement2024 Sustainability ReportAbout Us
124123
GHG Veri?cation Statement
CONTENTSSafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesChairwoman andCEO's Message
SustainableDevelopmentManagement
2024 Sustainability ReportAbout Us
126125
Indicators
Wastes
Training on environmentalprotection and pollutionprevention and control
Air emissions
Wastewater
Total water consumptionWater usage per unit of revenueTotal procurement of packaging materialsPurchase volume of FSC-certi?ed paperpackaging materialsTotal waste dischargedGeneral industrial wasteHazardous wasteDomestic wasteKitchen wasteRecycled wasteNon-hazardous waste emission intensityHazardous waste emission intensitySulfur oxidesNitrogen oxidesVolatile organic compoundsTotal volume of wastewater dischargedChemical oxygen demand (COD)Ammonia nitrogenTotal phosphorusTotal nitrogenNumber of training sessionsNumber of employees trainedTotal training duration
Unit10,000 tonston/million revenue in RMBtontontontontontontontonton/millionrevenue in RMBton/millionrevenue in RMBtontonton10,000 tonstontontontontimesparticipantshour
149.33
245.77
5,270.00
846.00
10,923.559,599.45
85.01
581.09
658.00
7,331.00
1.78
0.01
2.32
7.46
3.30
123.85
54.01
2.03
0.79
10.10
3,6223,313
2023
163.83
305.04
8,494.231,635.0012,204.4410,521.68
144.22
1,184.42
354.12
7,125.01
2.25
0.03
1.75
6.22
3.05
171.54
102.52
0.80
1.04
11.23
2,9874,806
2024
ESG Key Performance TablesEnvironmental Performance
The scope of statistics includes all operational production bases of Bloomage Biotech located within China. The total comprehensive energy consumption (intons of standard coal) is calculated based solely on the comprehensive energy consumption of fossil fuel energy. Due to the increased production volume atBloomage Biotech's Tianjin production base this year, the total consumption of fossil energy for heat and electricity, as well as the total water usage, have allincreased. The symbol "/" indicates that the item is not applicable.
WaterPackaging materialsIndicators
Greenhouse gases
Energy
Total GHG emissions(Scope 1 and 2)GHG emissions per unit ofrevenue (Scope 1 and 2)Scope 1 emissionsScope 2 emissionsScope 3 emissions
Self-generated
renewableelectricity
Natural gasGasolineDiesel oilPurchased electricity (thermal power)Purchased renewable electricity (wind power)
Purchased heat from fossil fuelsPurchased heat from biomass fuelTotal comprehensive energy consumptionComprehensive energy consumption intensity
Unit
tCO?etCO?etCO?e/million revenuein RMBtCO?e/million revenuein RMBtCO?etCO?etCO?etCO?ecubic meterlitrelitrekWhkWhkWhkWhkWhGJGJtons of standard coaltons of standard coal/million revenuein RMB
2023
100,902.09/
16.61
/43,554.7357,347.36//15,686,83621,7068,93966,931,210/3,521,9132,401,7251,120,188174,331.7338,282.6935,071.79
5.77
2024
113,510.99109,785.94
21.14
20.44
37,412.2776,098.7272,373.66183,852.3913,073,45330,1127,93477,625,77113,375,6183,745,4852,312,1921,433,293245,503.80153,263.0535,346.54
6.58
Location-basedMarket-basedLocation-basedMarket-basedLocation-basedMarket-based
Total amountPhotovoltaicelectricity generationBiogas electricitygeneration
CONTENTSSafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesChairwoman andCEO's Message
SustainableDevelopmentManagement2024 Sustainability ReportAbout Us
128127
Employee turnover rate
Employee Development
Internal promotions
Total employee turnover rate Male Female Aged 51 or above Aged 31 to 50 Aged 30 or below Mainland ChinaRegions or countries outside the mainland (including Hong Kong, Macao, and Taiwan) Male Female Management General sta? Male Female Management General sta?Total number of employees trainedAverage hours of employee trainedTotal investment in employee trainingProportion of employees receiving performance appraisalsTotal number of promotionsInternal promotion rate Number of male employees promoted internally Proportion of male employees promoted internally Number of female employees promoted internally Proportion of female employees promoted internally Senior management Proportion of senior management promoted internally Middle management Proportion of middle management promoted internally Aged 51 or aboveAged 31 to 50Aged 30 or below
Turnover rate by
genderTurning rate by age
Turning rate by
regionProportion oftrained employees
by genderTraining participation
rate by rankAverage traininghours by genderAverage training
hours by rank
Number ofpromotions bygender
Number ofpromotions by rank
Number ofpromotions by age
Social Performance
Indicators
Employment
Employee Diversity
Total number of employees Male Female Aged 51 or above Aged 31 to 50 Aged 30 or below Senior management Middle Management General sta? Mainland ChinaRegions or countries outside the mainland (including Hong Kong, Macao, and Taiwan) Female senior management (executives) Proportion of women in senior management Female middle management (above the manager level) Proportion of women in middle management Number of R&D employees Proportion of R&D employees Number of female R&D employees Proportion of female R&D employees General sta? Disabled employees Number of employees of ethnic minorities Number of employees of non-ethnic minorities Doctor's degree and Professor Master's degree Bachelor's degree Below bachelor's degree
Unit
personpersonpersonpersonpersonpersonpersonpersonpersonpersonpersonperson%person%person%person%personpersonpersonpersonpersonpersonpersonperson
4,6552,3442,311
2,0172,568
3,9844,637
50.00
49.47
19.87
62.20
4,643
4,524
1,7122,253
2023
4,4442,2682,176
2,1722,205
4,2434,428
50.00
41.45
20.70
62.72
4,427
4,324
1,6992,069
2024
Number ofemployees by gender
Number ofemployees by age
Number ofEmployees by rank
Number ofemployees bygeographic location
Number andproportion of
women inmanagement
Number andproportion of R&D
employees
Number of
employees byphysical condition
Number ofemployees by ethnic
group
Number ofemployees by
education
Indicators
%%%%%%%%%%%%hourhourhourhourparticipantshourRMB 10,000%person%person%person%person%person%personpersonperson
Unit
28.46
-------
53.39
46.61
20.72
79.28
22.19
23.15
38.52
18.49
-
22.83
506.57
/////////////
2023
28.75
26.80
30.76
17.52
18.00
38.51
28.75
29.41
48.97
51.03
11.51
88.49
29.17
24.16
32.52
25.84
6,279
26.61
267.25
7.25
35.40
64.60
1.24
7.76
2024
CONTENTSSafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesChairwoman andCEO's Message
SustainableDevelopmentManagement2024 Sustainability Report
"-" indicates the item was not counted; "/" indicates the item is not applicable.
About Us
130129
Indicators
Intellectual property rights
Responsible Marketing
Social welfare
Suppliers
Cybersecurity
Cumulative number of invention patents authorized Cumulative number of design patents authorized Cumulative number of utility model patents authorized Cumulative number of trademark rights authorized Cumulative number of software and copyright authorizations Cumulative number of invention patents applied to main business Cumulative number of domestic patent authorizations Cumulative number of overseas patent authorizations Cumulative number of domestic trademark authorizations Cumulative number of overseas trademark authorizations Annual number of invention patent authorizations Annual number of design patent authorizations Annual number of utility model patent authorizations Annual number of trademark right authorizations Annual number of software and work copyright authorizations Annual number of invention patents authorized for main business Annual number of domestic patent authorizations Annual number of overseas patent authorizations Annual number of domestic trademark authorizations Annual number of overseas trademark authorizationsParticipants in trainingCumulative Duration of responsible marketing trainingTotal number of suppliers Mainland China Hong Kong, Macao, and Taiwan, China Overseas countries or regionsSigning rate of compliance commitment letters of suppliers of production materialsNetwork and data security violationsTotal investment in public welfare
Unititemitemitemitemitemitemitemitemitemitemitemitemitemitemitemitemitemitemitemitemparticipantshourcountcountcountcount%countRMB million
4,346
3,749
8,5852,714
2.68
2023
5,057
4,180
22,24315,3121,3391,333
9.61
2024
Cumulativenumber ofintellectualproperty rights
Cumulative number
of intellectualpropertyauthorizations by
region
Annual numberof intellectualproperty rights
Annual numberof intellectual
propertyauthorizations by
region
Responsible
Marketing
Indicators
Employee Compensation
Employee Bene?ts
Employee Health and Safety
Unadjusted average gender pay gapAverage gender pay gapMedium gender pay gap Number of employees covered Number of stocks covered Proportion of the amount of stocks coveredProportion of employees' social security contributionsSupplementary medical insurance for regular employeesPhysical examination coverage rate for regular employees Number of occupational health and safety training Number of employees trained on occupational health and safety Number of safety education for suppliers, contractors, etc. Number of participants in safety education for suppliers, contractors, etc. Total hours of occupational health and safety training Number of work-related injuries Number of work-related deaths Number of working days lost due to work-related injuries Work-related accidents per million work hours Total investment Investment in employee safety liability insurance Internal safety audit rate Recti?cation rate of safety audit
Unit%%%personshare%%%%timesparticipantstimesparticipantshourcountpersonday%RMB 10,000RMB 10,000%%
---
4,800,000
16,675--23,533
0.32
935.05
13.76
2023
-7.71
92.84
78.46
4,800,000
1,75534,080
27,82336,629
1,082.22
13.52
2024
Employee stockownership plan
Occupationalhealth and safety
training
Work-related
injury incidents
Investment in
occupationalhealth and safety
Safety audit
The unadjusted average gender pay gap = (Average male pay - Average female pay) ÷ Average male pay × 100%. The male/female average wage ratio is thedi?erence in average hourly wages between male full-time relevant employees and female full-time relevant employees, expressed as a ratio of male/female.The male/female median wage ratio is the di?erence in median hourly wages between male full-time relevant employees and female full-time relevant employ-ees, expressed as a ratio of male/female.
CONTENTSSafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesChairwoman andCEO's Message
SustainableDevelopmentManagement2024 Sustainability ReportAbout Us
132131
Economic Performance
IndicatorsOperating revenueNet income attributable to parentR&D investmentProportion of R&D investment to total revenue
UnitRMB 100 millionRMB 100 millionRMB 100 million%
60.76
5.93
4.46
7.35
2023
53.71
1.74
4.66
8.68
2024Governance Performance
Indicators
Board composition andgovernance overview
Special training oncorporate governance
Number of directorsNumber of female directors in the BoardProportion of female directors in the BoardNumber of independent directors in the BoardProportion of independent directors in the BoardNumber of directors with industry experienceNumber of directors with risk management experienceNumber of directors with ?nancial management experienceProportion of independent directors of the Audit CommitteeProportion of independent directors of the Nomination CommitteeProportion of independent directors of the Remuneration andAssessment CommitteeProportion of independent Directors of the Strategy CommitteeProportion of independent directors in the ESG CommitteeNumber of supervisorsNumber of female supervisorsNumber of employee supervisors in the Board of SupervisorsProportion of employee supervisors in the Board of SupervisorsNumber of the Board meetings heldNumber of the Supervisory Board meetings heldNumber of the Shareholders' meetings heldNumber of meetings of each committeeNumber of compliance trainingCoverage rate of key personnel in compliance trainingNumber of anti-bribery trainingCoverage rate of key personnel in anti-bribery training
Unit
personperson%person%personpersonperson%%%%%personpersonperson%timestimestimestimestimes%times%
33.33
33.33
66.67/100
66.67
66.67
66.67
33.33
2023
33.33
33.33
66.67
66.67
66.67
33.33
2024
CONTENTSSafeguardDriving ForcesGrowthSymbiosisAchievementsResponsibilityAppendicesChairwoman andCEO's Message
SustainableDevelopmentManagement2024 Sustainability ReportAbout Us